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CHAPTER 1 
INTRODUCTION 
1.1. Non-alcoholic fatty liver disease (NAFLD) & Non-alcoholic 
Steatohepatitis (NASH) 
 Non-alcoholic fatty liver disease (NAFLD) is a pathological condition 
where the triglycerides accumulate in hepatocytes, which is also known as 
hepatic steatosis. This condition can lead to steatohepatitis and develop further 
to fibrosis and cirrhosis progressively, which is a hallmark characteristic of 
non-alcoholic steatohepatitis (NASH) (Neushwander & Caldwell, 2003). 
NAFLD is a common but often silent chronic liver disease which shows 
resemblance to alcoholic liver disease, clinically and histologically, but which 
occurs in people who consume little or no alcohol (Bacon et al., 1994). 
 
NAFLD is strongly correlated to obesity and insulin resistance, where it 
is recognised to represent as hepatic manifestation of metabolic syndrome 
(Dowman et al., 2011). The prevalence of NAFLD increased with patient 
exhibit one or more features of the metabolic syndrome which are insulin 
resistance (IR), obesity, glucose intolerance or diabetes, dyslipidemia and 
hypertension (Dowman et al., 2011). Marchesini et al. (1999) have reported 
that NAFLD patients who had IR assessed using the homeostasis model 
assessment (HOMA) index have a higher value of body mass index (BMI) 
(>30kg/m2), visceral fat distribution and glucose intolerance. These findings 
further support that NAFLD is strongly correlated with other features of the 
metabolic syndrome, which suggests NAFLD as another component of this 
syndrome (Cortez et al., 1999). The pathophysiology of metabolic syndrome 
(MS) and NAFLD maybe due, at least in part to polymorphisms of genes 
involved in insulin resistance, lipid metabolism and inflammation causing the 
metabolic abnormalities (Day, 2004). 
 
 There are also drugs that are capable of inducing steatosis such as 
glucocorticoids, amiodarone, synthetic oestrogens and highly active 
antiretroviral drugs (HAART) (Preiss et al., 2008; Stefan et al., 2008; 
Neushwander et al., 2003). Endocrine disorders such as Polycystic ovary 
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syndrome (PCOS) (Setji et al., 2006), hypopituitarism (Adams et al., 2004) and 
hypothyroidism (Loria et al., 2009) also lead to fat accumulation in the liver. 
 
The prevalence of NAFLD was estimated about 30% in adults and 3.5-
5% of adults have NASH (Dowman et al., 2011; Browning et al., 2004). 
Recent study have reported that NAFLD is affecting both genders, all 
ethnicities, prominently in all age segments including 53% of obese children 
(Dowman et al., 2011; Clark et al., 2003; McCullough et al., 2005). 
Approximately 20% of NASH patients are at risk of developing cirrhosis and 
dying from end stage liver disease or liver cancer in short or medium term 
follow-up studies. 90% of morbidly obese individual may have NAFLD and 
20% have NASH. However, the pathological changes may be progressive 
through this spectrum such that up to one third of patients with NASH will 
develop cirrhosis over longer-term follow up (Dowman et al., 2011; Clark et 
al., 2003).  
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1.2. Clinical Manifestation and Laboratory findings 
 A previous study reported that 48-100% of NASH patients are 
asymptomatic, despite their abnormal liver function test (LFT) (Bacon et al., 
1994). Based on physical examination, 75% of NASH patients have 
hepatomegaly and 25% have splenomegaly (Ludwig et al., 1980; Lee et al., 
1989). The serum alanine aminotransferase (ALT) was found to be increased 
up to 3 fold more than serum aspartate aminotransferase (AST) in 65-95 % of 
NASH patients, which is in contrast to alcoholic hepatitis (Powell et al., 1990; 
Bacon et al., 1994). In addition, the alkaline phosphatase (ALP) and gamma 
JOXWDU\O WUDQVIHUDVH Ȗ-GT) are elevated in up to one third of these patients 
(Neushwander et al., 2003). The liver synthetic and excretory functions, as 
determined by levels of clotting factors, albumin and bilirubin are usually 
within the normal range. (De Knegt, 2001) 
 
 Plasma glucose is elevated due to impaired glucose tolerance or 
diabetes mellitus (Reid et al., 2001; Chitturi et al., 2002). 51% of NASH 
patients were hyperinsulinemic, and this was further supported by an increase 
in C-peptide levels which is an indicator of insulin hyper secretion. 
Dyslipidemia can be observed in NASH where there is an elevation of serum 
triglycerides (TG) and, serum low density lipoprotein (LDL) cholesterol 
followed by low levels of serum high density lipoprotein (HDL) cholesterol. 
(Chitturi et al., 2002)   
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1.3. Histological Findings 
 Liver biopsy was set as the gold standard to determine the presence of 
NASH and its severity by evaluating the grade and stage of the disease (Bravo 
et al., 2001). Liver biopsy is crucial because there is no relationship between 
the degree of abnormal LFT and the severity of the histopathological findings 
of this disease (Sonsuz et al., 2000; Mofrad et al., 2003). The recently 
developed grading system of Brunt is used to determine the severity of 
steatohepatitis (Brunt & Tiniakos, 2010; Brunt et al., 1999). There is also other 
non-invasive method other than liver biopsy for NASH diagnosis 
conformation. Serum keratin 18 (K18) fragments is a marker of hepatocyte 
apoptosis, has been reported as promising biomarker for NASH, with 
sensitivity and specificity of up to 77% and 92% respectively (Feldstein et al., 
2009). 
 
 Hepatic steatosis is characterized by accumulation of fat droplets in 
hepatocytes also known as ballooning degeneration of hepatocytes (Figure 
1.1). Steatohepatitis is described by a macro vesicular or large droplet steatosis 
(2mm), associated with a necro-inflammatory reaction, which is situated in the 
lobular parenchyma. It consists of a mixed infiltrate of mononuclear cells and 
neutrophils, causing liver injury with ballooning of the hepatocytes. The degree 
of necro-inflammation is also based on the extent of hepatocellular steatosis 
and the ballooning together with the disarray of hepatocytes (Figure 1.2). 
(Brunt et al., 2005) 
 
 A recent study by National Institute of Diabetes and Digestive and 
Kidney Diseases (NIDDK) have suggested a common set of minimal criteria in 
order to diagnose NASH which include lobular inflammation, ballooning 
degeneration, fibrosis and steatosis (Kleiner et al., 2005). NASH is associated 
with a pericellular, perisinusoidal fibrosis in the perivenular area or a periportal 
fibrosis, in which the localization of the fibrosis will vary with the stage of the 
disease. Liver fibrosis is present in 37-84% of the liver biopsies and may result 
in cirrhosis, the prevalence of which varies from 7- 30% of biopsies. (De 
Knegt, 2001; Reid, 2001; Angulo, 2002; Clark et al., 2002) 
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Figure 1.1: Hepatic steatosis, ballooning degeneration of hepatocytes with 
glycogenated nuclei (as shown in arrow) (H&E, x 200)  
(Adapted from Brunt et al., 2005) 
 
Figure 1.2: Steatohepatitis, with several hepatocytes showing ballooning 
degeneration intermixed with steatosis and foci of inflammatory cells in 
hepatic lobules. Mallory hyaline showing eosinophilic and ropy inclusions in 
cytoplasm (H&E, x 400) (Adapted from Brunt et al., 2005). 
 
Figure 1.3: Perivenular/ pericellular fibrosis in zone 3  
(Masson trichrome x 200) (Adapted from Brunt et al., 2005) 
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1.4. Pathogenesis of Non-alcoholic Steatohepatitis (NASH) 
 $µPXOWL- KLW¶K\SRWKHVLVKDVEHHQVXJJHVWHGIRU1$)/'SURJUHVVLRQWR
NASH (Estep et al. 2009; Malhi and Gores, 2008; Miele et al. 2003; Charlton 
et al. 2002). The first hit was described as the development of hepatic steatosis 
due to insulin resistance (IR). Insulin resistance condition leads to increased 
serum levels of non esterified or free fatty acids (FFAs). Subsequently, 
increased FFA transport into hepatocytes would increased the hepatic de novo 
lipogenesis that exceed both the hepatic FFA ȕ-oxidation and very low-density 
lipoprotein (VLDL) export, leading to increased hepatic steatosis (Malhi and 
Gores, 2008). Miele et al. (2003) & Charlton et al. (2002) suggest that hepatic 
steatosis occurrence is largely due to the increase in lipogenesis and decreases 
in lipid export out from the liver.  
 
 Accumulation FFAs in hepatocytes promote apoptosis through a 
number of pathways, including increased stress of membrane bound organelles 
such as mitochondria, endoplasmic reticulum (ER), and lysosomes (Malhi and 
Gores, 2008). FFAs activate a number of complex intracellular pathways, 
including induction of activation of c-jun N-terminal kinase, the pro-apoptotic 
protein Bax and Toll-like receptor 4 to induce lipotoxicity. All these activation 
pathways lead to lysozomal and mitochondrial permeabilization leading to 
increase in oxidative stress, pro-inflammatory cytokines gene expression, ER 
stress, and hepatocyte apoptosis (Malhi and Gores, 2008). All these factors will 
lead to fibrosis and cirrhosis. In some patients it develops progressively to 
hepatocellular carcinoma (Day, 2002). 
 
However recent evidence suggests that both steps may occur 
VLPXOWDQHRXVO\,W¶VZLGHO\DFFHSWHGWKDWR[LGDWLYHVWUHVVSOD\VDSLYRWDOUROHLQ
the liver injury progression (McClain et al., 2007). There are various factors 
WKDW FDXVH R[LGDWLYH VWUHVV ZKLFK DUH VHYHULW\ RI ,5 UDWH RI ȕ-oxidation, 
disturbance in type of fat accumulated within hepatocytes, overproduction of 
cytokines and adipokines associated with inflammatory process that 
accompany fat accumulation both systemically and within the liver and finally 
endoplasmic reticulum (ER) stress that arises because of accumulation of mis-
folded protein. One or more of these mechanisms may be involved in different 
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proportions in any given individual leading to a final common pathway of 
progressive liver injury and advanced fibrosis. (Marra et al., 2008; McClain et 
al., 2007) 
 
 
Figure 1.4: Non-alcoholic steatohepatitis pathogenesis (Adapted from Lam & 
Younossi,  2011). 
IR and visceral obesity are characterized as the risk factors involved in 
NASH (Wanless & Lentz, 1990). The basal rate of whole body lipolysis 
depends on the total body fat mass, when there is an expansion of adipose 
tissue it would lead to an increase in plasma free fatty acid (FFA) 
concentrations due to lipolysis of adipose tissue. An increased in FFAs level 
leads to up regulation RI 71)Į H[SUHVVLRQ 71)Į inhibits the insulin-
stimulated tyrosine phosphorylation of insulin receptor and insulin receptor 
substrate (IRS-1) in adipocytes, thus interfering the insulin signalling. This 
condition would disrupt the insulin mediated suppression of lipolysis in 
adipose tissue leading insulin resistance in adipose tissue (Fruhbeck et al., 
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2001; Hube et al., 1999; Mohamed-Ali, et al., 1998; Peraldi et al., 1996; 
Hotamisligil et al., 1995).  
 
 Previous studies have described that NASH has a stronger correlation 
with visceral obesity rather than peripheral obesity (Chitturi et al., 2002). This 
is because the visceral adipocytes tend to be more prone to lipolysis than those 
from the peripheral adipose tissue (Arner. P, 1998). Visceral adipose tissue 
appears to be less mature than the subcutaneous adipose tissue and produces 
more FFA, tumour necrosis factor (TNF)-Į DQG UHVLVWLQ IROORZHG E\ ORZHU
amounts of adiponectin. Resistin is an amino acid protein expressed in white 
adipose tissue that plays a role in insulin resistance (Steppan et al., 2001). 
Upregulation of resistin level in mice lead to increase in plasma glucose and 
insulin level (Banerjee et al., 2004). Resistin expression is down regulated by 
Thiazolidinediones (Troglitazone, Rosiglitazone & Piolgitazone) and fasting 
condition in mice model (Steppan et al., 2001). Over expression of Resistin in a 
mouse model caused dyslipidemia which is characterized by increased in 
serum total cholesterol and triglyceride levels, and decreased in high density 
lipoprotein cholesterol concentration (Sato et al., 2005). 
  
Whereas adiponectin is an adipocyte-derived hormone that is expressed 
in adipose tissue (Maeda et al., 1996). Adiponectin exerts its function by 
augmenting insulin sensitivity and also acts as an anti-inflammatory agent. 
Adiponectin down regulates SREBP-1C expression, which is a master 
regulator of fatty acid synthesis (Shklyaev et al., 2003). In addition, 
adiponectin also increased ȕ-oxidation of free fatty acids and decreases de 
novo free fatty acids production within hepatocytes. These effects will protect 
hepatocytes against triglyceride accumulation. (Wang et al., 2006; Xu et al., 
2003) 
  
 Visceral adiposity is an immediate source of FFA that is delivered 
directly to the liver via the portal vein. An elevation of plasma FFA and TNF-Į
concentration caused activation of inhibitor kappa kinase beta (IKKȕ LQ 
adipocytes and hepatocytes. IKKȕ DFWLYDWLRQ GHFUHDVHV WKH W\URVLQH
phosphorylation of insulin receptor substrate (IRS) 1 and 2 followed by 
inactivation of phosphatidylinositol 3-kinase (PI3-K) and down regulates other 
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insulin signalling events (Shulman, 2000). Thus, insulin cannot activate the 
glucose transport mechanism-4 (GLUT-4), so the glucose is not transported 
into the cells (Shulman, 2000; Day, 2002). The anti-lipolysis effect of insulin 
in adipose tissue is also impaired in this condition, which leads to further 
elevation of FFA concentration contributing to obesity related IR. FFA impairs 
the ability of insulin to suppress hepatic glucose output. Steatosis occurs when 
the liver is overloaded by FFAs and is unable to secrete them into the 
circulation. (Diez et al., 2003; Musso et al., 2003) 
 
FFA and their metabolites are ligands for the transcription factor, 
peroxisome proliferator-activated receptor-Į 33$5-Į 33$5-Į SOD\V DQ
important role in fat oxidation where it regulates the transcription of enzymes 
LQYROYHG LQ PLWRFKRQGULDO DQG SHUR[LVRPDO ȕ-oxidation and also cytochrome 
3 HQ]\PHV ZKLFK LQYROYHG LQ Ȧ-oxidation. Leptin concentrations were 
found higher in hepatic insulin resistance, where it helps to ease the entry of 
FFAs into mitochondrial through carnitine palmitoyl-tranferase-1 (CPT-1) 
activation. This process is NQRZQ PLWRFKRQGULDO ȕ-oxidation. Therefore, both 
of these processes caused an increased fatty acid oxidation. (Day, 2002) 
 
Conversely, FFA metabolism augments the production of reactive 
oxygen species (ROS) such as singlet oxygen, super oxide anion, hydrogen 
peroxide (H2O2), hydroxyl radical and up regulates uncoupling protein-2 
(UCP-2) expression. The ROS extract the hydrogen atoms from fatty acids and 
create a destructive chain reaction known as lipid peroxidation (Benzie, 1996). 
Lipid peroxidation causes disruption of membranes and produces reactive 
metabolites like malondialdehyde (MDA), 4-hydroxynonenal (HNE), which 
affect cellular dysfunction (Day, 2002). Loguercio et al. (2001) reported that 
MDA and HNE levels are increased about 90% in NASH patients compared to 
patients with steatosis, illustrating the augmentation of oxidative stress.  
 
TNF-ĮDQGOLSLGSHUR[LGDWLRQ products (Day, 2002) have been reported 
to restrict the electron-transport chain of the mitochondria, damage the 
mitochondrial DNA, and deplete the mitochondrial protein, worsening the 
mitochondrial dysfunction and increasing the production of ROS. 
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0LWRFKRQGULDOGDPDJHIXUWKHU UHVWULFWVȕ-oxidation of lipid and increasing the 
steatosis. (Day, 2002)   
 
 0LWRFKRQGULDO ȕ-oxidation produces energy, but it causes leakage in 
HOHFWURQ WKDW FUHDWHV 526 'D\  3HUR[LVRPDO ȕ-oxidation is an 
intracellular process that metabolizes FFA to Acetyl-CoA. Acetyl-CoA is then 
transported into the mitochondria for further degradation. Peroxisomes can 
oxidize long-chain FFA more rapidly than mitochondria and boost the capacity 
RI FHOOV WR PHWDEROL]H ))$ 'XULQJ ȕ-oxidation, peroxisomes produce H2O2, 
promoting oxidative stress. (Benzie, 1996) 
 
 ROS and lipid peroxidation end products cause direct damage to the 
hepatocytes causing disruption of the membranes, proteins and DNA (De 
Knegt, 2001; Day, 2002). They also induce an inflammatory response by up-
regulating the pro-inflammatory cytokines [TNF-Į DQG WUDQVIRUPLQJ JURZWK
factor (TGF-ȕ@ LQILOWUDWLRQ RI SRO\morph nuclear and mononuclear 
leukocytes, activation of kupffer cells, and expression of Fas-ligand. This can 
lead to necrosis, apoptosis and Fas-ligand-mediated cell death. (Angulo et al., 
2001)  
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Figure 1.5: Mechanisms of fat accumulation in non-alcoholic steatohepatitis. 
Insulin resistance causes an influx of FFAs to the liver, owing to increased 
lipolysis, especially in the visceral adipose tissue. Increased de novo 
lipogenesis and fat from the diet also contribute to the fatty-acid pool. Both 
VLDL generation and FFA oxidation are increased and are sufficient to 
prevent intrahepatic lipid accumulation. (DNL: de novo lipogenesis; GNG: 
gluconeogenesis; ROS: reactive oxygen species; TG: triglycerides; VLDL: 
very low-density lipoproteins) (Adapted from Marra et al., 2008). 
 
 Hepatic stellate cells (HSCs) are known as lipocytes, fat-storing cells or 
Ito cells. This cell is one of the non-parenchemal cells (NPCs) that are 
responsible for fibrosis development. The role of leptin and its receptor (Ob-R) 
were investigated in fibrosis condition using Zucker (fa/fa) rats, where the rats 
were induced with thioacetamide (TAA) resulting in HSCs activation. These 
HSCs produce excess of extracellular matrix components and transformed into 
myofibroblast-like cells (Ikejima et al., 2002). TNF-Į7*)-ȕ0'$DQG+1(
were capable to activate the HSCs, resulting in the production of connective 
tissue growth factor (CTGF) and other extracellular matrix proteins needed for 
fibrosis (Galli et al., 2002). CTGF is expressed excessively and in parallel with 
the amount of liver fibrosis in NASH patients. It is also up-regulated by 
hyperinsulinemia and hyperglycemia. (Paradis et al., 2001) 
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Leptin is the product of the obese gene (ob) that regulates food intake 
and body weight. Homozygus mutation of the leptin gene is associated with 
obesity. Hyperleptinemia is present in NASH, obese patients with Hepatitis C 
virus (HCV) and also chronic alcoholic hepatitis patients who have increased 
predisposition of cirrhosis (Ikejima et al., 2002). Marra, F. (2002) has reported 
that leptin may play a crucial role in developing fibrosis in NASH by 
stimulating HSCs via their surface receptor (Marra, F. 2002). Leptin also 
caused an increase in phagocytosis and proinflammatory cytokine levels and T-
cell mediated immune responses in the liver. Hence, leptin may be involved in 
the pathogenesis of the inflammatory response and fibrosis observed in variety 
of liver disease associated with obesity. (Ikejima et al., 2002) 
 
Kupffer cells activation up regulates the proinflammatory cytokine 
secretion (PDGF and TGFȕ) to activate the stellate cells during liver injury 
(Cai et al., 2005). Endothelin 1 (ET1) is a potent vasoconstrictor produced by 
sinusoidal endothelial cells that exert a paracrine effect particularly on stellate 
cells rather than hepatocytes and kupffer cells. ET1 regulates stellate cells 
contractility that increases intrahepatic portal hypertension. ET1 also exert 
proliferative effects on activated stellate cells (Rockey, 1997). Transforming 
growth factor-ȕ7*)ȕ LVDJURZth inhibitor that inhibits cell proliferation 
particularly epithelial cells, promotes transdifferentiation of HSC to 
P\RILEUREODVWDQG(&0DFFXPXODWLRQ7*)ȕSURPRWHVĮ60$SURGXFWLRQLQ
activated stellate cells during liver injury. (Gressner & Weiskirchen, 2006) 
 
 Cytokine secretion due to fat accumulation 71)Į 7*)ȕ, IL-6), 
oxidative stress, ER stress triggers hepatic damage and further promotes 
inflammation and insulin resistance (Marciniak & Ron, 2006). NF-kB 
activation exacerbates liver injury and is involved in maintenance of the cell 
survival by exerting anti-apoptotic effect (Schwabe & BreQQHU 71)Į
mediates JNK (c-Jun N-terminal kinase) signalling pathway, whereas both 
inflammation and insulin resistance activate the pathway. JNK signalling 
pathway is activated in obesity and insulin resistance condition (Sethi & 
Hotamisligil, 1999; Boden, 1997). Genetic deletion of JNK1 in lean and obese 
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mice decreased adiposity, improved insulin sensitivity and enhanced insulin 
receptor signalling capacity (Hirosumi et al., 2002). 
 
 
Figure 1.6: Mechanisms of inflammation in NASH. Damage to hepatocytes 
caused by fat loading and resulting lipotoxicity leads to the activation of 
intracellular signalling pathways, which leads to the expression of several 
cytokines that are responsible for the recruitment of inflammatory cells. 
Hepatic damage also affects the biology of other liver cells, such as Kupffer 
cells, which become activated and contribute to cytokine secretion. 
Recruitment of inflammatory cells is also conditioned by factors produced by 
activated hepatic stellate cells and sinusoidal endothelial cells. Most liver-
resident cells are targeted by adipokines secreted by visceral adipose tissue. 
These events lead to a vicious circle that causes worsening of liver damage, 
further inflammation, maintenance of steatosis, disease progression and insulin 
resistance. (CAM: cell adhesion molecule; ECM: extracellular matrix; ER: 
endoplasmic reticulum; JNK: c-Jun N-terminal kinase, PDGF: platelet-derived 
growth factor; TGF-ȕ transforming growth factor-ȕ. (Adapted from Marra et 
al., 2008). 
 
 
 
 
 14 
 
1.5. Treatment of NASH 
 At the present moment there is no generally accepted treatment for 
NASH. Regular exercise and diet control are the alternative therapy to drugs, 
and they effectively improved the liver function test (Marchesini et al., 2001) 
and histological changes (Dixon et al., 2004). But, in some studies the 
histological changes worsened with drastic weight loss (Andersen et al., 1991).
  
 There are two classes of insulin sensitizing agents, metformin and 
thiazolidinediones (TZDs) that are used to treat insulin resistance (IR). 
Metformin was effective in improving the insulin sensitivity, reducing ALT 
and glucose levels (Marchesini et al., 2001), but did not produce any 
improvement in fibrosis in patients with NASH. (Nair et al., 2004) 
 
TZD are the new class of antidiabetic drugs which consist of 3 
compounds that are clinically used, Troglitazone (Rezulin ®), Rosiglitazone 
(Avandia ®) and Pioglitazone (Actos ®). In 1997, Troglitazone was the first 
TZD to gain approval from the Food and Drug Administration (FDA) and was 
used clinically in obese and diabetic patients. Troglitazone enhances insulin 
sensitivity and promote adipocytes differentiation. Unfortunately, Troglitazone 
caused severe hepatotoxicity that leads to death in over 500 cases. Finally, 
Troglitazone was withdrawn from the market in 2000 (Caldwell et al., 2001). 
The second generation of TZDs are Rosiglitazone and Pioglitazone have 
proven to have low rates of hepatotoxicity (Neuschwander-Tetri et al., 2003).  
 
 Neuschwander-Tetri et al. (2003) have reported that Rosiglitazone 
given to NASH patients (4mg daily for 48 weeks) caused a significant 
improvement in insulin sensitivity (the ability to suppress endogenous glucose 
production) and mean serum ALT. Rosiglitazone also showed a significant 
improvement in hepatocytes ballooning, numbers of kupffer cells and the 
global necroinflammatory grade. The characteristic of zone 3 fibrosis of NASH 
was also improved. Therefore, Rosiglitazone changes the pattern of 
inflammation from lobular to portal predominance. (Neuchwander et al., 2003) 
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 Pioglitazone given to 55 randomised NASH patients (45mg daily plus 
hypocaloric diet) significantly enhanced insulin sensitivity, normalised serum 
ALT level, and reduced serum AST levels. Histological findings showed that 
Pioglitazone improved steatosis, necrosis ballooning and inflammation, but did 
not show a significant change in fibrosis compared to a placebo group. (Belfort 
et al., 2006) 
 
 Both Rosiglitazone (Neuchwander et al., 2003) and Pioglitazone 
(Lutchman et al., 2007) caused peripheral weight gain. Fatigue or mild lower-
extremities edema were reported with Rosiglitazone (Neuchwander et al., 
2003) and Pioglitazone (Belfort et al., 2006), but these side effects were only 
observed in few patients. Pioglitazone has been reported to be more effective 
than Rosiglitazone in reducing low density lipoprotein (LDL) cholesterol and 
triglycerides in type 2 diabetes patients (Miyazaki et al., 2001). This is because 
Pioglitazone is not only DIXOO33$5ȖDJRQLVWEXWDOVRDSDUWLDO33$5ĮDJRQLVW
unlike Rosiglitazone that only exhibits 33$5ȖDJRQLVW effects (Sakamoto et al., 
2000). 
 
TZDs exert their anti-diabetic effect through by acting as ligands for the 
peroxisome proliferator-activated receptor-Ȗ 33$5-Ȗ :KHQ DFWLYDWHG
PPAR-ȖZLOOKHWHURGLPHUL]HZLWKUHWLQRLG;UHFHSWRU5;5DQGIRUPD33$5-
Ȗ-RXR complex, then this complex will bind to a specific DNA sequence in the 
promoter of a target gene to induce the transcription via PPAR-response 
elements (PPREs) (Kliewer et al., 1992; Keller et al., 1993). The binding of 
ligand to PPARȖ will result in changes in the expression levels of PPAR target 
genes. 
 
 TZDs act as insulin sensitizers by increasing the glucose uptake in 
adipose tissue and skeletal muscle. A study conducted in Type 2 DM animal 
models proved that TZDs can reduce plasma glucose levels and triglycerides to 
normal values. Similar findings were observed when TZDs were given to type 
2 diabetes patients, where they reduced plasma glucose, insulin, triglycerides 
and FFAs (Gastaldelli et al., 2007).  
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Obesity is strongly associated with adipocyte hypertrophy, and leads to 
hepatic and peripheral IR as well as overproduction of FFAs, TNF-Į DQG
leptin (Kadowaki, 2000). When PPAR-ȖLVDFWLYDWHGE\DOLJDQG, an elevation 
in the level of adipocyte differentiation is observed leading to the production of 
more numerous, smaller adipocytes. These small adipocytes are more insulin-
sensitive, producing less FFA, TNF-Į DQG OHSWLQ 7KHUHIRUH LQVXOLQ LV PRUH
HIIHFWLYHDQGWKHUHLVOHVVQHHGIRUWKHSDQFUHDWLFȕ-cells to elevate their insulin 
secretion (Figure 1.7 Right Panel). This improvement in glucose and lipid 
metabolism is accompanied by weight gain and an increase in subcutaneous fat 
(Miyazaki et al., 2002). 
 
Figure 1.7: Left Panel: Insulin resistance condition affect the fat cells caused 
increased in FFAs, TNF-Į DQG /HSWLQ Right Panel: Mechanism of TZDs 
action on PPAR-Ȗ FDXVHG LPSURYHG LQVXOLQ VHQVLWLYLW\ DGLSRF\WHV
differentiation and increased glucose uptake (Adapted from Kahn et al., 2000).  
 
Pioglitazone used in type 2 diabetes treatment, caused an elevation in 
adiponectin levels improving insulin resistance and reduced hepatic fat content 
(Bajaj et al., 2004). Both rosiglitazone and pioglitazone reduced plasma resistin 
(Bajaj et al., 2004; Jung et al., 2005) and impaired TNF-ĮDFWLYDWLRQ,ZDWDHW
al., 2001; Hernandez et al., 2004) in both type 2 diabetes patients and animal 
models. A previous study has reported that, both pioglitazone and rosiglitazone 
retarded the liver fibrosis in rats via PPAR-ȖUHFHSWRUVWLPXODWLRQOHDGLQJWRWKH
reduction of activation of HSCs and subsequent collagen synthesis (Galli et al., 
2002). 
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Figure 1.8: Mechanism of action of TZDs in vivo in humans. TZDs increased 
lipogenesis and increased subcutaneous adipose tissue mass and body weight. 
TZDs decrease circulating or urinary markers of cardiovascular risk and 
vascular inflammation such as plasminogen-activator inhibitor type 1, C-
reactive protein, matrix metalloproteinase 9 (MMP-9), and urinary endothelin 
excretion. (Adapted from Yki-Jarvinen, 2004) 
 
 Yki-Jarvinen (2004) has reported that both Pioglitazone and 
Rosiglitazone reduced the risk of cardiovascular disease by improving the 
glucose and lipid metabolism. Rosiglitazone given to diabetes patients with 
coronary artery disease caused reduction MMP-9, interleukin-6 (IL-6), C-
reactive protein and plasminogen-activator inhibitor type-1 which are 
cardiovascular risk markers (Marx et al., 2003). 
 
 Other than that, the effects of PPAR Ȗ OLJDQG ZHUH DOVR REVHUYHG LQ
stellate cells and kupffer cells. PPAR ȖOLJDQGV-deoxy-protaglandin J2 (15d-
PGJ2) and ciglitazone both inhibit PDGF induced stellate proliferation and 
Į60$H[SUHVVLRQVLQKXPDQ*DOOLHWDOThe PPAR ȖDJRQLVW$'833 
(Pioglitazone hydrochloride) was also reported to decrease both 
OLSRSRO\VDFFKDULGH/36LQGXFHGQLWULFR[LGH12DQG71)ĮOHYHOs  in a rat 
kupffer cells culture model (Uchimura et al., 2001). 
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Aithal et al. (2008) have reported that (30mg/day) Pioglitazone (PGZ) 
was given to non-diabetic NASH patients for 12 months, this dose induced an 
increased in body weight, followed by reduction in plasma glucose, HbA1c, 
insulin C peptide, alanine aminotransferase (ALT) Ȗ-glutamyltransferase 
(GGT) and ferritin compared to placebo treated group. Histological scoring 
with PGZ treatment also have shown some improvement in hepatocellular 
injury, Mallory±Denk bodies, and fibrosis scoring but no change in steatosis 
scoring compared to placebo treated group. 
 
Currently there are no data on the underlying molecular mechanism 
either on NAFLD progression or Pioglitazone mechanism of action in non-
diabetic NASH patients. Therefore the aims of this study were to further 
investigate the aforementioned molecular mechanism. This study was a follow-
up study from Aithal et al. (2008), where the liver biopsy and liver paraffin 
blocks taken from both placebo and pioglitazone were used to study genes, 
protein and immunohistochemistry expression of stellate cell markers and 
hepatocyte markers expression in order to achieve the study objectives. 
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1.6. Research Objectives 
x To investigate the molecular mechanism underlying the progression of 
NAFLD from normal liver as well as how it leads to the progression of 
NASH. 
x To investigate the molecular mechanisms underlying the effects of 
Pioglitazone and placebo treatment in non-diabetic NASH patients. 
x To investigate the behaviour and molecular expression of human 
hepatic stellate cells in culture plated on different culture surface mimic 
the in vivo condition of Space of Disse. 
x To determine the expression of adipogenic, nuclear receptors and 
stellate cells activation markers in the in vitro culture model of human 
hepatic stellate cell over time. 
x To determine the effects of nuclear receptor ligands upon activation and 
proliferation upon PDGF-BB incubation in a human hepatic stellate 
cells in vitro culture model. 
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CHAPTER 2 
Methods & Materials 
2.1. Subjects and study design 
Patients were recruited for the randomised double-blind placebo trial 
IURP WKH 4XHHQ¶V 0HGLFDO &HQWUH LQ 1RWWLQJKDP DQG 'HUE\ &LW\ *HQHUDO
Hospital. Patients between the ages of 18 and 70 years who were able to give 
consent were initially screened by medical history and physical examination. 
Patients with weekly alcohol consumption >210g for men and >140g for 
women were excluded from this study. Patients with disease including hepatitis 
B and C, heart failure, renal impairment and hepatic steatosis were also 
excluded, as subjects taking medication for fatty liver disease. Each patient had 
an ultrasound examination of the liver and liver biopsy was performed 
according to a standard protocol. Diagnosis of NASH was confirmed on 
histology by the presence of fat and evidence of hepatocyte injury, 
inflammation or fibrosis. (Aithal et al., 2008) 
 
All NASH patients entered a 3 month run in period prior to 
randomisation and were instructed by a dietician to reduce their calorie intake 
by 500 Kcal per day as well as performing modest exercise (such as walking, 
swimming or gardening etc) regularly for 30-40 minutes per day at least 5 days 
per week. Sixty one patients were randomised to receive either 30 mg/day of 
Pioglitazone (30 patients) (Takeda Pharmaceuticals UK) or placebo (31 
patients) for 12 months. (Aithal et al., 2008) 
 
Anthropometric data (height, weight, and waist:hip ratio), blood count, 
standard liver function test and fasting blood samples for determination of 
glucose, insulin, HbA1c and lipid profile were collected at baseline and the end 
of Pioglitazone treatment. At each 4 monthly visit, brief examination was 
carried out in particular to look for adverse side effects. The compliance was 
also monitored during this visit using tablet counts. Liver biopsies were 
collected at the end of 1-year treatment from both Pioglitazone and placebo 
group. (Aithal et al., 2008) 
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All materials used in this work were of the highest available quality and were 
purchased from Sigma, UK or BDH unless otherwise stated. 
2.2. RNA isolation and purification 
2.2. 1. Materials for RNA isolation and purification 
Tri Reagent (Ambion Inc, USA); 1-Bromo-3-Chloro-propane (BCP), (Sigma, 
UK); Sodium  Acetate  (NaAc)  2M  pH  4.0;  Isopropanol  (Sigma,  UK);  
70%  Ethanol;   RNAse free  water  (Qiagen,  UK);  RNAse  free  DNAse  
(Qiagen, UK); RNAse   Cleanup Mini Kit (Qiagen, UK)  
 
2.2. 2. Method for RNA isolation and purification 
50mg of the frozen tissue was transferred into a polypropylene snap-cap tube 
containing 2ml of ice-cold monophasic lysis reagent (TRI reagent), followed 
by 15-30 seconds homogenization at room temperature using tissue 
homogenizer (Ultra-turrax,T25, IKA®-Labortechnik). Then, the homogenates 
was left for 5 minutes at room temperature to permit complete dissociation of 
nucleoprotein complexes; 0.4 ml of BCP was added per ml of monophasic lysis 
reagent, followed by vortexing of the sample. The sample was then centrifuged 
at 10,000g for 15 minutes at 4q C.  The upper aqueous phase was transferred 
into a fresh tube, and the supernatant bottom phase kept for protein extraction. 
0.25ml NaAc (2M, pH 4) and 0.7ml Isopropanol were added per ml of aqueous 
phase, and the sample was then stored overnight at -20qC. The precipitated 
RNA was collected by centrifugation at 13,000rpm for 15 minutes at 4qC in a 
microfuge. The pellet was washed twice with 70% ethanol followed by 10 
minutes centrifugation 13,000rpm at 4qC. The ethanol was removed with a 
disposable pipette tip, and the open tube left on the bench for 5 minutes to 
allow the ethanol to evaporate. The pellet was then dissolved in 30-ȝO RI
RNAse-free H2O. Total RNA was purified after DNase treatment using the 
51$HDV\ 0LQL .LW DFFRUGLQJ WR WKH PDQXIDFWXUHU¶V LQVWUXFWLRQV. The total 
RNA concentration was measured at the absorbance of 260 nm using 
Nanodrop-1000 Spectrophotometer (Thermo Scientific, USA) and the integrity 
of RNA was checked using an Agilent 2100 Bioanalyzer (Agilent 
Techonologies, USA).  
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2.3. cDNA synthesis & Taqman Real time-PCR validations 
2.3.1. Materials for cDNA synthesis & Taqman Real time-PCR validations 
SuperScrLSW,,,5HYHUVH7UDQVFULSWDVH8ȝO,QYLWURJHQ8.;)LUVW
VWUDQGEXIIHU,QYLWURJHQ8.0'77,QYLWURJHQ8.QJȝO5DQGRP
3ULPHU 3URPHJD 8. P0 G173 PL[ 3URPHJD 8. 51DVH287
Recombinant Ribonuclease Inhibitor (40 8ȝO,QYLWUogen, UK). 
 
2.3. 2. Method for cDNA synthesis & Taqman Real time -PCR Validations 
A total of 200ng of RNA was reverse transcribed into cDNA using Superscript 
III Reverse Transcriptase (RT) (Invitrogen 8. DFFRUGLQJ WR PDQXIDFWXUHU¶V
instructions. The mRNA concentrations of selected genes were quantified 
using ABI Prism 7700 sequence detection system instrument and software 
(Applied Biosystems, USA). cDNA was diluted in 1:8 dilution and 3µl of 
synthesized cDNA was mixed with Taqman Universal PCR master mix 
(Applied Biosystem, USA) and gene specific primer and probe mixture 
(Eurofins MWG Operon, Germany) in a final volume of 13µl and all samples 
were run in triplicates Relative expression levels were determined using five-
point serial dilution standard curve, generated from human liver cDNA.  
 
Assays were deemed acceptable if there was no more than 0.5 cycle threshold 
(Ct) difference between the values of a triplicate, the slope of the standard 
curve was between -3.2 to -3.6 and the  r2 was between 0.95-0.99 (Figure 2.1). 
The mRNA expression levels of specific genes were normalized to the 
geometric mean of the mRNA expression level of ȕ-actin and HMBS which 
were used as the reference genes IRU WKH OLYHUELRSV\VDPSOHVDQGȕ-actin for 
human stellate cell samples.  
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The primers and probes used in this study are designed using Primer Express 
III software shown in Appendix 1. 
B E T A  A C T IN  S T D  c u r v e
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Figure 2.1: Taqman Real-time PCR standard curve showing the slope value (-3.43) and 
correlation co-officient (r2) value (0.99). 
 
2.4. Method for Custom Taqman Low Density Array 
The selected probe ID genes were sent to Applied Biosystem (USA) to design 
384 wells micro fluidic card with 4 samples per card. A total of 400ng of RNA 
was reverse transcribed into cDNA using Superscript III Reverse Transcriptase 
(RT) (Invitrogen8. DFFRUGLQJ WR PDQXIDFWXUHU¶V LQVWUXFWLRQV ȝl of 
synthesized cDNA was mixed with ȝl of HPLC water and 110ȝl of 
Taqman® Universal PCR master mix, No AmpErase® UNG (Applied 
Biosystem, USA).  
The mRNA concentrations of selected genes in the samples were quantified 
using ABI PRISM® 7900HT sequence detection system instrument (Applied 
Biosystems, USA). The gene expression was later quantified using SDS RQ 
Manager Software, Applied Biosystem (USA). 
 
 
 
 
 
 
 
 
 
Log quantity cDNA 
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2.5. Pre-Amplification technique for stellate cells cDNA  
The aim of this technique is to amplify the lower expression of target genes in 
human hepatic stellate cells to quantify the gene expressions. 
2.5.1. Materials for Pre-amplification technique for stellate cells cDNA 
TaqMan PreAmp Master Mix (2X) or Taqman® Fast Master Mix; Reverse and 
Forward primers of target genes; Tris-EDTA (TE) Buffer (1X) ; cDNA 
samples. 
2.5.2. Method for Pre-amplification technique for stellate cells cDNA 
ȝORIHDFKUHYHUVHDQGIRUZDUGSrimer were pooled in 2ml eppendorf tube. In 
this study there were 18 target genes (as shown in table 5.1 in chapter 5) and 1 
UHIHUHQFH JHQH ȕ-actin) which were amplified (19 pairs of primers). The 
pooled assay mix must be diluted 50 times. The calculation of pooled assay 
mix is as shown as below: 
3RROHG$VVD\0L[GLOXWLRQȝO;SDLUVRISULPHUV 
          ȝORISRROHGSULPHUVPL[ 
From the above calculation these pooled primers mix has been diluted 38 
times. The final dilution is 50 times. Therefore, the pooled primers mix was 
diluted 12 times with TE buffer to reach final dilution of 50 times. Therefore, 
ȝO RI 7( EXIIHU ȝO ;  ZDV DGGHG WR WKH SRROHG SULPHUV PL[ WR
become Pooled Assay Mix. Then all the samples were prepared for PCR 
PUHDPSOLILFDWLRQ UHDFWLRQ ȝO RI 7DT0DQ 3UH$PS 0DVWHU 0L[ X) was 
DGGHGLQWRD3&5UHDFWLRQWXEHIROORZHGE\ȝORI3RROHG$VVD\0L[DQG
ȝORIQJF'1$VDPSOH7KHILQDOYROXPHIRUWKH3&5UHDFWLRQLVȝO
The PCR Preamplification reaction was performed as shown in Table below: 
Table 2.1: PCR Preamplification reactions 
 Hold 10 cycles 
Temperature 95°C 95°C 60°C 
Time 10 minutes 15 seconds 4 minutes 
 
The PCR product is diluted in 1:5 dilutions with 1X TE buffer after the PCR 
reaction. Then these samples were used for the Taqman Real time PCR for 
target gene quantification and analysis for the human hepatic stellate cells 
experiments. 
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2.6. Protein expression analysis 
2.6. 1. Materials for Protein expression analysis 
Solutions 
5X SDS Urea Buffer 
P0 7ULV +&O  ZY 6'6   YY ȕ-PHUFDSWRHWKDQRO ȕ-ME), 7M 
Urea (Urea was dissolved in deionised water first using Amberlite Monobed 
resin for 30 minutes), 0.1% (w/v) Bromophenol blue. (Sigma Chemicals, UK) 
4X Separation gel buffer 
1.5M Tris Base; 0.4% (w/v) SDS pH 8.8 with concentrated HCl 
4X Stacking gel buffer  
0.5M Tris Base; 0.4% (w/v) SDS pH 6.8 with concentrated HCl 
12% Separation gel (for 4 mini gels) 
18.6ml 30% (w/v) Acrylamide; 11.4ml HPLC water; 10ml 4X separation 
EXIIHUS+ȝOZY$PPRQLXPSHUVXOIDWH$36ȝO7(0(' 
4X Stacking gel (for 4 mini gels) 
4ml 30% (w/v) Acrylamide; 26ml HPLC water; 10ml 4X Stacking buffer 
S+ȝOZY$PPRQLXPSHUVXOIDWH$36ȝO7(0(' 
10X Running Buffer (1000ml) 
144g Glycine; 30Tris Base; 100ml 10% (w/v) SDS, made up to 1litre with 
HPLC water 
10X Transfer Buffer (SDS free) (1000ml) 
30g Tris Base; 144g Glycine, made up to 1litre with HPLC water 
Transfer Buffer working solution 
80ml 10X Transfer Buffer; 160ml Methanol, made up to 800ml with HPLC 
water 
10X Tris Buffered Saline (TBS) (1000ml) 
24.23g Tris Base; 80.06g Sodium Chloride (NaCl) pH 7.6 with concentrated 
HCl 
1X Tris Buffered Saline-Tween 20 (TBS-T) 
100ml 10X TBS with 1ml of Tween 20, made up to 1litre with HPLC water 
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Coomassie Blue R350 solution 
0.4g of Coomassie blue R350 was dissolved in 200mL of 40% (v/v) methanol 
in HPLC water with stirring as needed. The solution was filtered to remove any 
insoluble material and 200ml of 20% (v/v) acetic acid was added in the 
solution. 
Coomassie Gel fixing solution 
500mL of USP-grade 95% (v/v) ethanol was added to 300ml of HPLC water, 
100ml of glacial acetic acid and the total volume was adjusted to 1litre with 
HPLC water.   
Coomassie Gel destaining solution 
500mL of HPLC-grade methanol was added to 300ml of water, 100ml of 
glacial acetic acid and the total volume adjusted to 1litre with HPLC water.   
Coomassie Gel Storage solution 
25ml of glacial acetic acid made up to a final volume of 500ml of HPLC water. 
 
2.6. 2. Method for Protein Extraction  
The remaining supernatant bottom phase from the RNA extraction (as 
described in section 2.2.2) was used for protein extraction. After removing the 
aqueous phase, 1.9ml of Isopropanol (Sigma, UK) was added per ml of 
supernatant, and the mixture was left at room temperature for 10 minutes. Then 
the samples were centrifuged at 5000rpm for 10 minutes at 4°C. The 
supernatant was removed and the pellet washed 3 times with 0.3M Guanidium-
HCl in 95% alcohol. Finally, 2ml of ethanol was added and the solution was 
incubated for 20 minutes at room temperature followed by centrifugation at 
7500rpm for 5 minutes at 4°C. The, supernatant was discarded and the protein 
pellet was dissolved in SDS Urea buffer by sonication (1 time for 10 seconds) 
and boiled for 5 minutes. The protein sample was then centrifuged at 
13000rpm for 10 minutes.  
 
2.6. 3. Western blotting gel electrophoresis 
The gel electrophoresis was run at 120 Volt for 2 hours followed by 
transferring the protein from the gel on to nitrocellulose membrane at 105volt 
IRUKRXUDFFRUGLQJWKHPDQXIDFWXUHU¶VGHVFULSWLRQ(Bio-Rad, USA). 
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2.6. 4. Immunodetection following western blotting 
The nitrocellulose membrane was blocked with 5% (w/v) Marvel 1X TBS-T 
washing solution for one hour on a shaker. The blocking solution was 
discarded, followed by addition of primary antibody in 5% (w/v) Marvel 1X 
TBS-T and the membrane was incubated overnight at 4°C. Following primary 
antibody incubation, the membrane was washed with 3X 10 sec washes and 3 
times 5 minutes washes with TBS-T. 
The secondary antibody (1:10000 dilution) in 5% (w/v) Marvel 1X TBS-T 
solution was then added and the membrane was incubated for one hour at room 
temperature. The membrane was then washed 3X 10sec washes and 1X 5 
minutes with 1X TBS-T. Finally the membrane was immersed in distilled 
water for 5 minutes prior to scanning of the membrane using the Odyssey® 
Infrared Image system (LICOR Biosystem, USA) using 700nm (red channel) 
and 800nm (green channel) with the focus offset to membrane imaging. 
Densitometry was performed using Odyssey® Imaging System Software 
(LICOR Biosystem, USA). 
 
Table 2.2: List of antibody used for western blotting protein expressions in this study. 
Primary Antibody  Dilution used 
ȕ-actin, (A5441) Sigma-Aldrich USA 1:5000 
Proliferating cell nuclear antigen (PCNA) (SC-7907), Santa 
Cruz, USA 
1:200 
Peroxisome proliferator activator receptor (PPAR)-Ȗ6&-
7273),Santa Cruz, USA 
1:100 
Į-VPRRWKPXVFOHDFWLQĮ60$$6LJPD-Aldrich, 
USA 
1:200 
Secondary Antibody  Dilution Used 
IRDye® 700CW Conjugated Goat Anti-Rabbit IgG, (926-
32221) Licor Bioscience,  USA 
1:10000 
IRDye® 800CW Conjugated Goat Anti-Mouse IgG, 
(92632210) Licor Bioscience, USA 
1:10000 
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2.7. Immunohistochemistry 
2.7.1. Materials for immunohistochemistry 
Solutions 
Xylene, Industrial Methylated Spirit (IMS) from Fisher Scientific, UK 
Citrate saline buffer  
21g Citric acid; 250ml of 1M Sodium Hydroxide (NaOH), pH 6.0, made up to 
10litres with distilled water 
TRIS/HCl Buffered saline (TBS) 
81g Sodium Chloride (NaCl); 6g TRIS (hydroxymethyl methylamine); 42ml 
Hydrochloric acid (HCl) 1M, pH 7.6. pH was adjusted to 7.6 with 1M NaOH 
and made up to a volume of 10litres.  
1% acid alcohol 
30ml Concentrated HCl; 2.1ltres Industrial methylated spirit (IMS), 900ml of 
deionised water    
6FRWW¶V7DS:DWHU 
10.5g Sodium Hydrogen Carbonate (NaHCO3); 60g Magnesium sulphate 
(MgSO4), 3litres of deionised water   
0D\HU¶V+DHPDWR[\OLQ 
50g aluminium potassium sulphate (alum) dissolved in 1000 ml distilled water. 
1g of haematoxylin was then added followed by addition of 0.2g sodium iodide 
and 20ml acetic acid. The solution was boiled, allowed to cool to room 
temperature and filtered through Whatman 3M filter paper before use. 
 
+DUULV¶V+DHPDWR[ylin (without acetic acid) 
HD Supplies, UK 
 
Methlygreen stain 
DAKO, Denmark 
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2.7.2. Method for rehydrating the immuno sample slide 
The sample slide was immersed in 2 Xylene bath for 5minutes and 2 minutes. 
Then the slide was immersed in 3 bath of IMS for 30 sec each bath. The slide 
was rinsed in distilled water for 5 minutes. 
 
2.7.3. Method for antigen retrieval of immuno sample slide 
The slide was placed onto a plastic rack followed by an immersion in 850ml of 
citrate saline buffer in a plastic container. The container was then moved into 
the microwave with the lid was placed onto the container. The sample was then 
LUUDGLDWHG DW µ0('+,*+¶ IRU PLQXWHV IRU DQWLJHQ UHWULHYDO SXUSRVH $IWHU
that the sample was taken out from the solution, was left in running cold tap 
water for 15minutes. The sample immunostained using specific kits and the 
protocol was followed as described by the manufacturer. List of 
immunostaining kits used in this study is as shown below: 
 
Table 2.3: List of immunostaining kit used in this study 
Immunostaining Kit 
Single Immunohistochemistry uVLQJ 'DNR 5HDO 'HWHFWLRQ 6\VWHP
Peroxidase/DAB+, Rabbit/ Mouse Kit, Dako (K5001) 
'XDOLPPXQRKLVWRFKHPLVWU\VWDLQLQJXVLQJ WKH(Q9LVLRQ*_'RXEOHVWDLQ6\VWHP
Rabbit/Mouse (DAB+/Permanent Red Kit, Dako (K5362) 
TUNEL immunohistochemistry using ApopTag® Peroxidase In situ Apoptosis 
Detection Kit (S7100) Chemicon International (USA) 
TUNEL - In situ cell death detection kit, fluorescein (11684795910), Roche, Germany 
 
2.7.4. Method for counterstaining the immuno slide sample 
The slide was washed in running tap water for 15minutes, and then followed by 
LQFXEDWLRQ LQ 0D\HU¶V KDHPDWR[\OLQ IRU  PLQXWHV ,I XVLQJ +DUULV
Haematoxylin incubate the slide for 6 minutes. After that, the slides was rinsed 
in running cold water followed by 5 seconds dip in 1% acid alcohol and then 
ULQVHGLQUXQQLQJFROGZDWHU7KHVOLGHZDVLQFXEDWHGLQ6FRWW¶VWDSZDWHUIRU
30 seconds followed by rinsed in running cold water. The slide was dehydrated 
in 3 IMS bath for 30 seconds each and 2 bath of Xylene followed by mounting 
with DPX (BDH Supplies, UK) of the section with coverslip. 
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2.8. TUNEL assay 
2.8. 1. Material for positive control tissue for TUNEL assay 
DN buffer Solution 
PORI07ULV %DVHS+  ȝORI  0 0DJQHVLXP&KORULGH 0J&O2); 
1.54mg Dithiothreitol (DTT) made up to 100ml of distilled water. 
 
2.8. 2. Method for positive control tissue for TUNEL assay 
Section was pre-treated with DN Buffer at room temperature for 5 minutes 
after performing both DEPC treatment and antigen retrieval with Proteinase K 
DV GHVFULEHG E\ WKH PDQXIDFWXUHU¶V NLW '1DVH  HQ]\PH 4LDJHQ 8.
GLVVROYHG LQ'1%XIIHUZLWK ILQDOFRQFHQWUDWLRQRIȝJPOZDV LQFXEDWHGRQ
the section for 10 minutes at room temperature. Finally the section was rinsed 
with distilled water for 3minutes each 5 times. 
 
2.9. Double immunoflourescence staining 
2.9.1 Materials for double immunoflourescence staining 
Buffer 1 (Washing buffer for immunoflourescence) 
2 tablet of Phosphate buffer saline (PBS) (Dulbecco A); 2g Bovine serum 
albumin (BSA); 200ȝO7ZHHQ-20 made up to 200ml of distilled water. 
DABCO Fluorescent mounting medium 
200mg DABCO (1-4-Diazabicyclo-2-2-2-octane), Sigma-Aldrich, UK; 10ml 
1X PBS (Dulbecco A); 90ml Glycerol (ICN Biomedical Inc, USA). Solution 
was mixed together and stored at 4°C. 
'$3,¶-diamino-2-phentl-indole, dehydrochloride) stock solution 
10mg DAPI (Invitrogen, UK) was dissolved in 10ml of distilled water to make 
1mg/ml stock solution. For working solution used 1:500 dilutions on to the 
section for 10 minutes. 
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2.9.2. Method for double immunoflourescence staining 
The sample slide was rehydrated and antigen retrieved as describes previous in 
section 2.6.2 and 2.6.3. The section was blocked with peroxidase blocking 
solution (S2023, Dako) for 15 minutes followed by washed with deionised 
water. Then the section was incubated with first blocking serum (10% serum 
from the species that the secondary antibody was raised in) for 30 minutes to 
block unspecific binding of the antibodies in Buffer 1. The serum was decanted 
followed by first primary antibody in Buffer 1 incubation in a humidified 
chamber for overnight at 4°C. The first primary antibody solution was 
decanted and washed the section 3 times in Buffer 1 for 5 minutes each wash. 
The first secondary antibody (labelled with Fluorochrome-1) in Buffer1 
was incubated on the section for 1 hour at 4°C in dark. Finally the first 
secondary antibody solution was decanted and the section was washed 3 times 
in Buffer 1 for 5 minutes each in dark. The similar process of blocking and 
incubation of second primary antibody and second secondary antibody 
were repeated as described previously. Then the section was washed quickly 
and incubated on DAPI (1:500) dilution for 10 minutes and followed by quick 
washed once again. The section was then mounted with DABCO mounting 
medium and sealed the coverslip with nail polish and store in the dark -20°C or 
4°C. 
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Table 2.4: List of sources and dilution of primary antibody used for these 
study. 
Primary Antibody  Dilution Incubation period 
Į60$0'DNR'HQPDUN 1:250 1hour at room temperature 
Desmin (M0760) Dako, Demark 1:50 1hour at room temperature 
CRBP1 (SC-30106), Santa Cruz, USA 1:200 1hour at room temperature 
GFAP (Z0334) Dako, Denmark 1:100 1hour at room temperature 
GFAP Ab-1 (MS-280-P1),  
Thermo Scientific, USA 
1:100 Overnight at 4°C 
Caspase 3, (G748A) Promega, UK 1:500 3 hours at room temperature 
M30 (12140322001), Roche Germany 1:50 3hours at room temperature 
33$5Į36LJPD-Aldrich, UK 1:200 1 hour at room temperature 
33$5ȕ6&-7197), Santa Cruz, USA  1:100 3hours at room temperature 
33$5Ȗ6&-7273), Santa Cruz, USA 1:100 1 hour at room temperature 
Ki67 (PA0118) Vision Biosystems 
%RQG UK (Ready to use for 
immunohistochemistry) 
- 1 hour at room temperature 
Secondary Antibody  Dilution Incubation period 
Alexa Fluor® 488 Goat anti-rabbit IgG 
(H+L), (A11008) Invitrogen, UK 
1:500 1 hour at 4°C in the dark 
5KRGDPLQH5HG-X Goat anti-rabbit IgG 
(H+L), (R6394) Invitrogen, UK 
1:500 1 hour at 4°C in the dark 
Alexa Fluor® 488 Goat anti-mouse IgG 
(H+L), (A11001) Invitrogen, UK 
1:500 1 hour at 4°C in the dark 
5KRGDPLQH 5HG-X  Goat anti-mouse 
IgG (H+L), (R6393) Invitrogen, UK 
1:500 1 hour at 4°C in the dark 
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2.10. Stereology Count of hepatic stellate cells 
The dissector method was used for stereology count (Mayhew, 1996). It was 
done randomly and blindly in order to prevent biasness. The number and 
diameter of HSCs and hepatocytes are taken from 25 frames using the 40X 
objective magnification, only positive cell bodies containing nucleus in the box 
and the ones that touches the dotted lines were counted. The cell that touches 
the straight lines must not be counted.  
 
Then the % Cell / %Total cell volume were calculated in the formula stated 
below: 
 NV   =                    NN                   
           ----------------------------------  
 
                                [D
 
X
 
(4 / ʌ)] + T       
Nv   = Number of cell per unit volume 
NN  = Number of nucleus per frame 
D   = Diameter (ȝm);  ʌ = 3.142 
T   = Thickness of the section (ȝm) 
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2.11. Liver Perfusion 
2.11.1. Materials for liver perfusion 
Solutions 
10x Hanks-Hepes (HH) buffer pH 7.4 
80g NaCl; 4.0g KCl; 0.6g KH2PO4; 1.2g Na2HPO4 12H20; 47.6g HEPES; 0.1g 
Phenol red; 4.0g NaOH    
All components were dissolved in 1litre of Steripak water, sterilised by 
autoclaving or vacuum filtration and store at 4°C in glass bottle. 
Soltran solution for transport and flushing of tissue 
Soltran buffer from Baxter was diluted to 300mOsmol/l (500ml Soltran + 
300ml sterile water) 
EGTA, 25mM 
4.8g EGTA (Sigma E3889) dissolved in 250ml 1X HH, 25ml 1M NaOH. Made 
up to 500ml with 1X HH, autoclaved and stored at 4°C. 
Calcium chloride, 250mM 
 9.2g of calcium chloride (dihydrate) in 250ml of Steripak water. Autoclaved 
and stored at 4°C. 
MBG solution (HH+) 
31g sodium bicarbonate (Sigma S6297), 25g glucose (Sigma G7021) and 7.5g 
methionine (Sigma M9500) were dissolved in 500ml Steripak water, Filter 
sterilised (use filter unit for Duran bottle), and stored at -20°C in 50ml aliquots. 
Percoll/HBSS:  
Percoll (Amersham 17-0891-01, density 1.131 g/ml) was diluted in 9:1 with 
10x HBSS and stored in 10ml aliquots at 4°C. 
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2.11.2. Preparation for liver perfusion 
The water bath was heated to 43°C followed by thawing 50ml of MBG 
solution. Both the tissue culture hood was sterilised and then the sterilised 
perfusion tubing was recirculated with 70% IMS followed sterilised water 
(1litre). The perfusion buffer was made up with 1X HH supplemented with 
20ml of MBG in 1litre solution. 
The following solutions were prepared in Duran bottles: 
a) 1X HH buffer + 10mL MBG + 10mL EGTA in 500ml solution 
b) 1X HH buffer + 20mL MBG + 20mL EGTA in 1litre solution 
c) 1X HH buffer + 10mL MBG (without EGTA) in 1litre solution (100ml 
of solution was removed for mincing the tissue after 
digestion/perfusion)  
d) 1X HH buffer + 10mL MBG + 10mL calcium chloride + 65 U 
collagenase + 80mg trypsin inhibitor in 500ml solution 
All these solutions were warmed up in the water bath and aerated with 95% 
oxygen, 5% CO2 before used. 
 
2.11.3. Method for liver perfusion 
1. The tissue was collected from theatre in cold Soltran buffer from Baxter then 
the tissue was weighed for the record. Then the tissue was flushed with diluted 
cold Soltran using a syringe. Tissue was cannulated and perfused with 1500ml 
perfusion buffer with EGTA, using Watson-Marlow 323 pump set at 45rpm 20 
minutes. This solution was not recirculated.  
2. The tissue was then flushed with perfusion buffer without EGTA prior to 
collagenase digestion for 6 minutes and this solution was not recirculated. 
Then, changed to the perfusion buffer with collagenase solution and was 
recirculated for approx. 20 minutes until the lobe is soft and blanched. 
3. The tissue was carefully removed and placed into perfusion buffer without 
EGTA and minced gently with blunt-ended scissors and then filtered through a 
250-ȝP DQG WKHQ D -ȝP Q\ORQ PHVK 7KH ILOWHU ZDV IOXVKHG ZLWK +%66
solution. 
4. The filtered solution was divided into 50ml tubes and collected by 
centrifugation at 50g for 4min at room temperature using Heraeus Biofuge 
Primo centrifuge. There were 2 layers observed, where the supernatant was 
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used for the non-parenchemal cells (NPCs) isolation and cell pellet contains 
hepatocytes. 
 
2.12. Non-parenchemal cells isolation 
2.12.1. Materials for Non-parenchemal cells isolation 
Solutions 
Phosphate buffer solution (PBS), Dulbecco A 
1 tablet of PBS in 100ml of deionised water. 
PBS with 0.3% Bovine Serum Albumin (BSA), Sigma-Aldrich 
1 tablet of PBS in 100ml of deionised water; 0.3g BSA 
10X PBS  
10 tablet of PBS in 100ml of deionised water. 
100% Percoll solution 
Take 9 parts of Percoll add 1 part of 10X PBS 
Histodenz 27.6% (w/v), Sigma-Aldrich, USA 
27.6g dissolved in 100 ml of distilled water. Please cover the tube with 
aluminium foil, because Histodenz is light sensitive. 
 
2.12.2. Method for non-parenchemal cells (NPC) isolation 
1. The supernatant obtained from the liver perfusion (as described in 
section 2.10.3) containing NPCs was spun down at 300g for 10mins at 
4°C.  
2. Then the pellet was gently resuspended in 20ml PBS containing 0.3% 
BSA solution followed by 16ml of 27.6% (w/v) of Histodenz, which 
gave a final concentration of 13% (w/v) and centrifuged at 900g for 30 
minutes at 4°C.  
3. The supernatant was transferred into a new tube, and diluted up to a 
volume of 40ml in PBS with 0.3% BSA, and then shaken at 150 rpm 
for 30 minutes at 4°C. After that, the solution was centrifuged at 300g 
for 10 minutes at 4°C 
4. Following centrifugation, the cell pellet was collected by gently 
resuspended in 6ml of PBS and with 6.6ml of 100% Percoll solution, 
made up 52% Percoll with NPCs.  
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5. 2ml of 52% Percoll with NPCs was pipetted in 50ml tubes followed by 
4ml of 50% Percoll, 4ml of 35% Percoll and 1ml of PBS with 0.3% 
followed by centrifugation at 900Xg for 30 minutes at 4°C.  
6. Three different cell bands were obtained with the one at the top of layer 
was enriched in hepatic stellate cells (HSCs) (Fraction 1), the one at the 
interface between the two Percoll gradient cushions mainly enriched in 
liver endothelial cells (LECs) (fraction 2) and one near the bottom of 
the centrifugation tube enriched in Kupffer cells (KCs) (fraction 3) (See 
Figure 2.2). 
7. The HSCs was collected and washed with PBS at 1000rpm for 5 
minutes and cell pellet was resuspended in RPMI-1640 media 
containing 10% heat-inactivated foetal calf serum (FCS), 4mmol L-
glutamine, 100µg/ml Penicillin, 100µg/ml Streptomycin  and transfer to 
humidified chamber at 37°C with 5% CO2  in separate flask. Culture 
media was changed every 48 hour thereafter. 
 
Figure 2.2: Schematic description of separated liver NPC band after Percoll 
centrifugation. Fraction 1 (hepatic stellate cells); Fraction 2 (liver endothelial 
cells); Fraction 3 (Kupffer cells). 
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2.13. Method for thin layer Matrigel (B&D Biosciences) coating 
Matrigel was thawed overnight at 4°C. The pre-cooled pipette was used to mix 
the matrigel basement membrane matrix for homogeneity on ice. Dilute 
Matrigel basement membrane was diluted in 1:2 dilutions using the cold 
Roswell Park Memorial Institute (RPMI) serum free medium on ice. 400µl of 
diluted matrigel basement membrane matrix was added onto each well (12 well 
plates) on ice. Then, incubate at 40ºC for an hour with lid closed. Then, the 
unbound material was aspirated and followed by rinsed gently using the serum 
free media before the plate was used. 
 
2.14. Collagen coating on cell culture plates 
2.14.1. Materials for collagen coating on cell culture plates 
100mg of collagen (Sigma, UK) was dissolved in 100ml 0.1M acetic acid, to 
give a final concentration of 1mg/ml. The collagen solution was filtered 
WKURXJKDVWHULOH)DOFRQȝPFHOOXORVHDFHWDWHPHPEUDQHILOWHULQWRDVWHULOH
100ml Duran bottle. This solution was stored for up to 3 months at 4°C until 
use or longer. 
2.14.2. Method for collagen coating for 12-well plate 
Calf skin collagen solution (1 mg/ml) was diluted 1:10 dilution with sterile 
ZDWHU WR REWDLQ D ZRUNLQJ FRQFHQWUDWLRQ RI  ȝJPO The plastic dish was 
coated ZLWK  ȝJFP2 (use 120 ȝOZHOO ZLWK 12.0 cm2/well) and incubated 
overnight in a class II culture cabinet with lid being removed. The excess fluid 
was removed from the coated surface followed by one wash with cold sterile 
PBS (2 ml/well) and another wash with sterile water (again 2ml/well). 
The plate was dried in tissue culture cabinet or non-humidified incubator at 
37ºC), once dried; the plate was stored at room temperature or for longer term 
in a fridge. 
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2.15. Sub-culturing the human hepatic stellate cells (HSCs) 
2.15.1. Materials for sub culturing the human hepatic stellate cells (HSCs) 
1X Phosphate Buffered Saline (PBS), Dulbecco A 
1 tablet of PBS in 100ml of deionised water and followed by autoclaved 
for sterilization 
10X Trypsin EDTA solution (Sigma, UK) 
Dilute 1:10 with sterile PBS, aliquot into universal containers and stored  
at -20°C.  
 
2.15.2. Methods for sub culturing human hepatic stellate cells (HSCs) 
When cells were confluent, the media was aspirated and replaced and 
rinsed with 1X PBS. 5ml of trypsin EDTA solution was added in 75cm2 
size flask and incubated for 10 minutes 37°C in tissue culture non-
humidified chamber. The trypsin solution was swirled around the flask to 
detach the cells from the flask. Then 15ml of RPMI medium was added 
and mixed. The cell mixture was pipetted out from the flask into a 50ml 
tube, followed by centrifugation at 1000rpm for 5 min. The supernatant 
was aspirated and the pellet was resuspended in fresh media. The cells 
were diluted and were plated accordingly depending on the required 
number of cells needed to perform the experiment. 
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2.16. MTT assay 
MTT assay is a colorimetric assay for measuring the mitochondrial reductase 
activity in proliferating cells. It measures the cleavage of yellow tetrazolium 
salt MTT to purple formazan crystals by metabolic active cells. 
 
2.16.1. Materials MTT assay (11465007001) Roche, Germany 
Solutions 
MTT labelling reagent 
5ml MTT (3-[4, 5-dimethylthiazol-2-yl]-2, 5-dipheyltetrazolium bromide) with 
5mg/ml concentration. Keep it away from light. 
Solubilization solution (1X, ready to use) 
10% SDS in 0.01M HCl.  Keep it away from light 
 
2.16.2. Method for MTT cell proliferation assay 
The MTT assay was performed as described by the manufacturer. The 
wavelength of the measure absorbance of the formazan product is read 550nm 
(test fliter) with reference absorbance set as 650nm (reference filter) using 
Dynex Technologies MRX II.   
 
2.17. Statistical Analysis 
Data are presented as mean ± SEM. Descriptive, Levene test, One-way 
ANOVA and Bonferroni post hoc test were used to analyze all the data. A p 
value < 0.05 was considered as statistically significant. 
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CHAPTER 3 
Immunohistochemistry & Protein Expression in human liver: Assessment 
of the effects of Pioglitazone therapy in NASH patients. 
 
3.1. Introduction 
 Pioglitazone (PGZ) is PPAR Ȗ DJRQLVW WKDW PDLQly acts on adipose 
tissue by promoting adipocyte differentiation and proliferation and decreasing 
lipolysis (Miyazaki et al., 2002). In type 2 diabetic patients treated with 
Pioglitazone, glucose uptake, fatty acid oxidation and improved insulin 
sensitivity in skeletal muscle are all observed (Coletta et al., 2009). Meanwhile 
in the liver of type 2 diabetic patients, hepatic fat content and  endogenous 
glucose production (gluconeogenesis) are reduced and hepatic insulin 
sensitivity is increased with PGZ treatment (Ravikumar et al., 2008; Bajaj et 
al., 2003). Thus the effects of pioglitazone upon liver fat content and insulin 
resistance may reflect the effects of whole body glucose and fat metabolism.  
     
Aithal et al. (2008) described that non-diabetic NASH patients treated 
with Pioglitazone had reduced hepatocellular injury and fibrosis compared to 
placebo treated patients whereas there was no significant change in liver fat 
content between these two groups. This suggests that pioglitazone therapy may 
target other processes in addition to lipid metabolism which are of relevance in 
NASH. In human liver PPAR J is primarily expressed in the non parenchemal 
cell fraction ± in particular stellate cells. It has been reported that treatment of 
stellate cells with PPAR J agonists inhibits stellate cell activation and 
progression to the activated myofibroblastic phenotype. The possibility that 
Pioglitazone exerts its effects directly upon hepatic stellate cells in terms of 
regulation of cellular activation, proliferation and gene expression was 
therefore investigated by immunohistochemistry of hepatocyte and hepatic 
stellate cell (HSC) markers involved injury, apoptosis and proliferation (as 
shown in Table 3.1) were studied in human tissue sections. Single 
immunohistochemistry method was used followed by counter staining with 
0D\HUµV RU +DUULV¶V +DHPDWR[\OLQ DV GHVFULEHG LQ &KDSWHU  0DWHULDOV DQG
Methods). This analysis was then complemented by mRNA and protein 
analysis of core liver biopsy samples taken from the same group of patients.  
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Table 3.1: List of antibodies used in this study. 
Antibody Function Cell type stained 
Į60$ actin family of proteins and a marker of 
activated HSCs (Safadi et al.,2002) 
 
Vascular portal area (arterioles and 
veins) in normal liver, activated 
HSCs  (Van Rossen et al., 2009) 
 
CRBP1 mediates retinol esterification to retinyl 
esters and retinol oxidation to retinal and 
retinoic acid (Blomhoff et al., 1991) 
both quiescent and activated HSCs,  
very low levels in hepatocytes, 
billiary epithelial cells  
(Van Rossen et al., 2009) 
 
Desmin Muscle-specific class III intermediate 
filament and quiescent marker of HSCs  
(Van Rossen et al., 2009) 
 
quiescent HSCs in rats (Geerts et 
al., 2001) and vascular smooth 
muscle cells in arterioles in 
humans (Van Rossen et al., 2009) 
 
GFAP Involved in vascular remodelling in hepatic 
damaged tissue where there is an increase in 
neovascularisation during liver fibrosis  
(Corpechot  et al., 2002) 
 
quiescent HSCs located in the 
lobule near portal tracts in normal 
liver, early stage of HSCs 
activation  throughout the lobule  
(Carotti et al., 2008) 
 
PPAR Ȗ Marker of quiescent HSC, controls 
adipogenic gene expressions  
(She et al., 2005) 
 
Not clearly shown in the both 
human and animal liver 
PPAR ȕ Regulates pro-proliferation and involved in 
activation of HSCs (Hellemans et al., 2003)  
 
hepatocytes and HSCs 
PPAR Į Regulates mitochondrial & peroxisomal 
IDWW\DFLGȕ-oxidation  
(Van Raalte et al., 2004) 
 
hepatocytes 
Caspase 3 plays a key role in the execution of  
apoptotic cell both by extrinsic (death 
ligand) and intrinsic (mitochondrial) 
pathways (Feldstein et al., 2005) 
 
apoptotic hepatocytes  
(Feldstein et al., 2003) 
 
TUNEL  labelling  DNA fragments utilizing terminal 
deoxynucleotidyl transferase (TdT) for 
detection of apoptotic cells 
(www.chemicon.com) 
 
Apoptotic cells 
M30 Determine early epithelial cell apoptosis 
by recognizing specific caspase cleavage 
sites (Caulin et al., 1997) 
 
apoptotic hepatocytes  
(Feldstein et al., 2009) 
Ki67 Promotes cell proliferation associated with 
ribosomal RNA transcription. Inhibition of 
Ki-67 leads to inhibition of ribosomal RNA 
synthesis. (Bullwinkel et al., 2006) 
 
Only expressed in mitotic cells 
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RESULTS 
3.2. HSCs marker single immunohistochemistry 
Cellular retinol binding protein 1 (CRBP1) is a carrier protein involved in 
retinol transportation and it is expressed in both quiescent and activated stellate 
cells but the expression was lesser in other hepatic cell types (Van Rossen et 
al., 2009). In liver injury, quiescent stellate cells are transformed into 
myofibroblast-like FHOOVWKDWH[SUHVVĮVPRRWKPXVFOHDFWLQĮ60$ZKLFKLVD
marker of activated stellate cell phenotype (Safadi et al., 2002). 
Immunohistochemistry was performed on human NASH liver formalin-fixed, 
paraffin-embedded (FFPE) samples to confirm both CRBP1 and Į60$
expression as shown in Figure 3.1 below. 
  
 
)LJXUH  &5%3 DQG Į60$ LPPXQRKLVWRFKHPLVWU\ VWDLQLQJ LQ 1$6+ SDWLHQWV ))3(
sections from human liver biopsies taken from NASH patients were deparaffinised and 
subjected to immunohistochemistry as described in section 3.2. CRBP1 (A) was used as a 
PDUNHURIWRWDOVWHOODWHFHOOVQXPEHUDQGĮ60$%ZDVXVHGDVDPDUNHURIDFWLYDWHGVWHOODWH
cells (myofibroblast). Photographs are representative of 7 sections each taken from 7 patients. 
Black circles show stellate cells positively staining with CRBP1 and red circles show positive 
VWDLQLQJRIDFWLYDWHGVWHOODWHFHOOVZLWKĮ60$ 
 
 
A 
B 
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Į60$	&5%3GRXEOHLPPXQRVWDLQLQJ 
In an attempt to identify the total stellate cell number and the proportion 
of activated stellate cells in this population, double immunoflourescence was 
carried out using anti-CRBP1 and anti-Į60$DQWLERGLHV 
  
 
 
                     
)LJXUH&5%3DQGĮ60$GRXEOHLPPXQRIORXUHVFHQFHVWDLQLQJLQ1$6+SDWLHQWV))3(
sections from human liver biopsies taken from NASH patients were deparaffinised and 
subjected to double immunoflourescence as described in section 3.2.1. CRBP1 was used as a 
PDUNHURIWRWDOVWHOODWHFHOOVQXPEHUDQGĮ60$ZDVXVHGDVDPDUNHURIDFWLYDWHGVWHOODWHcells 
(myofibroblast). Photographs are representative of 7 sections each taken from 7 patients. Green 
VWDLQLQJ VKRZV DFWLYDWHG VWHOODWH FHOOV SRVLWLYHO\ VWDLQLQJ ZLWK Į60$ UHG VWDLQLQJ VKRZV
stellate cells positively staining with CRBP1; yellow staining show the co-localisation of 
Į60$	&5%3VWDLQLQJEOXHVWDLQLQJVKRZV'$3,VWDLQLQJRIQXFOHL 
 
 'RXEOHLPPXQRIORXUHVFHQFHRI&5%3DQGĮ60$VKRZHGHYLGHQFHRI
co-localization; this further indicated that CRBP1 is a marker for total stellate 
cell number rather than quiescent cells as has been previously suggested. There 
is a problem with double immunoflourescence staining in that whilst the 
expression is clear, it is hard to count the cell numbers making stereology 
counting unreliable. 
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Į60$	&5%3double immunohistochemistry  
Double immunohistochemistry was performed in order to achieve 
objectives as mentioned previously. 
 
 
)LJXUH  &5%3 DQG Į60$ GRXEOH LPPXQRKLVWRFKHPLVWU\ VWDLQLQJ LQ 1$6+ SDWLHQWV
FFPE sections from human liver biopsies taken from NASH patients were deparaffinised and 
subjected to double immunohistochemistry without methylgreen counterstaining (A) and with 
methlygreen counterstaining (B) as described in section 3.2.2. CRBP1 was used as a marker of 
total stellate cells numbHU DQG Į60$ ZDV XVHG DV D PDUNHU RI DFWLYDWHG VWHOODWH FHOO
Photographs are representative of 7 sections each taken from 7 patients. Red staining shows 
DFWLYDWHG VWHOODWH FHOOV SRVLWLYHO\ VWDLQLQJ ZLWK Į60$ %ODFN VWDLQLQJ VKRZV VWHOODWH FHOOV
positively staining with CRBP1.  
 
Double immunohistochemistry leads to false positive staining, where 
the initial staining (anti-CRBP1) need to be over stained to prevent a loss of 
signal following application of the second antibody (anti-Į60$ &RXQWHU-
staining with methlygreen as described in the method for dual 
immunohistochemistry kit, reduced the ability to verify positively stained cells. 
Since, double immunostaining is unsuitable to achieve the determination of 
HSC number; single immunohistochemistry staining was identified as the 
preferred method for stereology counting. All the immunostaining was 
independently verified by a consultant histopathologist (Dr Philip V. Kaye). 
 
 
A 
B 
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Į-VPRRWKPXVFOHDFWLQĮ-SMA) immunohistochemistry  
Į-SMA immunohistochemistry in normal liver, NAFLD & NASH patients 
   
              Appendix (Control tissue)                                     Normal liver 
             
                          NAFLD          NASH 
 
)LJXUH  Į60$ LPPXQRKLVWRFKHPLVWU\ VWDLQLQJ LQ KXPDQ OLYHU ))3( VHFWLRQV IURP
human liver biopsies taken from normal liver, NAFLD and NASH patients were deparaffinised 
DQGVXEMHFWHGWRVLQJOHLPPXQRKLVWRFKHPLVWU\DVGHVFULEHGLQVHFWLRQĮ60$ZDVXVHG
as a marker of activated stellate cells. Photographs are representative of 34 sections each taken 
from 34 patients. Brown staining shows activated stellate cells; vascular smooth muscle also 
SRVLWLYHO\VWDLQHGZLWKĮ60$DURXQGWKHVLQXVRLGDOHGJH 
 
Į60$VWDLQLQJZDVHYLGHQWDURXQGEORRGYHVVHOV LQQRUPDO OLYHU0HDQZKLOH
LQ1$)/'DQG1$6+WKHUHZDVDFOHDULQFUHDVHLQĮ60$VWDLQLQJLQVWellate 
cells. 
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6WHUHRORJ\ FRXQWLQJ ZDV SHUIRUPHG RQ Į60$ VWDLQHG VHFWLRQV DV
shown in Table 3.2.1 below: 
 
Table 3.2.1: 6WHUHRORJ\ FRXQWLQJ RI Į60$ positive hepatic stellate cells in normal liver, 
NAFLD and NASH patients. Data is presented as % of cell/ % total cell volume. 
Groups/ 
Markers 
 Normal liver 
(n = 7) 
NAFLD 
(n = 7) 
NASH 
(n = 20) P value 
 
Į-SMA 
 
22.60 ± 1.71a,b 
 
41.57 ± 3.10a 
 
43.73 ± 2.71b 0.004a; 0.000b 
(a: Normal liver Vs NAFLD; b: Normal liver Vs NASH; c: NAFLD Vs NASH) (n = number of 
patients) Stereology counting was performed as described in method section 2.10. Data are 
presented as mean ± S.E.M. 
 
Į60$ WKH PRVW UHOLDEOH  PDUNHU RI  DFWLYDWHG VWHOODWH FHOO QXPEHU
showed a  significant increase in both steatosis and NASH patients as 
compared to normal liver. 
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Į-SMA immunohistochemistry in Pioglitazone & Placebo treated NASH 
patients 
 
  
                        Pioglitazone                                                                Placebo 
)LJXUH  Į60$ LPPXQRKLVWRFKHPLVWU\ VWDLQLQJ LQ KXPDQ 1$6+ WUHDWHG OLYHU ))3(
sections from human liver biopsies taken from Piogliltazone and placebo treated NASH 
patients were deparaffinised and subjected to single immunohistochemistry as described in 
VHFWLRQ  Į60$ ZDV XVHG DV D PDUNHU RI DFWLYDWHG VWHOODWH FHOOV 3KRWRJUDSKV DUH
representative of 21 sections each taken from 21 patients. Brown staining shows activated 
stellate cells; YDVFXODUVPRRWKPXVFOHDOVRSRVLWLYHO\VWDLQHGZLWKĮ60$DURXQGWKHVLQXVRLGDO
edge. 
 
Į60$VWDLQLQJZDVHYLGHQWDURXQGEORRGYHVVHOVLQ3*=WUHDWHGOLYHU
Meanwhile in placebo treated NASH patients; there was a clear increase in 
Į60$VWDLQLQJLQVWHOODWHFHOOV6WHUHRORJ\FRXQWLQJZDVSHUIRUPHGRQĮ60$
stained sections as shown in Table 3.2.2 below: 
 
Table 3.2.2: 6WHUHRORJ\ FRXQWLQJ RI Į60$ positive hepatic stellate cells in NASH/Pre-trial, 
Pioglitazone and Placebo treated NASH patients. Data is presented as % of cell/ % total cell 
volume. 
Groups/ 
Markers 
NASH/ Pre-trial 
(n = 20) 
Pioglitazone 
(n =9) 
Placebo 
(n = 12) P value 
 
Į-SMA 
 
43.73 ± 2.71a 
 
35.57 ± 2.36a,c 
 
44.97 ± 1.44c 0.034a; 0.006c 
(a: NASH/Pretrial Vs Pioglitazone; b: NASH/Pretrial Vs Placebo; c: Pioglitazone Vs Placebo) 
(n= number of patients) Stereology counting was performed as described in method section 
2.10. Data are presented as mean ± S.E.M. 
 
 
 In the samples taken from the study, Pioglitazone treated patients 
showed a significant reductiRQLQĮ60$SRVLWLYHVWHOODWHFHOOVDVFRPSDUHGWR
pre-trial and placebo groups.  
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3.2.4. CRBP1 immunohistochemistry 
3.2.4.1. CRBP1 immunohistochemistry in normal liver, NAFLD & NASH 
patients 
  
                           Normal liver           NAFLD 
 
                                                                       NASH 
Figure 3.5.1: CRBP1 immunohistochemistry in human liver. FFPE sections from human liver 
biopsies taken from normal liver, NAFLD and NASH patients were deparaffinised and 
subjected to single immunohistochemistry as described in section 3.2.4. CRBP1 was used as a 
marker of total stellate cell number. Photographs are representative of 34 sections each taken 
from 34 patients. Black circles show stellate cells positively staining with CRBP1. Black 
arrows show sinusoidal areas positively staining with CRBP1. 
 
In normal liver, CRBP1 stained stellate cells and around the sinusoidal lining. 
CRBP1 staining was similar in terms of indicating total cell number in the 
sample groups. Stereology counting was performed on CRBP1 stained sections 
as shown in Table 3.3.1 below: 
Table 3.3.1: Stereology counting of CRBP1 positive hepatic stellate cells in normal liver, 
NAFLD and NASH patients. Data is presented as % of cell/ % total cell volume. 
Groups/ 
Markers 
 Normal liver 
(n = 7) 
NAFLD 
(n = 7) 
NASH 
(n = 20) P value 
 
CRBP1 
 
45.70 ± 3.21 
 
48.74 ± 2.63 
 
52.17 ± 1.95 NS 
(a: Normal liver Vs NAFLD; b: Normal liver Vs NASH; c: NAFLD Vs NASH) (n = number of 
patients) Stereology counting was performed as described in method section 2.10. Data are 
presented as mean ± S.E.M. 
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3.2.4.2. CRBP1 immunohistochemistry in Pioglitazone & Placebo treated 
NASH patients 
 
  
                   Pioglitazone        Placebo 
 
Figure 3.5.2: CRBP1 immunohistochemistry in human NASH treated liver. FFPE sections 
from human liver biopsies taken from Pioglitazone and placebo treated patients were 
deparaffinised and subjected to single immunohistochemistry as described in section 3.2.4. 
CRBP1 was used as a marker of total stellate cell number. Photographs are representative of 21 
sections each taken from 21 patients. Black circles show stellate cells positively staining with 
CRBP1. Black arrows show sinusoidal areas positively staining with CRBP1. 
 
Stereology counting was performed on CRBP1 stained sections as shown in 
Table 3.3.2 below: 
Table 3.3.2: Stereology counting of CRBP1 positive hepatic stellate cells in NASH/Pre-trial, 
Pioglitazone and Placebo treated NASH patients. Data is presented as % of cell/ % total cell 
volume. 
Groups/ 
Markers 
NASH/ Pre-trial 
(n = 20) 
Pioglitazone 
(n =9) 
Placebo 
(n = 12) P value 
 
CRBP1 
 
52.17 ± 1.95 
 
46.78 ± 2.51c 
 
53.75 ± 2.93c 0.075c 
(a: NASH/Pretrial Vs Pioglitazone; b: NASH/Pretrial Vs Placebo; c: Pioglitazone Vs Placebo) 
(n= number of patients) Stereology counting was performed as described in method section 
2.10. Data are presented as mean ± S.E.M. 
 
 
 In the samples taken from the study, Pioglitazone treated patients 
showed a reduction in CRBP1 positive stellate cells as compared to placebo 
group with a trend.  
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3.3. Quiescent stellate cells markers 
The data presented thus far indicate that CRBP1 is a marker for stellate 
cells regardless of activation state. It was considered desirable to attempt to 
quantify quiescent stellate cell number in order to compare with the activated 
and total cell numbers. There are several other markers of stellate cells that 
have been described. Desmin (Geerts et al., 2001) and GFAP (Gard & Dutton, 
1985) have been described as marker of quiescent stellate cells in animal 
PRGHOV 1XFOHDU UHFHSWRU 33$5Ȗ SOD\V D UROH LQ PDLQWDLQLQJ WKH TXLHVFHQW
phenotype of stellate cells and expression of PPARJ has been reported to 
decrease markedly upon stellate cell activation. (She et al., 2005), and 
3LRJOLWD]RQH LV DQ DJRQLVW RI 33$5Ȗ <NL-Jarvinen, 2004). Therefore 
DQWLERGLHV WR 'HVPLQ *)$3 DQG 33$5Ȗ ZHUH XVHG LQ DWWHPSW WR LGHQWLI\
quiescent, adipogenic stellate cells. 
 
3.3.1. Desmin immunohistochemistry 
 
Adenocarcinoma (Control tissue) 
      
                               Normal liver                                                       NASH   
Figure 3.6: Desmin immunohistochemistry in human liver. FFPE sections from human liver 
biopsies taken from normal liver and NASH patients were deparaffinised and subjected to 
single immunohistochemistry as described in section 3.3.1. Desmin was assessed as a marker 
of quiescent stellate cells. Photographs are representative of 55 sections each taken from 55 
patients. Red arrows show cells positively desmin stained on the control tissue. Black arrows 
show non-specific lipofuscan, which is a yellow-brown pigment granule. 
  
No evidence of Desmin staining suggested that human hepatic stellate cells 
may differ in their expression of quiescent markers as compared to rodents.  
 
 52 
 
3.3.2. GFAP immunohistochemistry (Z0334, DAKO) 
 
 
Brain Cortex  
Control Tissue 
   
         Normal Liver                NASH   
 
   
                                      Normal Liver                NASH   
 
Figure 3.7: GFAP immunohistochemistry in human liver using antibody from DAKO. FFPE 
sections from human liver biopsies taken from normal liver and NASH patients were 
deparaffinised and subjected to single immunohistochemistry as described in section 3.3.2. 
GFAP has been described as an early marker of stellate cell activation. Photographs are 
representative of 55 sections each taken from 55 patients. Red arrows show astrocytes 
positively stained with GFAP. No expression was observed in study samples with GFAP 
(1:4000) antibody dilution as shown in normal liver (A) and NASH (B) patients. The staining 
was repeated with this antibody using a 1:100 dilution as shown in normal liver (C) and NASH 
(D) patients. 
 
 GFAP expression is not detected in human liver when immunostained 
using Z0334 from DAKO using neither a 1:4000 nor 1:100 dilution. Carotti et 
al. (2008) reported that GFAP was expressed in human hepatitis C patients, 
particularly staining the hepatic stellate cells. Therefore, the GFAP 
immunostaining was repeated again in this study using an alternative antibody 
as described. 
 
 
 
 
A B 
C D 
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3.3.3. GFAP immunohistochemistry (GA-5, Thermo Scientific) 
3.3.3.1. GFAP immunohistochemistry in normal liver, NAFLD & NASH patients 
 
                 
                      Brain Cortex (Control tissue)       Acute hepatitis C patient (Carotti et al (2008) 
   
                   Normal liver      NAFLD 
  
 NASH 
Figure 3.8.1: GFAP immunohistochemistry in human liver using antibody from Thermo 
Scientific. FFPE sections from human liver biopsies taken from control tissue, normal liver, 
NAFLD and NASH were deparaffinised and subjected to single immunohistochemistry as 
described in section 3.3.3. Photographs are representative of 34 sections each taken from 34 
patients. Red arrows show both astrocytes and stellate cells positively stained with GFAP.  
 
The GFAP antibody stained HSCs and vascular smooth muscle tissue 
throughout the study group.  
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Stereology counting was performed for stellate cells that are positively stained 
with GFAP as shown in Table 3.4.1 below: 
 
Table 3.4.1: Stereology counting of GFAP positive hepatic stellate cells in normal liver, 
NAFLD and NASH patients. Data is presented as % of cell/ % total cell volume. 
Groups/ 
Markers 
 Normal liver 
(n = 7) 
NAFLD 
(n = 7) 
NASH 
(n = 20) P value 
 
GFAP 
 
46.06 ± 2.82b 
 
43.58 ± 2.47c 
 
53.91 ± 1.02b,c 
0.003b;  
0.000c 
(a: Normal liver Vs NAFLD; b: Normal liver Vs NASH; c: NAFLD Vs NASH) (n = number of 
patients) Stereology counting was performed as described in methods section 2.10. Data are 
presented as mean ± S.E.M. 
 
GFAP expression in stellate cells was increased significantly in NASH patients 
as compared to normal liver and steatosis. 
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3.3.3.2. GFAP immunohistochemistry in Pioglitazone & Placebo treated NASH 
patients 
 
     
                             Pioglitazone                                                             Placebo  
   
Figure 3.8.2: GFAP immunohistochemistry in human NASH treated liver using antibody from 
Thermo Scientific. FFPE sections from human liver biopsies taken from Pioglitazone and 
placebo treated NASH patients were deparaffinised and subjected to single 
immunohistochemistry as described in section 3.3.3. Photographs are representative of 21 
sections each taken from 21 patients. Red arrows show both astrocytes and stellate cells 
positively stained with GFAP.  
 
The GFAP antibody stained HSCs and vascular smooth muscle tissue. 
Stereology counting was performed for stellate cells that are positively stained 
with GFAP as shown in Table 3.4.2 below: 
 
Table 3.4.2: Stereology counting of GFAP positive hepatic stellate cells in NASH/Pre-trial, 
Pioglitazone and Placebo treated patients. Data is presented as % of cell/ % total cell volume. 
Groups/ 
Markers 
NASH 
(n = 20) 
Pioglitazone 
(n =9) 
Placebo 
(n = 12) P value 
 
GFAP 
 
53.91 ± 1.02 
 
50.42 ± 3.18 
 
53.14 ± 2.11 NS 
(a: NASH/Pretrial Vs Pioglitazone; b: NASH/Pretrial Vs Placebo; c: Pioglitazone Vs Placebo) 
(n = number of patients) Stereology counting was performed as described in methods section 
2.10. Data are presented as mean ± S.E.M. 
 
GFAP expression did not show any significant difference throughout the study 
groups as shown above. 
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3.3.433$5ȖLPPXQRKLVWRFKHPLVWU\ 
 
 
Colon tissue (Control tissue) 
  
          Normal liver       NASH 
Figure 3.9: PPAR Ȗ LPPXQRKLVWRFKHPLVWU\ LQKXPDQ OLYHU))3(VHFWLRQV IURPKXPDQ OLYHU
biopsies taken from normal liver, NASH patients and control tissue were deparaffinised and 
subjected to single immunohistochemistry as described in section 3.3.4. PPAR ȖLVDPDUNHURI
quiescent stellate cells. Photographs are representative of 7 sections each taken from 7 patients. 
White arrows show colonic epithelial cells positively stained with PPAR Ȗ%OXHDUURZVVKRZ
back ground staining and lipofuscan in human normal liver and NASH patients.  
 
No evidence of PPAR ȖH[SUHVVLRQZDVREVHUYHGLQKXPDQOLYHUZKLFK
was surprising given the clear positive staining seen in the control colonic 
epithelial tissue. Hepatic stellate cells are known to express PPAR Ȗ6KHHWDO
2005), thus it is unclear why this antibody stained the colonic epithelial cells 
but not the stellate cells. There is very little immunohistochemistry data for 
PPAR ȖLQWKHOLWHUDWXUHZLWKYHU\IHZRIWKHFRPPHUFLDOO\DYDLODEOHDQWLERGLHV
having been shown to be compatible with immunohistochemistry as distinct 
from western blotting (Wang & Cheng, 2008). PPAR ȖSURWHLQH[SUHVVLRQ LQ
stellate cells was not determined in this study group. 
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3.4.Nuclear receptors 
PPAR ȕ ZDV UHSRUWHG WR EH LQYROYHG LQ VWHOODWH FHOO SUROLIHUDWLRQ DQG
activation (Hellemans et al., 2003). When the stellate cells become activated, 
PPAR Ȗ H[SUHVVLRQ LV GLPLQLVKHG IROOowed by an increase in PPAR ȕ
expression (She et al., 2005; Hellemans et al., 2003). PPARE is also highly 
expressed in hepatocytes. PPAR Į PRGXODWHV WKH DFWLYLWLHV RI PLWRFKRQGULDO
DQGSHUR[LVRPDOȕ-R[LGDWLRQDVZHOODVPLFURVRPDOȦ-oxidation, and thus plays 
a key role in energy expenditure in hepatocytes but is not described as being 
expressed in stellate cells (Pyper et al., 2010). 
 
33$5ȕLPPXQRKLVWRFKHPLVWU\ 
 33$5 ȕ LPPXQRKLVWRFKHPLVWU\ LQ QRUPDO OLYHU 1$)/' 	 1$6+
patients 
  
     Normal liver       NAFLD 
 
                                                                       NASH 
)LJXUH33$5ȕLPPXQRKLVWRFKHPLVWU\LQKXPDQ liver. FFPE sections from human liver 
biopsies taken from normal liver, NAFLD and NASH patients were deparaffinised and 
subjected to single immunohistochemistry as described in section 3.4. 33$5ȕLVDPDUNHURI
stellate cells activation and proliferation. Photographs are representative of 34 sections each 
taken from 34 patients. Red arrows show hepatocytes and red circles show HSCs positively 
VWDLQHGZLWK33$5ȕ 
 
,Q QRUPDO OLYHU 33$5 ȕ H[SUHVVLRQ ZDV VHHQ LQ KHSDWRF\WHV DQG
stellate cells, meanwhile in steatosis and NASH expression in hepatic stellate 
cells was clearly more evident.  
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Stereology counting was performed on PPAR ȕVWDLQHGFHOOVDVVKRZQ
in Table 3.5.1 below: 
Table 3.5.1: Stereology counting of hepatic stellate cells and hepatocytes positively stained 
with PPAR E in normal liver, NAFLD and NASH patients. Data is presented as % of cell/ % 
total cell volume. 
Groups/ 
Markers 
 Normal liver 
(n = 7) 
NAFLD 
(n = 7) 
NASH 
(n = 20) P value 
33$5ȕ
Hepatocytes 
 
18.01 ± 2.22 
 
13.08 ± 1.41 
 
15.77 ± 1.44 NS 
 
33$5ȕ+6&V 
 
15.46 ± 3.14b 
 
28.18 ± 1.26c 
 
15.40 ± 1.65b,c 0.003b; 0.000c 
(a: Normal liver Vs NAFLD; b: Normal liver Vs NASH; c: NAFLD Vs NASH) (n = number of 
patients) Stereology counting was performed as described in methods section 2.10. Data are 
presented as mean ± S.E.M. 
 
PPAR ȕH[SUHVVLRQZDVHOHYDWHGLQ WKHVWHOODWHFHOOVRI WKHVWHDWRVLVJURXSDV
compared to others. 
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33$5ȕLPPXQRKLVWRFKHPLVWU\LQ3LRJOLWD]RQH	3ODFHERWUHDWHG1$6+
patients 
 
    
             Pioglitazone      Placebo 
Figure 3.10.2: PPAR ȕ LPPXQRKLVWRFKHPLVWU\ LQ KXPDQ 1$6+ WUHDWHG OLYHU))3( VHFWLRQV
from human liver biopsies taken from Pioglitazone and placebo treated NASH patients were 
deparaffinised and subjected to single immunohistochemistry as described in section 3.4. 
33$5ȕLVDPDUNHURIVWHOODWHFHOOVDFWLYDWLRQDQGSUROLIHUDWLRQ3KRWRJUDSKVDUHUHSUHVHQWDWLYH
of 21 sections each taken from 21 patients. Red arrows show hepatocytes and red circles show 
+6&VSRVLWLYHO\VWDLQHGZLWK33$5ȕ 
 
6WHUHRORJ\FRXQWLQJZDVSHUIRUPHGRQERWK33$5ȕVWDLQHGFHOOVDVVKRZQLQ
Table 3.5.2 below: 
 
Table 3.5.2: Stereology counting of hepatic stellate cells and hepatocytes positively stained 
with PPAR E in NASH/Pre-trial, Pioglitazone and Placebo treated NASH patients. Data is 
presented as % of cell/ % total cell volume. 
Groups/ 
Markers 
NASH 
(n = 20) 
Pioglitazone 
(n =9) 
Placebo 
(n = 12) P value 
33$5ȕ 
Hepatocytes 
 
15.77 ± 1.44b 
 
15.90 ± 2.06c 
 
8.94 ± 0.96b,c 
0.001b ; 
0.010c 
 
PPAR ȕ HSCs 
 
15.40 ± 1.65 
 
11.81 ± 1.46c 
 
15.54 ± 2.62c 0.075c 
(a: NASH/Pretrial Vs Pioglitazone; b: NASH/Pretrial Vs Placebo; c: Pioglitazone Vs Placebo) 
(n = number of patients) Stereology counting was performed as described in methods section 
2.10. Data are presented as mean ± S.E.M. 
 
 33$5ȕKHSDWRF\WHVH[SUHVVLRQZDVGHFUHDVHGVLJQLILFDQWO\LQSODFHER
treated group compared to Pre-trial and Pioglitazone group. Pioglitazone 
treated patients showed a reduction in PPAR ȕ+6&VH[SUHVVLRQZLWKDWUHQG
compared to placebo treated group.  
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33$5ĮLPPXQRKLVWRFKHPLVWU\ 
Potential effects of Pioglitazone acting via PPAR Į ZKHUH LW KDV EHHQ
described as being a weak agonist of PPAR ĮSakamoto et al., 2000) make 
this an important target to study. 
 33$5 Į LPPXQRKLVWRFKHPLVWU\ LQ QRUPDO OLYHU 1$)/' 	 1$6+
patients 
  
                     Normal liver          NAFLD 
 
     NASH  
)LJXUH33$5ĮLPPXQRKLVWRFKHPLVWU\LQKXPDQOLYHU))3(VHFWLRQVIURPKXPDQOLYHU
biopsies taken from normal liver, NAFLD and NASH patients were deparaffinised and 
subjected to single immunohistochemistry as described in section 3.4.2. Photographs are 
representative of 34 sections each taken from 34 patients. Red arrows show hepatocytes 
SRVLWLYHO\VWDLQHGZLWK33$5Į 
 
33$5ĮH[SUHVVLRQZDVRQO\IRXQGLQKHSDWRF\WHVDVH[SHFWHG 
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Stereology counting was performed on PPAR ĮVWDLQHGFHOOVDVVKRZQLQ7DEOH
3.6.1 below: 
 
Table 3.6.1: Stereology counting of hepatocytes positively stained with PPAR D in normal 
liver, NAFLD and NASH patients. Data is presented as % of cell/ % total cell volume. 
Groups/ 
Markers 
 Normal liver 
(n = 7) 
NAFLD 
(n = 7) 
NASH 
(n = 20) P value 
33$5Į 
Hepatocytes 
 
18.86 ± 2.22 
 
17.11 ± 2.01 
 
21.17 ± 2.07 NS 
(a: Normal liver Vs NAFLD; b: Normal liver Vs NASH; c: NAFLD Vs NASH) (n = number of 
patients) Stereology counting was performed as described in methods section 2.10. Data are 
presented as mean ± S.E.M. 
 
1RVLJQLILFDQWGLIIHUHQFHZDVREVHUYHGLQ33$5ĮH[SUHVVLRQWKURXJKRXWWKH
study group. 
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33$5ĮLPPXQRKLVWRFKHPLVWU\LQ3LRJOLWD]RQH	3ODFHERWUHDWHG
NASH patients 
   
  Pioglitazone     Placebo 
Figure 3.11.2: PPAR Į LPPXQRKLVWRFKHPLVWU\ LQ KXPDQ1$6+ WUHDWHG OLYHU))3( VHFWLRQV
from human liver biopsies taken from Pioglitazone and placebo treated NASH patients were 
deparaffinised and subjected to single immunohistochemistry as described in section 3.4.2. 
Photographs are representative of 21 sections each taken from 21 patients. Red arrows show 
KHSDWRF\WHVSRVLWLYHO\VWDLQHGZLWK33$5Į 
 
StereolRJ\FRXQWLQJZDVSHUIRUPHGRQ33$5ĮVWDLQHGFHOOVDVVKRZQLQ7DEOH
3.6.2 below: 
 
Table 3.6.2: Stereology counting of hepatocytes positively stained with PPAR D in NASH/Pre-
trial, Pioglitazone and Placebo treated NASH patients. Data is presented as % of cell/ % total 
cell volume. 
Groups/ 
Markers 
NASH 
(n = 20) 
Pioglitazone 
(n =9) 
Placebo 
(n = 12) P value 
PPAR Į 
Hepatocytes 
 
21.17 ± 2.07a 
 
13.53 ± 1.47a , c 
 
22.26 ± 1.70c 
0.020a ; 
0.012c 
(a: NASH/Pretrial Vs Pioglitazone; b: NASH/Pretrial Vs Placebo; c: Pioglitazone Vs Placebo) 
(n = number of patients) Stereology counting was performed as described in methods section 
2.10. Data are presented as mean ± S.E.M. 
 
PPAR ĮH[SUHVVLRQZDVGHFUHDVHGVLJQLILFDQWO\ZLWK3*=WUHDWPHQWFRPSDUHG
to placebo and pre-trial group. 
 
 
 
 
 
 
 
 
 
 
 63 
 
3.5. Apoptotic and cell proliferation markers 
3LRJOLWD]RQH UHGXFHG WKH QXPEHU RI Į60$ DQG 33$5 ȕ SRVLWLYH +6&V
suggesting that the activated stellate cell number and cell proliferation are 
reduced. Markers of apoptosis and cell proliferation were studied to determine 
the fate of the stellate cell. Caspase 3, M30 and TUNEL assay were used as 
markers of apoptosis and Ki67 was used as a marker for cell proliferation. 
 
3.5.1. Caspase 3 immunohistochemistry 
 
              
                         Tonsil carcinoma                        Normal liver 
                                 Control tissue 
              
                                      NASH                                                Pioglitazone                                        
 
Figure 3.12: Caspase 3 immunohistochemistry in human liver. FFPE sections from human liver 
biopsies taken from normal liver, NASH, Pioglitazone treated NASH patients were 
deparaffinised and subjected to single immunohistochemistry as described in section 3.5.1. 
Caspase 3 is a marker of apoptosis. Photographs are representative of 55 sections each taken 
from 55 patients. Red arrows show cells positively stained with Caspase 3. 
 
Caspase 3 expressions were diffused and granulated in all samples 
tested, and was difficult to distinguish from lipofuscan in the liver samples. 
Therefore, TUNEL assay was used to determine apoptotic cell numbers. 
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3.5.2. TUNEL assay immunoflourescence 
        
  
                            Tonsil carcinoma                                           Normal liver                                                    
                               Control tissue 
 
   
        NAFLD                       NASH 
 
Figure 3.13: TUNEL assay immunoflourescence in human liver. FFPE sections from human 
liver biopsies taken from normal liver, NAFLD and NASH patients were deparaffinised and 
subjected to single immunoflourescence as described in section 3.5.2. TUNEL assay is a 
marker of apoptosis. Photographs are representative of 55 sections each taken from 55 patients. 
Yellow arrows show cells positively stained with TUNEL assay.  
 
 TUNEL assay immunoflourescence was evident in the positive control 
tissue as well as in the study group samples. Very little staining was evident in 
normal liver sections. It was not possible to identify the cell type by TUNEL 
assay immunoflourescence. Thus, as it was desirable to determine the level of 
apoptosis in stellate cells and hepatocytes separately, immunohistochemical 
analysis was attempted. 
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3.5.3. TUNEL assay immunohistochemistry 
 
  
       NASH treated with DNAse                               Normal liver 
               (Control Tissue) 
  
          NAFLD                                    NASH 
 
   
        Pioglitazone        Placebo 
 
Figure 3.14: TUNEL assay immunohistochemistry in human liver. FFPE sections from human 
liver biopsies taken from normal liver, NAFLD, NASH, Pioglitazone and placebo treated 
NASH patients were deparaffinised and subjected to single immunohistochemistry as 
described in section 3.5.3. Photographs are representative of 55 sections each taken from 55 
patients. Red circles show positive cells stained with TUNEL assay.  
 
NASH liver sections treated with DNAse were used as the control 
tissue as described in method section 2.8.2. TUNEL assay showed apoptotic 
cells, clearly identifiable as stellate cells by their morphology. Apoptotic 
epithelial cells were not evident using the TUNEL assay; therefore 
Cytokeratin-18 (M30), which has been reported to be a reproducible and 
specific marker of epithelial cell apoptosis was assayed to determine the 
number of apoptotic epithelial cell particularly in hepatocytes.  
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3.5.4. Cytokeratin-18 (M30) immunohistochemistry 
 
  
                 Normal Colon (Control tissue)                Normal liver 
             
                                  NAFLD                                                      NASH  
                    
                                 Pioglitazone                                                Placebo 
 
Figure 3.15: M30 immunohistochemistry in human liver. FFPE sections from human liver 
biopsies taken from normal liver, NAFLD, NASH, Pioglitazone and placebo treated NASH 
patients were deparaffinised and subjected to single immunohistochemistry as described in 
section 3.5.4. M30 is a marker of epithelial cell apoptosis. Photographs are representative of 55 
sections each taken from 55 patients. Red arrows show hepatocytes positively stained with 
M30. 
 
 M30 expression was evident in both control and the study samples. 
Hepatocyte M30 expression was clearly elevated in steatosis as compared to 
other groups.  
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Stereology counting was performed on both M30 and TUNEL assay stained as 
shown in Table 3.7.1 and Table 3.7.2 below: 
Table 3.7.1: Stereology counting of hepatic stellate cell and hepatocyte apoptosis markers in 
normal liver, NAFLD and NASH patients. Data is presented as % of cell/ % total cell volume. 
Groups/ 
Markers 
 Normal liver 
(n = 7) 
NAFLD 
(n = 7) 
NASH 
(n = 20) P value 
 
M30 
 
1.73 ± 0.50 
 
4.01 ± 1.64 
 
2.38 ± 0.47 NS 
 
TUNEL 
 
16.96 ± 4.78 
 
22.17 ± 8.33 
 
27.85 ± 2.41 NS 
(a: Normal liver Vs NAFLD; b: Normal liver Vs NASH; c: NAFLD Vs NASH) (n = number of 
patients) Stereology counting was performed as described in method section 2.10. Data are 
presented as mean ± S.E.M. 
 
Table 3.7.2: Stereology counting of hepatic stellate cell and hepatocyte apoptosis markers in 
NASH/Pre-trial, Pioglitazone and Placebo treated NASH patients. Data is presented as % of 
cell/ % total cell volume. 
Groups/ 
Markers 
NASH 
(n = 20) 
Pioglitazone 
(n =9) 
Placebo 
(n = 12) P value 
 
M30 
 
2.38 ± 0.47 
 
1.84 ± 0.22 
 
1.94 ± 0.52 NS 
 
TUNEL 
 
27.85 ± 2.41 
 
24.32 ± 4.03 
 
31.05 ± 3.13 NS 
(a: NASH/Pretrial Vs Pioglitazone; b: NASH/Pretrial Vs Placebo; c: Pioglitazone Vs Placebo) 
(n = number of patients) Stereology counting was performed as described in method section 
2.10. Data are presented as mean ± S.E.M. 
 
 No significant differences were observed in terms of apoptotic cell 
number between groups.  
 
3.5.5. Ki67 immunohistochemistry 
 $V VWHOODWH FHOO QXPEHUV DV GHWHUPLQHG E\ *)$3 DQG Į60$ EXW QRW
CRBP1) may increase, a proliferation cell marker was used to determine 
whether stellate cells showed a different rate of proliferation between groups. 
Thus, the rate of cell proliferation was another important parameter to 
investigate using the anti-Ki67 antibody.  
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3.5.5.1. Ki67 immunohistochemistry in normal liver, NAFLD & NASH 
patients 
                         
                                            Control (Colon Tumor) 
  
                                               Normal liver (40X) 
  
                                                 NAFLD (40X) 
   
                                                   NASH (40X) 
Figure 3.16.1: Ki67 immunohistochemistry in human liver. FFPE sections from human liver 
biopsies taken from normal liver, NAFLD and NASH patients were deparaffinised and 
subjected to single immunohistochemistry as described in section 3.5.5. Photographs are 
representative of 19 sections each taken from 19 patients. Red circles show hepatocytes, Blue 
circles show non-parenchemal cells, Black circles show immune cells positively stained with 
positive Ki67. 
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There are 3 types of cells stained in Ki67 immunohistochemistry; 
hepatocytes, non-parenchemal cells and immune cells. Non-parenchemal cells 
were identified by their longitudinal shape while immune cells were identified 
as small round cells. Hepatocytes were identified as double or single nucleated 
cells positively stained with Ki67. All results were independently verified by 
histopathology consultant Dr Philip V. Kaye. 
 
,W¶V QRW SRVVLEOH IRU DOO FDVHV WR GLIIHUHQWLDWH ZKHWKHU .L VWDLQV
kupffer cells, stellate cells or endothelial cells; therefore all the non-
parenchemal cells were included as a single category. Stereology counting was 
performed on Ki67 stained cells as shown in Table 3.8.1 below: 
 
Table 3.8.1: Stereology counting of Ki67 stained cells in normal liver, NAFLD and NASH 
patients. Data is presented as % of cell/ % total cell volume. 
Group Normal liver 
(N=5) 
NAFLD 
(N=6) 
NASH/ Pretrial 
(N=8) 
P value 
% Hepatocyte 11.11 
± 10.62 
23.41 
± 0.15 
16.41 
± 0.15 
 
NS 
% Non-
parenchemal cell 
9.74 
± 13.97 
13.34 
± 0.01 
11.32 
± 0.11 
 
NS 
% Immune  
cell 
2.82 
± 6.30 
7.29 
± 0.12 
9.00 
± 0.08 
 
NS 
% 
Total cell 
23.67 
± 12.42 
44.04 
± 10.50 
36.73 
± 7.38 
 
NS 
(a: Normal liver Vs NAFLD; b: Normal liver Vs NASH; c: NAFLD Vs NASH) (n = number of 
patients) Stereology counting was performed as described in method section 2.10. Data are 
presented as mean ± S.E.M. 
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3.5.5.2. Ki67 immunohistochemistry in Pioglitazone & Placebo treated NASH 
patients 
   
               Pioglitazone treated NASH patients (40X) 
  
                   Placebo treated NASH patients (40X) 
Figure 3.16.2: Ki67 immunohistochemistry in human NASH treated liver. FFPE sections from 
human liver biopsies taken from Pioglitazone and placebo treated NASH patients were 
deparaffinised and subjected to single immunohistochemistry as described in section 3.5.5. 
Photographs are representative of 13 sections each taken from 13 patients. Red circles show 
hepatocytes, Blue circles show non-parenchemal cells, Black circles show immune cells 
positively stained with positive Ki67. 
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Table 3.8.2: Stereology counting of Ki67 stained cells in NASH/Pre-trial, Pioglitazone and 
Placebo treated NASH patients. Data is presented as % of cell/ % total cell volume. 
Group NASH/ 
Pretrial 
(N=8) 
Pioglitazone 
(N=6) 
Placebo 
(N=7) 
P value 
% Hepatocyte 16.41 
± 0.15 
11.44 
± 11.20 
25.15 
± 0.09 
NS 
% Non-
parenchemal cell 
11.32 
± 0.11 
9.21 
± 10.23 
19.37 
± 0.08 
NS 
% Immune 
cell 
9.00 
± 0.08 
7.98 
± 7.82 
13.59 
± 0.12 
NS 
% 
Total cell 
36.73  
± 7.38b 
22.53  
± 7.77c 
58.11  
± 2.95b,c 
0.022b; 
0.002c 
(a: NASH/Pretrial Vs Pioglitazone; b: NASH/Pretrial Vs Placebo; c: Pioglitazone Vs Placebo) 
(N = number of patients) Stereology counting was performed as described in method section 
2.9. Data are presented as mean ± S.E.M. 
 
There were no discernable differences between the cell types examined, but 
Pioglitazone appeared to decrease overall cell proliferation regardless of cell 
type. 
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3.6. Protein expression of PCNA in human liver samples 
Western blotting was used to determine Proliferating cell nuclear antigen 
(PCNA) levels in total liver protein extracts as an alternative marker of cell 
proliferation. 
 
3.6.1. PCNA protein expression in human liver samples 
a.Normal liver (n=7) 
  Beta actin (42 KDa) 
  PCNA (36 KDa) 
      Hela cell  
 
b.NAFLD (n=7) 
  Beta actin (42 KDa) 
  PCNA (36 KDa) 
                  Hela cell 
 
c. NASH/Pretrial (n=8) 
   Beta actin (42kDa) 
   PCNA (36kDa) 
                    Hela cell 
 
d. Pioglitazone treated NASH patients (n=7) 
 Beta actin (42KDa) 
 PCNA (36 KDa) 
       Hela cell 
 
e. Placebo treated NASH patients (n=6) 
 Beta actin (42KDa) 
 PCNA (36KDa) 
                           Hela cell 
Figure 3.17: Beta actin and PCNA protein expressions in normal liver, NAFLD, 
NASH, Pioglitazone and placebo treated NASH patients. (n = number of patients) 
 
PCNA protein expression was studied in parallel with the Ki67 
stereology counting. HeLa cell protein was used as a positive control. 
Densitometry results of PCNA immunoblotting are as shown in Figure 3.18.1 
and 3.18.2 over leaf.  
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3.6.2. PCNA protein expressions quantification 
 
 
Figure 3.18.1: PCNA protein expression in normal liver, NAFLD and NASH. (N= number of 
patients; ** p <0.05; *** S3&1$SURWHLQ H[SUHVVLRQ ZDV QRUPDOLVHG ZLWKȕ-actin. 
Data are presented as mean ± S.E.M. 
 
 
Figure 3.18.2: PCNA protein expression in Pre-trial, Pioglitazone & Placebo treated NASH 
patients. (N= number of patients; ** p <0.05; ***p <0.001). PCNA protein expression was 
QRUPDOLVHGZLWKȕ-actin. Data are presented as mean ± S.E.M. 
 
PCNA expression was higher in steatosis and NASH compared to 
normal liver. PGZ treated patients showed a reduction in PCNA expression as 
compared to pre-trial and placebo groups. 
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3.7. Discussion  
During liver injury, stellate cells lose their vitamin A storing capacity 
and transformed into activated myofibroblast-OLNHFHOOVZKLFKH[SUHVVĮVPRRWK
PXVFOHDFWLQĮ60$)ULHGPDQ7KHVHFHOOVWKHQSURGXFHH[WUDFHOOXODU
matrix (ECM) which can lead to fibrosis followed by cirrhosis (Carroti et al., 
2008; Friedman, 2000) Į60$ LV PDUNHU RI DFWLYDWHG +6&V LQ KXPDQV
(Schmitt-Graff et al.,1991) and in normal liver it can be seen around the 
vascular area of portal tract veins & arteries (Van Rossen et al., 2009). The 
GDWDIURPWKLVVWXG\VKRZHGWKDWĮ60$OHYHOVDUHLQFUHDVHG in both steatosis 
DQG 1$6+ SDWLHQWV FRPSDUHG WR QRUPDO OLYHU DQG Į60$ H[SUHVVLRQ ZDV
reduced significantly by PGZ treatment.  
 
Cellular retinol binding protein 1 (CRBP1) is reported to be a quiescent 
marker for HSCs where it is involved in mediating both retinol esterification to 
retinyl esters and retinol oxidation to retinal and retinoic acid (Blomhoff et al., 
1985). Based on dual immunohistochemistry and double immunoflourescence 
RIĮ-SMA and CRBP1, there was clear co-localization of both markers but also 
some cells only stain with one marker. Since CRBP1 stained both quiescent 
and activated stellate cells, stereology counting of this staining is an indicator 
of total stellate cell number. There were no significant differences in CRBP1 
expression between the groups studied. 
 
Glial fibrillary acidic protein (GFAP) is a neuronal marker that is not 
only expressed in  both astrocytes and non-myelinating Schwann cells (Lim et 
al., 2007), but has also been reported as being expressed in quiescent hepatic 
stellate cells (Buniatian et al., 1996), pancreatic stellate cells (Apte et al., 1998) 
and in kidney podocytes (Buniatian et al., 1998). GFAP expression has been 
shown to increase in acute inflammation but is decreased in chronic 
inflammation in the livers of rats treated with carbon tetrachloride (CCl4) 
(Nikki et al., 1996).  
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 GFAP was found to be expressed in stellate cells, and around the 
vascular portal area. Stereology counting indicated that in NASH patients, 
GFAP expression was increased as compared to normal liver and steatosis. A 
previous study has reported that GFAP is a marker for early injury in the liver, 
where the expression was increased in both recurrent post-transplant hepatitis 
C virus (HCV) and chronic HCV patients and decreased expression was 
observed in cirrhotic-HCV patients (Carroti et al., 2008). In this study, no 
significant differences were observed between PGZ and placebo treated 
patients.  
 
,QFRQFOXVLRQĮ60$H[SUHVVLRQZKLFKGHQRWHVDQ LQFUHDVH LQVWHOODWH
cell activation, is elevated in NAFLD and NASH, and is reduced following 
pioglitazone treatment. Whether the increased in GFAP expression is a marker 
of liver injury and its significance in terms of stellate cell phenotype is not 
clear. Using dual immunoflourescence for CRPB1 and GFAP and also a-SMA 
and GFAP would be informative in terms of understanding the sub-population 
of stellate cells that express GFAP. CRBP1 expression data suggest no change 
in overall number of stellate cells during the progression from normal liver to 
NAFLD and NASH.   
 
Peroxisome proliferator activated receptors (PPARs) are nuclear 
receptors of which there are three isotypes: PPAR-Į ȕ DQG Ȗ 33$5 Į LV
highly expressed in hepatocytes and plays a major role in lipid metabolism 
(Peters et al., 2005). Meanwhile PPAR ȖUHJXODWHVDGLSRJHQHVLVDQGLWLVKLJKO\
expressed in adipose tissue (Tontonoz et al., 1994). PPAR ȕ LV H[SUHVVHG in 
many cell types  is an important regulator of high density lipoprotein (HDL) 
cholesterol level, skeletal muscle fatty acid catabolism and glucose 
homeostasis (Leibowitz et al., 2000; Oliver et al., 2001; Grimaldi et al., 2005; 
Lee et al., 2006), but the role of PPAR ȕLQOLYHULVQRWFOHDU 
 
PPAR ȕH[SUHVVLRQZDVREVHUYHGLQERWKKHSDWRF\WHVDQGVWHOODWHFHOOV
In NAFLD, PPAR ȕ H[SUHVVLRQ ZDV LQFUHDVHG VLJQLILFDQWO\ LQ VWHOODWH FHOOV
meanwhile in placebo treated patient, hepatocytes PPAR ȕ H[SUHVVLRQ ZDV
reduced significantly as compared to both pre-trial and PGZ treated patients. 
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PPAR ȕ LV D PDUNHU RI DFWLYDWHG DQG RU SUROLIHUDWLRQ VWHOODWH FHOOV ,W
was highest in NAFLD, with no further increased in NASH. The number of 
cells stained far less than other markers incluGLQJ Į60$ VXJJHVWV WKDW      
PPAR ȕH[SUHVVHGLQDVXE-SRSXODWLRQRIVWHOODWHFHOO33$5ȖH[SUHVVLRQFRXOG
not be detected using the available antibodies in the liver. A previous study 
suggests that upon activation PPAR Ȗ H[SUHVVLRQ LV GHFUHDVHG 6KH HW al., 
2005), and PPAR ȕ H[SUHVVLRQ LV VXEVHTXHQWO\ LQFUHDVHG LQ VWHOODWH FHOOV LQ
culture (Hellemans et al., 2003) but we are unable to confirm this in vivo due to 
the inability to detect PPAR Jat the protein level. PPARs are generally seen as 
anti-proliferative (Gizard et al., 2005; Harman et al., 2004; Han et al., 2007) 
and anti-inflammatory (Michalik & Wahli, 2006) EXW WKH ȕ LVRW\SH KDV EHHQ
implicated in the proliferative phase of wound healing via interaction with the 
TGFE/SMAD pathway (Michalik & Wahli, 2006). The role of PPAR ȕ LQ
stellate cells should still be a matter for debate.  
 
 M30 or cytokeratin-18 (CK-18) is a marker of hepatocyte cell death and 
is a marker of early apoptosis caspase activity. Furthermore, plasma CK-18 
levels were higher in NASH patients when compared to NAFLD (Feldstein et 
al., 2009). TUNEL assay is an alternative of measuring the levels of apoptosis 
is cells or tissues where DNA defragmentation occurs and apoptotic bodies are 
stained. Feldstein et al. (2003) reported that, using the TUNEL assay, in 
conjunction with caspase 3 and 7 staining, hepatocyte apoptosis was greater in 
NASH as compared to simple steatosis. Indeed, increased apoptosis in NASH 
has been widely reported. In this current study, both M30 and TUNEL 
stereology counting did not reveal any significant difference between the 
groups examined. The reason for the differences observed in terms of apoptosis 
between this and previous studies is difficult to ascertain. Both M30 and 
TUNEL assays in this study indicated higher levels of apoptosis in NAFLD 
and NASH patients as compared to histologically normal control tissue, but the 
data failed to reach significance. It is possible that either a lack of sensitivity 
and/or background levels of staining masked the differences in apoptotic cell 
number in this study. 
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Ki67 is a marker of cell proliferation which is widely used for cancer 
prognosis (Scholzen and Gerdes, 2000). Ki67 is expressed in G1, S, G2 and M 
phases but not during G0 phase of the cell cycle (Gerdes et al., 1991; 
Bullwinkle et al., 2006). PCNA is another marker widely used in the analysis 
of proliferation in normal and neoplastic tissue (Demeter at al., 1994). It is 
expressed in the nucleus of cells during DNA synthesis (Essers et al., 2005) 
and is expressed during G0, G1, and further induced in S phase of the cell cycle 
(Celis et al., 1987). 
 
The current study showed that PGZ decreased both hepatic PCNA and 
Ki67 expression compared to pre-trial and placebo treated groups. For Ki67 no 
changes in proliferation of a particular cell type were observed, thus it is 
unclear whether PGZ influences hepatocyte, immune cell or non-parenchymal 
cell proliferation or whether all cell types are equally affected. PGZ has 
previously been shown to reduce cell proliferation in partial hepatectomy rat 
(Yamamoto et al., 2008) as well as in cancer (Takano et al., 2008). The 
relationship between the effect of PGZ upon cell proliferation and the 
beneficial therapeutic effect seen in NASH patients is not clear. If PGZ inhibits 
stellate cell proliferation then it is possible that this may be influential in 
reducing fibrosis, but this effect would be hard to dissect out from the potential 
anti-inflammatory actions of PGZ. 
 
Overall these data suggest that PGZ exerts its effects at least in part by 
reducing the numbers of activated stellate cells in the livers of NASH patients. 
It is also possible that inhibition of stellate cell proliferation is also a beneficial 
effect of PGZ therapy. Whether these effects are mediated via changes in 
whole body metabolism or are due to the direct action of PGZ upon stellate 
cells is a matter for conjecture. 
 
 
. 
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CHAPTER 4 
Gene Expression in human liver: Assessment of the effects of Pioglitazone 
therapy in NASH patients. 
 
4.1. Taqman RT-PCR Principle and gene expression analysis 
 RNA samples from liver biopsies were analyzed using the Agilent 
Bioanalyser 2100 to determine the RNA integrity and RNA integrity number 
(RIN). Some of these samples partially degraded with sample having RIN 
YDOXH RI  7DTPDQ Real-time Polymerase chain reaction (RT-PCR) was 
used to quantify the gene expression in this study. Taqman RT-PCR is an 
absolute quantitation method that generates copy numbers for each test sample 
by relating test sample cycle threshold (Ct) values, back to a standard curve of 
Ct values based on a dilution series of cDNA samples containing the target 
species of interest (Hughes & Moody, 2007). 
 
 TaqMan probes are hydrolysis probes that are designed to increase the 
specificity of real-time PCR assays. TaqMan probes consist of a fluorophore 
covalently DWWDFKHGWRWKH¶-end of the oligonucleotide probe and a quencher 
DW WKH ¶-end (Figure 4.1). TaqMan probe annealed within a DNA region 
amplified by a specific set of primers. As the Taq polymerase extends the 
primer and synthesizes the nascent strand, the 5' to 3' exonuclease activity of 
the polymerase degrades the probe that has annealed to the template. 
Degradation of the probe releases the fluorophore from it and breaks the close 
proximity to the quencher, thus relieving the quenching effect and allowing 
fluorescence of the fluorophore. The quencher molecule quenches the 
fluorescence emitted by the reporter (fluorophoreZKHQH[FLWHGE\WKHF\FOHU¶V
light source via FRET (Fluorescence Resonance Energy Transfer). As long as 
the reporter (fluorophore) and the quencher are in proximity, quenching 
inhibits any fluorescence signals (Figure 4.1). (Applied Biosystem) 
 
 Hence, fluorescence detected in the real-time PCR thermal cycler is 
directly proportional to the fluorophore released and the amount of DNA 
template present in the PCR and displayed as an amplification plot (Figure 
4.2). (Applied Biosystem) 
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Figure 4.1: Taqman Probe chemistry mechanism (Applied Biosystem) 
 
Figure 4.2: Amplification curve of Taqman Real-time PCR. (Applied Biosystem) 
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The referHQFHJHQHȕ-actin) was studied first using Taqman Real-time 
PCR to asses whether or not these samples were of sufficient quality to 
produce reliable gene expression data for the analysis. The Taqman Real-time 
PCR slope should be within the range (-3.2 to -3.6) and correlation coefficient 
(r2) also should be from 0.95 to 0.99 (Hughes & Moody, 2007) as shown in 
Figure 4.3 below: 
B E T A  A C T IN  S T D  c u r v e
0
1 0
2 0
3 0
4 0
-2 .5 - 1 .5 - 0 .5
log Quantity
C
t
 V
a
lu
e
 
slope -3.430398149 
intercept 23.81719783 
r2 -0.989169953 
 
Figure 4.3 Taqman Real-WLPH 3&5 RI UHIHUHQFH JHQH ȕ-actin) gene expression 
standard curve using serial dilution of human liver cDNA. 
 
 The reference gene expression results were acceptable for all samples. 
Target gene expression of genes involved in carbohydrate and lipid metabolism 
gene were studied initially. Target gene expression was normalised using the 
JHRPHWULFPHDQRIUHIHUHQFHJHQHV>ȕ-actin & hydroxymethylbilane synthase 
(HMBS)] and the results are shown in Table 4.1. 
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Results  
4.2. Taqman Real-time PCR gene expression in Pre-trial, Pioglitazone and 
placebo treated NASH patients. 
 
Table 4.1: Effects of 12 months of Pioglitazone treatment on gene expression 
in NASH patients. 
Target gene Pre-trial 
(n = 22) 
Pioglitazone 
(n = 12) 
Placebo 
(n = 12) 
P VALUE 
ChREBP 2.156 
± 0.435 B 
3.971 
± 1.049 B 
2.117 
± 0.520 
0.049 B 
SREBP1C 1.478 
± 0.258 A 
2.150 
± 0.610 C 
0.310 
± 0.062 A,C 
0.022 A 
0.002 C 
CPT1 0.492 
± 0.156 
0.793 
± 0.275 
0.476 
± 0.136 
NS 
PDK4 1.679 
± 0.369 
2.137 
± 0.481 
0.842 
± 0.295 
NS 
PK2 1.549 
± 0.363 
1.317 
± 0.377  
1.227 
± 0.337  
NS 
GCK 0.658 
± 0.284 
0.794 
± 0.374 
1.401 
± 0.725 
NS 
Gene expression values are normalised using the geometric mean of the reference genes  
>ȕ- actin and HMBS]. Data are presented as mean ± SEM. Carbohydrate regulatory element 
binding protein (ChREBP), Sterol regulatory element binding protein-1C (SREBP-1C), 
Carnitine palmitoyl transferase-1 (CPT-1), Pyruvate dehydrogenase kinase 4 (PDK4), Pyruvate 
kinase 2 (PK2) and Glucokinase (GCK) 
(A: Pre-trial Vs Placebo; B: Pre-trial Vs Pioglitazone; C: Pioglitazone Vs Placebo) 
 
No significant differences between groups in terms of reference gene 
expression were observed. Taqman real-time PCR results indicated that PGZ 
increased both ChREBP and SREBP1C gene expression as compared to 
placebo. SREBP1C levels decreased in placebo group as compared to the pre-
WULDOJURXS1RVLJQLILFDQWGLIIHUHQFHV LQȕ-oxidation and glucose metabolism 
genes were observed in these samples. These results were surprising in that the 
two master regulators of lipogenesis were elevated in PGZ treated patients.   
 
PGZ increases lipogenesis in adipose tissue via activation of PPAR Ȗ
(Miyazaki et al., 2000), however, the whole-body insulin sensitizing effects of 
PGZ might be expected to reduce lipogenesis in the liver. Conversely both 
ChREBP and SREBP1C expression/activity are increased by glucose and 
insulin, thus increased lipogenesis by up regulation of these genes. As the 
target gene for SREBP1C (GCK) (Foretz et al., 1999; Kim et al., 2004) and 
ChREBP (PK2) (Iizuka & Horikawa, 2008) were unaltered the overall picture 
of the effects of PGZ on gene expression in NASH patients was unclear.  
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4.3. Taqman Low density array gene expression in human liver  
Microarray gene expression analysis followed by pathway-based 
interpretation of the subsequent data sets would provide a much more 
comprehensive picture of the transcriptional changes induced by PGZ. The 
relative poor quality of the RNA samples precluded this. It was decided that 
low density Taqman array would be used. Taqman Low density array is a 
relative quantitation meWKRG WKDW XVHV WKH ǻǻ&W PHWKRG WKDW FRPSDUHV WDUJHW
species mRNA levels between different samples by correcting for a reference 
gene and relating expression levels to a reference control for examples an 
untreated sample (Hughes & Moody, 2007). 
 
Target genes thought to be involved in the pathogenesis of 
NAFLD/NASH were selected. The official symbol, abbreviation and function 
of the gene selected for low density array analysis are listed in Table 4.2 and all 
the information was obtained from Ref Seq (NCBI) over leaf. 
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Table 4.2: List of gene categories, symbol, abbreviation and gene functions 
used in this study. 
Symbol Gene Function 
Reference genes 
18sRNA 18s ribosomal nucleic acid  Ribosomal RNA subunit 
ABL1 
c-abl oncogene 1, receptor 
tyrosine kinase 
cell differentiation, cell division, cell 
adhesion, and stress response. 
HPRT1  
hypoxanthine 
phosphoribosyltransferase1 
catalyzes conversion of hypoxanthine to 
inosine monophosphate and guanine to 
guanosine monophosphate for energy 
production 
MRPL19 
mitochondrial ribosomal 
protein L19 
  
protein synthesis within the mitochondrion 
Glycolysis genes 
ALDOB 
aldolase B, fructose-
bisphosphate 
catalyzes the reversible conversion of 
fructose-1,6-bisphosphate to glyceraldehyde 
3-phosphate & Dehydroxyacetone phosphate. 
LDHA Lactate Dehydrogenase B 
catalyzes lactate & NAD to pyruvate and 
NADH in the final step of glycolysis 
PFKL Phosphofructokinase, liver 
catalyzes fructose 6-phosphate to fructose 1,6-
bisphosphate a key step in glycolysis 
Gluconeogenesis genes 
ATF3 
Activating transcription 
factor 3 
Represses gluconeogenic enzymes in liver & 
increased in liver regeneration (Younossi, 
2005). 
G6PC 
Glucose 6-phosphatase, 
catalytic subunit 
catalyzes the hydrolysis of glc 6-phosphate to 
glucose and orthophosphate 
PCK2 
Phosphoenolpyruvate 
carboxykinase 2 
catalyzes the formation of 
phosphoenolpyruvate from oxaloacetate, with 
the release of carbon  dioxide and GDP. 
Pentose phosphate pathway genes 
G6PD 
Glucose 6-phosphate 
dehydrogenase 
produce NADPH, a key electron donor in the 
defense against oxidizing agents and in 
reductive biosynthetic reactions. 
TALDO1 Transaldolase 1 
key enzyme of the nonoxidative pentose 
phosphate pathway providing ribose-5-
phosphate for nucleic acid synthesis and 
NADPH for lipid biosynthesis. 
TKT Transketolase 
catalyzes the reverse reaction, the conversion 
of sedoheptulose-7-P and glyceraldehyde-3-P 
to pentose 
Glycogen metabolism genes 
GSK3B 
glycogen synthase kinase 3 
beta 
phosphorylating and inactivating glycogen 
synthase. GSK3B is involved in energy 
metabolism, neuronal cell development, and 
body pattern formation 
PGM1 phosphoglucomutase 1 
converted to glucose 6-phosphate by cytosolic 
phosphoglucomutase I. 
PYGL 
Phosphorylase Glycogen 
Liver 
catalyzes the removal of glucose residues, as 
glucose 1-phosphate, from the ends of 
glycogen branches 
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Symbol Gene Function 
Kreb cycle genes 
CA5A carbonic anhydrase 5A, 
catalyze the reversible hydration of carbon 
dioxide 
FH Fumarate hydratase 
catalyzes the formation of L-malate from 
fumarate 
MDH2 Malate dehydrogenase 2 
catalyzes the reversible oxidation of malate to 
oxaloacetate, utilizing the NAD/NADH 
cofactor system in the citric acid cycle 
PDK2 
Pyruvate dehydrogenase 
kinase 2 Phosphorylate PDC inhibiting glycolysis 
UCP2 Uncoupling protein 2 
reduce the mitochondrial membrane potential 
in mammalian cells. 
Glucose  transporter gene 
GLUT2 glucose transporter 2 
mediates facilitated bidirectional glucose 
transport 
Fatty acid synthesis genes 
ACC2 
acetyl-Coenzyme A 
carboxylase beta 
catalyzes the carboxylation of acetyl-CoA to 
malonyl- CoA, the rate-limiting step in fatty 
acid synthesis. 
ACLY ATP citrate lyase 
catalyzes  the formation of acetylCoA and 
oxaloacetate from citrate and CoA with a 
concomitant hydrolysis of ATP to ADP and 
phosphate 
ChREBP 
Carbohyrate response 
element binding protein Promotes fatty acid synthesis genes 
FASN Fatty acid synthase 
catalyze the synthesis of palmitate from 
acetyl-CoA and malonyl-CoA, in the presence 
of  NADPH, into long-chain saturated fatty 
acids 
ME1 Malic enzyme 1 
catalyzes the oxidative decarboxylation of 
malate to pyruvate 
SCD Stearoyl CoA desaturase 
catalyzes a rate-limiting step in the synthesis 
of unsaturated fatty acids. 
SREBP-1C 
Sterol regulatory element 
binding transcription factor 1 Promotes genes involved in sterol biosynthesis 
Triacylglycerol biosynthesis genes 
DGAT2 
Diacylglycerol O-
acyltransferase 2 
utilizes diacylglycerol and fatty acyl CoA as 
substrates in order to catalyze the final stage 
of  triacylglycerol synthesis 
GPD1 
Glycerol-3-phosphate 
dehydrogenase 1 
catalyzes the unidirectional conversion of 
glycerol-3-phosphate to dihydroxyacetone 
phosphate with concomitant reduction of the 
enzyme-bound FAD 
Triacylglycerol biosynthesis genes 
MTTP 
Mitochodrial triglyceride 
transfer protein 
play a central role in lipoprotein assembly 
 
PPAP2C 
Phosphatidic acid 
phosphatase type 2C 
convert phosphatidic acid to diacylglycerol, 
and promotes synthesis of glycerolipids & also 
in receptor-activated signal transduction 
mediated by phospholipase D 
THRSP 
Thyroid hormone responsive 
(SPOT14) 
This gene is rapidly up-regulated by signals 
that induce lipogenesis such as enhanced 
glucose metabolism and thyroid hormone 
administration. (LaFave et al., 2006) 
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Symbol Gene Function 
Lipid Metabolism genes 
ACADL 
acyl-Coenzyme A 
dehydrogenase, long chain 
catalyze the initial step of mitochondrial  
beta-oxidation of straight-chain fatty acid. 
ACADVL 
Acyl-Coenzyme A 
dehydrogenase, very long 
chain 
catalyzes the first step of the mitochondrial 
fatty acid beta-oxidation pathway. This acyl-
Coenzyme A dehydrogenase is specific to 
long-chain and very-long-chain fatty acids 
ACOX1 acyl-Coenzyme A oxidase 1 
 first enzyme of the fatty acid beta-oxidation 
pathway, which catalyzes the desaturation of 
acyl-CoAs to 2-trans-enoyl-CoAs. It donates 
electrons directly to molecular oxygen, 
thereby producing hydrogen peroxide. 
ACSL4 
Acyl-CoA synthetase long-
chain family member 4 
controls the level of free arachidonic acid 
(AA) regulating eicosanoid production 
ADIPOR1 Adiponectin receptor 1  Mediate increased AMPK expression 
ADIPOR2 Adiponectin receptor 2  0HGLDWHLQFUHDVH33$5ĮH[SUHVVLRQ 
CAT Catalase 
Antioxidant gene shown to be upregulated in 
the liver in response to CYP2E1-dependent 
oxidative stress. 
CD36 CD36 Promotes fatty acid uptake, transport 
ECHS1 
enoyl Coenzyme A 
hydratase, short chain, 1, 
mitochondrial 
catalyzes the hydration of 2-trans-enoyl-
coenzyme A (CoA) intermediates to L-3-
hydroxyacyl-CoAs. 
GSTA4 Glutathione S-transferase A4 
Cellular defenses against the oxidative stress. 
Increased in response to CYP2E1-dependent 
production of mitochondrial ROS, to TNF-Į
IL-6 and EGF. Younossi et al. (2005) reported 
that CAT and GSTA4 were upregulated in 
both NASH and obese control compared to 
non-obese control. 
HADHB 
hydroxyacyl-Coenzyme A 
dehydrogenase, beta subunit 
catalyzes the last three steps of mitochondrial 
beta-oxidation of long chain fatty acids. 
HMGCS2 
3-hydroxy-3-methylglutaryl-
Coenzyme A synthase 2 
Rate limiting enzyme of the HMG-CoA 
pathway of fatty acid metabolism 
(ketogenesis).  
LPL Lipoprotein Lipase 
dual functions of triglyceride hydrolase and 
ligand/bridging factor for receptor-mediated 
lipoprotein uptake 
NRF1 Nuclear respiratory factor 1 
protective function against oxidative stress and 
potentially a function in lipid homeostasis in 
the liver. 
Lipid Metabolism genes 
PHB Prohibitin 
A chaperon involved in the assembly of 
mitochondrial respiratory chain (Nitjmans et 
al., 2000). 
PLIN Perilipin 
coats lipid storage droplets in adipocytes, 
thereby protecting them until they can be 
broken down by hormone-sensitive lipase 
Cholesterol metabolism genes 
APOC3 Apolipoprotein C-III 
 inhibits lipoprotein lipase and hepatic lipase 
& delay the catabolism of triglyceride-rich 
particles 
APOE Apolipoprotein E 
Catabolises the triglyceride-rich lipoprotein 
constituents [Chylomicron and very low 
density lipoprotein (VLDL) remnants] 
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Symbol Gene Function 
Nuclear receptors genes 
FXR Farnesoid X receptor 
Suppressed cholesterol 7 alpha-hydroxylase 
(CYP7A1), the rate-limiting enzyme in bile 
acid synthesis from cholesterol. 
33$5Į 
Peroxisome proliferator-
activated receptor alpha 
regulates the expression of genes involved in 
fatty acid beta-oxidation and is a major 
regulator of energy homeostasis 
33$5ȕ 
Peroxisome proliferator-
activated receptor beta 
Regulates lipid metabolism, and epidermal 
cell proliferation 
3*&Į 
Peroxisome proliferator-
activated receptor gamma, 
coactivator 1 alpha 
enhances metabolically relevant pathways, 
such as gluconeogenesis, fatty acid oxidation, 
thermogenesis, oxidative phosphorylation and 
mitochondrial biogenesis 
3*&ȕ 
Peroxisome proliferator-
activated receptor gamma, 
coactivator 1 beta 
enhances metabolically relevant pathways, 
such as gluconeogenesis, fatty acid oxidation, 
thermogenesis, oxidative phosphorylation and 
mitochondrial biogenesis 
PXR Pregnane X receptor 
Regulates of the cytochrome P450 gene 
CYP3A4, binding to the response element of 
the CYP3A4 promoter as a heterodimer with 
the 9-cis retinoic acid receptor RXR. 
5;5Į Retinoid X receptor, alpha 
mediate the biological effects of retinoids by 
their involvement in retinoic acid-mediated 
gene activation. 
Adipogenic genes 
CEBPA 
CCAAT/enhancer binding 
protein (C/EBP), alpha 
Modulate leptin gene that help regulate body 
weight homeostasis 
CEBPB 
CCAAT/enhancer binding 
protein (C/EBP), beta 
regulation of genes involved in immune and 
inflammatory responses 
LXR-Į Liver-X-receptor alpha 
regulating the expression of genes involved in 
hepatic bile and fatty acid synthesis, glucose 
metabolism as well as sterol efflux 
LXR-ȕ Liver-X-receptor beta 
regulating the expression of genes involved in 
hepatic bile and fatty acid synthesis, glucose 
metabolism as well as sterol efflux 
33$5Ȗ 
Peroxisome proliferator-
activated receptor gamma Regulates of adipocyte differentiation. 
ADN Adipsin 
role for adipose tissue in immune system 
biology 
FABP4 Fatty acid binding protein 4 
Promotes in fatty acid uptake, transport, and 
metabolism 
Insulin signalling genes 
MAP2K4 
Mitogen-activated protein 
kinase kinase 4 
Directly activate the MAP kinases in response 
to various environmental stresses or mitogenic 
stimuli. Ceramides initiate apoptosis by 
activating MAP2K4 (Verheij et al., 1996), 
leading to activation of stress-activated protein 
kinase (SAPK) (Sanchez et al., 1994). 
UGCG 
UDP-glucose ceramide 
glucosyltransferase 
catalyzes the first glycosylation step in 
glycosphingolipid biosynthesis from 
ceramides (Icikawa et al., 1996).  
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Symbol Gene Function 
Inflammatory genes 
BCL2 B-cell CLL/lymphoma 2 Exert an anti-apoptotic effect 
CASP3 caspase 3 
plays a central role in the execution-phase of 
cell apoptosis 
CCL2 
chemokine (C-C motif) 
ligand 2 
regulates immunoregulatory and inflammatory 
processes 
,N%Į 
nuclear factor of kappa light 
polypeptide gene enhancer in 
B-cells inhibitor, alpha 
inhibitor of NFKB signalling which prevent 
nuclear migration of p65:p50 heterodimer 
 
IKKG 
inhibitor of kappa light 
polypeptide gene enhancer in 
B-cells, kinase gamma 
activates NF-kappaB resulting in activation of 
genes involved in inflammation, immunity, 
cell survival (Marra et al., 2007) 
IL6 interleukin 6 
induces a transcriptional inflammatory 
response through interleukin 6 receptor, alpha 
PDGFB 
platelet-derived growth 
factor beta Regulates cell growth and division. 
TGFB1 
Transforming growth factor, 
beta 1 
Profibrogenic cytokines that activates action 
the hepatic stellate cells and caused ECM 
accumulation  (Gressner & Weiskirchen, 
2006)  
TGFBR1 
transforming growth factor, 
beta receptor 1  TGFB1 binds to TGFBR1 to exert its effect 
TGFBR2 
transforming growth factor, 
beta receptor II 
regulate the transcription genes related to cell 
proliferation 
TNFRSF1B 
tumor necrosis factor 
receptor superfamily, 
member 1B Mediates anti-apoptotic effect. 
71)Į 
tumor necrosis factor (TNF 
superfamily, member 2) 
Regulates cell proliferation, differentiation, 
apoptosis, lipid metabolism, and coagulation.  
Hepatic stellate cells activation, fibrosis and regeneration genes 
FGF2 fibroblast growth factor 2 
 Promotes mitogemic, angiogenesis and 
stellate cells activation 
KLF6 Kruppel-like factor 6 tumor suppressor effects 
MMP1 Matrix metalloproteinase 1 
was expressed in human HSCs when plated on 
matrigel surface (Znoyko et al., 2006) 
MMP2 Matrix metalloproteinase 2 
Secreted by activated HSCs and caused ECM 
breakdown, promotes fibrosis (Preaux et al., 
1999) 
MMP9 Matrix metalloproteinase 9 
Secreted by activated kupffer cells and caused 
ECM breakdown (Preaux et al., 1999) 
MMP13 matrix metalloproteinase 13 
Was expressed in human L190 HSC cell line 
(Migita et al., 2005) 
PTGS2 
Prostaglandin-endoperoxide 
synthase 2 
Promotes prostaglandin biosynthesis & 
involved in inflammation and mitogenesis 
RBP4 
retinol binding protein 4, 
plasma 
translocating retinol from the liver stores to 
the peripheral tissues 
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Symbol Gene Function 
Hepatic stellate cells activation, fibrosis and regeneration genes 
RELN Reelin 
control cell-cell interactions critical for cell 
positioning and neuronal migration during 
brain development 
SPP1 secreted phosphoprotein 1 Promotes cell-matrix interaction 
TIMP1 
TIMP metallopeptidase 
inhibitor 1 
inhibitors of the matrix metalloproteinases 
(MMPs) and prevent cell apoptosis 
TIMP2 
TIMP metallopeptidase 
inhibitor 2 
 inhibitors of the matrix metalloproteinases 
(MMPs) and prevent cell apoptosis 
VEGFA 
vascular endothelial growth 
factor A 
mediates vascular permeability, inducing 
angiogenesis, vasculogenesis and endothelial 
cell growth, promoting cell migration, and 
inhibiting apoptosis 
Endoplasmic reticulum stress genes 
DDIT3 
DNA-damage-inducible 
transcript 3 
Regulator induced by ER stress and a key 
factor in the ER stress mediated apoptosis 
pathway. 
ERN1 
Endoplasmic reticulum to 
nucleus signalling 1 
possesses intrinsic kinase activity and an 
endo-ribonuclease activity and it is important 
in altering gene expression as a response to 
endoplasmic reticulum-based stress signals 
XBP1 X-box binding protein 1 
regulates the expression of genes important to 
the proper functioning of the immune system 
and in the cellular stress response  
 
 
Table 4.2 above indicates the 92 target gene selected. 4 of these genes 
showed no amplification in any of the experimental samples (IL6, PDGFB, 
MMP1 and MMP13) and 56 showed no significant differences between 
groups. All the target genes were normalised using the geometric mean of the 
reference genes (ABL1, HPRT1, MRPL19 and 18Srna). Quantitation of gene 
H[SUHVVLRQZDVFDOFXODWHGXVLQJWKHǻǻ&7PHWKRG+XJKHV	0RRG\ 
 
The gene expressions were analysed using SPSS 16 software, where 
One-way ANOVA with a Bonferroni Post Hoc test was used to analyse the 
results. Gene expression patterns were further analysed using Ingenuity 
Pathway Analysis (IPA) to identify the molecular pathways involved as shown 
in Appendix 2. 
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4.3. Taqman Low density array gene expression in human liver 
4.3.1. Taqman low density array gene expression in normal liver, NAFLD 
& NASH patients 
Table 4.3: Comparison of gene expression levels in normal liver, NAFLD & 
NASH samples measured using Low density Taqman arrays. 
 
Genes/  
Group 
 
Normal Liver 
(N = 7) 
 
NAFLD 
(N = 7) 
 
NASH 
(N = 22) 
 
 
P value 
Adipogenic gene 
&(%3Į 1.910 ± 0.367b 2.465 ± 0.229c 0.809 ± 0.096b,c 0.001b; 0.000,c 
Adipsin 1.361 ± 0.182b 0.894 ± 0.143c 0.462 ± 0.059b,c 0.000b; 0.026,c 
Lipid Metabolism 
ChREBP 1.027 ± 0.197 0.847 ± 0.145c 1.575 ± 0.138c  0.019c 
ME1 0.461 ± 0.047b 0.804 ± 0.161 1.549 ± 0.228b 0.016b 
THRSP 0.642 ± 0.085a 1.416 ± 0.139a 1.137 ± 0.111 0.018a 
Glucose Metabolism  
G6PC 3.958 ± 0.929a,b 0.818 ± 0.145a 0.717 ± 0.171b 0.000a,b 
PGM1 0.341 ± 0.082b 0.372 ± 0.031c 1.355 ± 0.187b,c 0.007b; 0.009c 
UCP2 36.481 ± 4.063b 25.638 ±10.473c 1.406 ± 0.419b,c 0.000b; 0.001c 
Inflammatory,  apoptosis, cell proliferation  markers 
7*)ȕ 1.899 ± 0.177a,b 1.147 ± 0.272a 0.637 ± 0.082b 0.022a; 0.000b 
7*)ȕ5 1.369 ± 0.152b 1.021 ± 0.189 0.752 ± 0.111b 0.022b 
(a: Normal liver Vs NAFLD; b: Normal liver Vs NASH; c: NAFLD Vs NASH) Data are 
presented as mean ± S.E.M. 
 
In NAFLD patients, CE%3ĮDQG7+563VKRZHGDVLJQLILFDQWLQFUHDVHG
compared to NASH and normal liver. Meanwhile in NASH patients; ChREBP, 
ME1 and PGM1 expression were increased whereas there was a significant 
UHGXFWLRQLQ&(%3Į$GLSVLQ*3&8&37*)%DQG7*)%5FRPSDUHGWR
NAFLD patients. All the other gene expressions were highlighted as shown in 
figures in over leaf. 
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4.3.2. Taqman low density array FABP4 and FASN gene expression in 
normal liver, NAFLD & NASH patients 
 
Figure 4.4: FABP4 gene expression in normal liver, NAFLD and NASH. Data are 
presented as mean ± S.E.M. (N= number of patients; * p<0.05; **p<0.01; 
***p<0.000).  
 
Figure 4.5: FASN gene expression in normal liver, NAFLD and NASH. Data are 
presented as mean ± S.E.M. (N= number of patients; * p<0.05; **p<0.01; 
***p<0.000).  
 
FABP4 gene expression was increased significantly in NAFLD patients 
compared to NASH patients. Meanwhile in NASH patients, FASN gene 
expression showed significant reduction compared to normal liver and NAFLD 
patients. 
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4.3.3. Taqman low density array ACSL4 and PXR gene expression in 
normal liver, NAFLD & NASH patients 
 
Figure 4.6: ACSL4 gene expression in normal liver, NAFLD and NASH. Data are 
presented as mean ± S.E.M. (N= number of patients; * p<0.05; **p<0.01; 
***p<0.000).  
 
Figure 4.7: PXR gene expression in normal liver, NAFLD and NASH. Data are 
presented as mean ± S.E.M. (N= number of patients; * p<0.05; **p<0.01; 
***p<0.000).  
 
ACSL4 gene expression was elevated in NASH patients compared to normal 
liver and NAFLD patients. Meanwhile, PXR gene expression was increased in 
NAFLD compared to NASH patients. 
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7DTPDQORZGHQVLW\DUUD\71)ĮDQG71)56)%JHQHH[SUHVVLRQLQ
normal liver, NAFLD & NASH patients 
 )LJXUH  71)Į JHQH H[SUHVVLRQ LQ QRUPDO OLYHU 1$)/' DQG 1$6+ 'DWD DUH
presented as mean ± S.E.M. (N= number of patients; * p<0.05; **p<0.01; 
***p<0.000).  
 
Figure 4.9: TNFRSF1B gene expression in normal liver, NAFLD and NASH. Data are 
presented as mean ± S.E.M. (N= number of patients; * p<0.05; **p<0.01; 
***p<0.000).  
 
71)Į JHQH H[SUHVVLRQ ZDV elevated in NASH compared to NAFLD and 
normal liver group. Meanwhile, TNFRSF1B gene expression was reduced in 
significantly in NASH compared to normal liver group.  
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4.3.5. Taqman low density array BCL2 and XBP1 gene expression in 
normal liver, NAFLD & NASH patients 
 
Figure 4.10: BCL2 gene expression in normal liver, NAFLD and NASH. Data are 
presented as mean ± S.E.M. (N= number of patients; * p<0.05; **p<0.01; 
***p<0.000).  
 
Figure 4.11: XBP1 gene expression in normal liver, NAFLD and NASH. Data are 
presented as mean ± S.E.M. (N= number of patients; * p<0.05; **p<0.01; 
***p<0.000).  
 
BCL2 gene expression was reduced significantly in NASH compared normal 
liver and NAFLD patients. Meanwhile, XBP1 which is a marker of ER stress 
was elevated in NASH patients compared to normal liver and NAFLD patients. 
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4.4. Taqman Low density array gene expression in Pre-trial/NASH treated 
patients  
4.4.1. Taqman low density array gene expression in Pre-trial/NASH, 
Pioglitazone and placebo treated NASH patients 
 
Table 4.4: Effects of 12 months treatment of Pioglitazone or Placebo on gene 
expression measured using Taqman low density arrays.  
 
Genes 
/Group 
 
NASH/Pretrial 
(N = 22) 
 
Pioglitazone 
(N = 13) 
 
Placebo 
(N = 11) 
 
P value 
Lipid Metabolism  
ACC2 1.284 ± 0.150b 1.868 ± 0.241 0.656 ± 0.085b 0.045b 
ADIPOR2 0.921 ± 0.171b 0.846 ± 0.140 0.350 ± 0.060b 0.048b 
HMGCS2 1.510 ± 0.348b 1.106 ± 0.183 0.257 ± 0.046b 0.033b 
Glucose Metabolism  
GPD1 1.063 ± 0.108b 1.148 ± 0.146 0.637 ± 0.093b 0.044b 
PPAP2C 0.399 ± 0.099b 0.227 ± 0.036 1.081 ± 0.344b 0.024b 
Nuclear receptors 
/;5Į 1.251 ± 0.120a 1.892 ± 0.302a 0.898 ± 0.110 0.042a 
PXR 0.776 ± 0.101a 1.453 ± 0.255a 0.657 ± 0.104 0.010a 
3*&Į 0.747 ± 0.133a 1.986 ± 0.570a 0.364 ± 0.081 0.012a 
5;5Į 1.191 ± 0.130a 1.977 ± 0.240a 0.898 ± 0.092 0.003a 
Inflammatory markers 
71)Į 1.103 ± 0.179b 0.543 ± 0.173 0.544 ± 0.119b 0.048b 
TNFRSF1B 0.688 ± 0.088a 1.310 ± 0.312a 0.614 ± 0.127 0.037a 
,N%Į 1.040 ± 0.103a 2.082 ± 0.265a 0.654 ± 0.092 0.000a 
(a: Pre-trial Vs Pioglitazone; b: Pre-trial Vs Placebo) Data are presented as mean ± SEM 
 Pioglitazone treatment induced up-UHJXODWLRQ RI /;5Į 3;5
33$5*&Į5;5Į71)56)%DQG ,N%Į0HDQZKLOH LQ WKHSODFHERJURXS
up regulation PPAP2C was observed followed by a reduction in ACC2, 
$',325 +0*&6 *3' DQG 71)Į DV FRPSDUHG WR SUH-trial samples. 
There other gene expressions were highlighted in figures showed in over leaf. 
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4.4.2. Taqman low density array ACADVL and UCP2 gene expression in 
Pre-trial, Pioglitazone and placebo treated NASH patients 
 
Figure 4.12: ACADVL gene expression in Pre-trial/NASH, Pioglitazone and placebo 
treated NASH patients. Data are presented as mean ± S.E.M. (N= number of patients; 
* p<0.05; **p<0.01; ***p<0.000).  
 
 
Figure 4.13: UCP2 gene expression in Pre-trial/NASH, Pioglitazone and placebo 
treated NASH patients. Data are presented as mean ± S.E.M. (N= number of patients; 
* p<0.05; **p<0.01; ***p<0.000).  
 
ACADVL and UCP2 gene expressions were increased significantly compared 
pre-trial NASH patients. 
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 7DTPDQ ORZ GHQVLW\ DUUD\ $32( DQG 33$5 ȕ JHQH H[SUHVVLRQ LQ
Pre-trial, Pioglitazone and placebo treated NASH patients 
 
Figure 4.14: APOE gene expression in Pre-trial/NASH, Pioglitazone and placebo 
treated NASH patients. Data are presented as mean ± S.E.M. (N= number of patients; 
* p<0.05; **p<0.01; ***p<0.000).  
 
)LJXUH  33$5 ȕ JHQH H[SUHVVLRQ LQ 3UH-trial/NASH, Pioglitazone and placebo 
treated NASH patients. Data are presented as mean ± S.E.M. (N= number of patients; 
* p<0.05; **p<0.01; ***p<0.000).  
 
$32( DQG 33$5 ȕ JHQH H[SUHVVLRQV ZHUH LQFUHDVHG VLJQLILFDQWO\ FRPSDUHG
pre-trial NASH patients. 
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A most striking and unexpected result of this analysis was the increase 
LQ33$5ȕH[SUession induced by PGZ. Both the size of the fold increase in 
expression and the relatively large standard error made this result require 
IXUWKHULQYHVWLJDWLRQ7KHUHIRUHWKH33$5ȕH[SUHVVLRQDQDO\VLVZDVUHSHDWHG
using conventional Taqman Real-time PCR using different, custom designed 
primers and probe (Table 4.5 and Figure 4.16).  
 
7DEOH  33$5 ȕ JHQH H[SUHVVLRQ OHYHOV LQ KXPDQ OLYHU PHDVXUHG XVLQJ FRQYHQWLRQDO
Taqman Real-Time PCR in normal liver, NAFLD and NASH. 
Group/ Gene Normal liver 
(N=7) 
NAFLD 
(N=7) 
NASH 
(N=22) 
P value 
33$5ȕ 0.862 ± 0.196 0.588 ± 0.103 0.718 ± 0.111 NS 
 
*HQH H[SUHVVLRQ YDOXHV DUH QRUPDOLVHG ZLWK UHIHUHQFH JHQH ȕ- actin). Data are presented as 
mean ± SEM. (a: Normal liver Vs NAFLD; b: Normal liver Vs NASH; c: NAFLD Vs NASH) 
 
 
 
)LJXUH  33$5 ȕ JHQH H[SUHVVLRQ LQ 3UH-trial/NASH, Pioglitazone and placebo 
WUHDWHG1$6+SDWLHQWV*HQHH[SUHVVLRQYDOXHVDUHQRUPDOLVHGZLWKUHIHUHQFHJHQHȕ- 
actin).  Data are presented as mean ± S.E.M. (N= number of patients; * p<0.05; 
**p<0.01; ***p<0.000).  
 
TKHUH DUH QR GLIIHUHQFHV LQ 33$5ȕ expression between normal liver, 
NAFLD and NASH samples. The differences in expression between the 
Pretrial and PGZ group was smaller (3 fold as compared to 5 fold) using the 
second Taqman assay. However this second analysis confirms the stimulation 
HIIHFWVRI3*=XSRQ33$5ȕH[SUHVVLRQ 
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4.5. Discussion 
Pioglitazone treatment appeared to increase the expression of lipogenic 
transcriptional factors as determined by Taqman real time PCR but the genes 
under the control of these transcription factors were not altered. Hence, custom 
Taqman low density arrays were used to analyse the effects of PGZ. All the 
target genes were normalised using the geometric mean of the control genes 
(A%/+357053/DQGV51$XVLQJWKHǻǻ&7TXDQWLWDWLRQPHWKRG
Using this technique, several genes did not amplify (MMP1, MMP13, PDGFB 
and IL6). The reason for the lack of detection of these genes is not clear; it may 
be due to design faults in the primer/probe set or lack of expression of these 
genes in human liver.  
 
A previous study has shown that IL6 was expressed in human 
hepatocellular carcinoma patients (Chew et al., 2010); meanwhile PDGFB was 
also detected in hepatitis C recurrent transplant patients (Ben-Ari et al., 2006). 
MMP1 was expressed in human liver myofibroblast cells during fibrosis 
(Znoyko et al., 2006) and MMP13 in L190 human HSCs line (Migita et al., 
2005). Further study is required in order to confirm the current findings of 
undetermined expression. 
  
4.5.1. Normal liver, NAFLD and NASH  
 ,Q1$)/'SDWLHQWVDGLSRJHQLFJHQHH[SUHVVLRQ&(%3Į)$%3DQG
Adipsin) was found higher compared to NASH patients. All these genes not 
only promote fat accumulation in the liver but also maintain the adipogenic 
phenotype of stellate cells reducing inflammation and fibrosis in these patients 
(Larter et al., 2008). FASN catalyses last step of fatty acid synthesis and was 
elevated in human NAFLD but not in NASH samples. An increase in FASN 
expression in both human and animal models of steatosis did not induce 
inflammation (Dorn et al., 2010). Therefore this current study further supports 
the notion that that fat accumulation does not directly cause liver injury in 
NAFLD patients.  
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 ACSL4 is a gene that controls the unesterified arachidonic acid level in 
cells (Younossi et al., 2005; Hertz et al., 1998). Younossi et al. (2005) reported 
WKDW ERWK $&6/ DQG Į-fetoprotein (AFP) gene expression was higher in 
NASH compared to steatosis patients. AFP is a serum marker of Hepatocellular 
carcinoma (HCC) diagnosis (Younossi et al., 2005; Magee et al., 1998). 
ASCL4 is also highly expressed in hepatocellular carcinoma (HCC) (Magee et 
al., 1998). ACSL4 was also up-regulated in NASH patients compared NAFLD 
in this study, this indicate that NASH patients maybe at risk of developing 
HCC, and that NASH is effectively a pre-cancerous state (Hashimoto & 
Tokushige, 2011).  
  
 ChREBP is a transcription factor that regulates lipogenesis in response 
to increased cellular carbohydrate (Dentin et al., 2004). The Ob/Ob mouse is an 
animal model of NAFLD, wherein these mice are hyperphagic, 
hyperinsulinemic, hyperlipidemic and hyperglycemic. Excessive 
accumulations of fat exacerbate insulin signalling in the liver leading to hepatic 
steatosis and insulin resistance (Postic et al., 2007). ChREBP expression was 
increased in Ob/Ob mice (Dentin et al., 2006). Both SCD1 and GPAT gene 
expression were reduced followed by up regulation of CPT1 gene expression in 
Ob/Ob mice with ChREBP inhibition. This condition indicates that the 
inhibition of ChREBP decreased TG synthesis and increased fat oxidation. 
ChREBP knockdown in Ob/Ob mice, improved insulin signalling by 
restoration of Akt and Foxo1 phosphorylation by insulin (Dentin et al., 2006). 
In this study, the ChREBP level was increased in NASH patients compared to 
NAFLD patients, indicating that increased in ChREBP leads to decreased in 
insulin sensitivity. 
 
 ME1 is cytosolic NADP-dependent enzyme that generates NADPH for 
fatty acid biosynthesis. ME1 expression has been shown to be up regulated by 
triiodothyronine (T3) (Yin et al., 2005): in high cholesterol fed mice ME1 is 
down regulated (Maxwell et al., 2003). SREBP1a and SREBP1c have been 
reported to activate ME1 expression animal model during lipogenesis 
(Shimano et al., 1999). In this study, ME1 expression was elevated in NASH 
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samples compared to normal liver indicating ME1 providing NADPH for fatty 
acid biosynthesis.  
 
 THRSP, otherwise known as S14 expression has been show to be up 
regulated in the streptozotocin-induced diabetic rat model after insulin and 
fructose administration. Meanwhile, administration of dibutryl cAMP and 
theophylline fully blocked the insulin-mediated increase in S14 gene 
transcription, indicating that hepatic cAMP levels play a negative role in 
regulating THRSP gene transcription in vivo (LaFave et al., 2006; Jump et al., 
1990). LaFave et al. (2006) reported that an increased in THRSP expression 
was associated with an increase in lipogenesis and a concomitant reduction in 
ȕ-oxidation (LaFave et al., 2006; Perez-Castillo et al., 1987). The elevated 
level of THRSP in NAFLD patients suggests that fat accumulation in the liver 
occurs at least in part due to the accumulation of endogenously synthesised 
triglyceride.  
  
PGM1 expression was elevated in NASH patients compared to NAFLD 
patients. This enzyme converts glucose 1-phosphate to glucose 6-phosphate at 
the penultimate step of glycogen breakdown. The elevated levels of PGM1 in 
NASH would be consistent with increased glucose production by the liver 
which occurs in insulin resistant states. Whether the development of NASH as 
distinct from simple lipid accumulation drives hepatic glucose output is not 
clear. NASH patients have hepatic inflammation and inflammatory states are 
known to cause insulin resistance. The picture is somewhat complicated by the 
fact that G6PC expression was found to be lower in NAFLD and NASH as 
compared to normal liver. G6PC converts glucose-6-phosphate into glucose 
and is the final step in the breakdown of glycogen and in gluconeogenesis. This 
observed reduction in G6PC expression is unexpected and given that another 
key component of the gluconeogenic pathway, PEPCK showed no differences 
in expression in the samples examined, it is difficult to draw firm conclusions 
regarding molecular regulation of glucose metabolism in these patients. 
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UCP2 is a mitochondrial membrane anion carrier that acts as negative 
regulator of mitochondrial superoxide production (Fleury et al., 1997). In the 
current study, UCP2 expression was decreased significantly in NASH as 
compared to normal liver and NAFLD patients. Previous study has reported 
that mRNA UCP2 expression in the liver was lowered in healthy patients but 
elevated in NASH patients (Serviddio et al., 2008). Further study need to be 
done using standard Taqman RT-PCR to confirm the current finding which 
seem to be in contradiction with previous study. 
 
 71)ĮH[SUHVVLRQZDVXSUHJXODWHGLQ1$6+IROORZHGE\GHFUHDVHGLQ
TNFRSF1B expression. TNFRSF1B or other wise known as p75 act as an anti-
LQIODPPDWRU\F\WRNLQHWKDWEORFNV71)ĮUHJXODWHGLQIODPPDWRU\SURFHVV7LOJ
et al., 2006). TNFRSF1B also mediates an anti-apoptotic effect by forming a 
heterocomplex with cellular inhibitor of apoptosis (c-IAP) 1 and 2 protein 
(RefSeq). BCL2 exert an anti-apoptosis effect in normal liver and NAFLD 
patients, in contrast to NASH patients in this study. Current finding showed 
that cells are progressing to apoptosis that will further exacerbate the liver 
LQMXU\LQ1$6+DV71)ĮPHGLates its action (Rust et al., 2000; Wieckowska et 
al., 2006). 
 
7*)ȕLQKLELWFHOOSUROLIHUDWLRQDQGGLIIHUHQWLDWLRQLQHSLWKHOLDOFHOODQG
LQKLELW H[WUDFHOOXODU PDWUL[ (&0 V\QWKHVLV 7*)ȕ H[HUWV Lts effect by 
ELQGLQJRQ7*)ȕ5(Huang & Huang, 2005). In NASH patients, reduction of 
ERWK 7*)ȕ DQG 7*)ȕ5 SURPRWHV FHOO SUROLIHUDWLRQ RI DFWLYDWHG FHOO DQG
increased extracellular matrix synthesis that will further worsen the injury. 
  
PXR is a nuclear receptor that regulates xenobiotic metabolism and has 
also been shown to have anti-inflammatory and anti fibrotic effects (Mencarelli 
et al., 2010; Wallace et al., 2010; Wahli, 2008). PXR expression was higher in 
NAFLD than in NASH. This finding indicates that, NASH patients exhibit 
inflammation and fibrosis compared to NAFLD patients. 
 
 XBP1 is an early marker of endoplasmic reticulum (ER) stress and 
regulates the unfolded protein response XBP1 has also more recently been 
shown to be an important regulator in lipogenesis after carbohydrate feeding in 
 102 
 
mice. XBP1 deficient mice showed a reduction in ACC2, DGAT2, SCD1 and 
SREBP2 expression leading to hypocholesterolemia and hypotriglyceridemia 
(Lee et al., 2008). Rutkowski et al. (2008) have reported that XBP1 activated 
acute ER stress responses that in turn can lead to hepatic steatosis and 
disruption of hepatic VLDL secretion (Ota et al., 2008). XBP1 expression was 
elevated in NASH patients as compared to normal and NAFLD patients. 
Interestingly other ER stress markers (DDIT3 and ERN1) showed similar 
expression in all samples. It would be interesting to examine the target genes of 
the XBP1 transcriptional response to see if they show elevated expression in 
NASH patients. 
 
Overall in NAFLD patients, fat accumulation exerts a protective effect 
in the liver from oxidative stress and inflammation as previously shown 
(Yamaguchi et al., 2007; Listerberger et al., 2003). Meanwhile in NASH 
patients, upregulation of apoptosis, stellate cell activation and proliferation, 
followed by oxidative stress and endoplasmic reticulum (ER) stress, exacerbate 
the liver injury. 
 
4.5.2. Effects of Pioglitazone in non-diabetic NASH patients 
 3LRJOLWD]RQH FDXVHG HOHYDWLRQV RI 3;5 ,N%Į DQG 71)56)%
expression compared to the pre-trial group. PXR is a xenobiotic activated 
nuclear receptor that exerts anti-inflammatory and anti fibrotic effects 
0HQFDUHOOLHWDO:DOODFHHWDO:DKOL1)NȕZDVERXQG
WR ,N%ĮDQG ,N%ȕ LQXQVWLPXODWHGFHOO WRSUHYHQWQXFOHDU WUDQVSRUWDWLRQ IURP
the cytoplasm (Baldwin, 1996). Specific kinase phosphorylation (viruses, 
cytokine, and activator of protein kinase C) (Kopp & Gosh, 1995; Siebenlist et 
al., 1994), causing rapid degradation of IkB subunit by proteosomes (DiDonato 
et al., 1996; Chen et al., 1996). This action leads NFkB translocation to the 
nucleus causing activation of proinflammatory cytokine, chemokines 
(chemotactic cytokine that attract inflammatory cell to site of inflammation) 
and anti-apoptotic effects (Barnes & Karin, 1997). TNFRSF1B or p75 play a 
UROH LQ EORFNLQJ 71)Į PHGLDWHV LQIODPPDWRU\ UHVSRQVH 7LOJ HW DO 
TNFRSF1B has been reported to mediate an anti-apoptotic effect by forming a 
heterocomplex with cellular inhibitor of apoptosis (c-IAP) 1 and 2 protein 
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(RefSeq). Overall, PGZ exert an anti-inflammatory and anti-fibrotic effects by 
up regulating all these markers in non-diabetic NASH patients. 
 
 3*&Į LV D QXFOHDU UHFHSWRU FR-activator, which increases 
mitochondrial IDWR[LGDWLRQLVVNHOHWDOPXVFOH0LXUDHWDO3*&ĮZDV
reported to activate both PPAR ȕ 0LXUD HW DO  DQG VXEVHTXHQWO\
ACADVL (Espinoza et al., 2010). ACADVL is a protein that is targeted to the 
inner mitochondrial membrane where it catalyzes the first step of the 
mitochondrial fatty acid beta-oxidation pathway. Pioglitazone treatment 
LQFUHDVHG3*&Į33$5 ȕDQG$&$'9/VXJJHVWLQJWKDWIDWW\DFLGR[LGDWLRQ
was increased by pioglitazone treatment. In addition, UCP2 expression was 
also elevated, which may in turn reduce the ROS production which is 
associated with increased beta-oxidation. 
 
 ChREBP and SREBP1C are transcriptional factors that are regulated by 
glucose and insulin to promote lipogenesis in the liver (Browning & Horton, 
2004). LXR is a ligand activated transcriptional factor that belongs to the 
nuclear receptor family. LXR regulates cholesterol and bile acid metabolism. 
The SREBP1C promoter contains an LXR binding site, and SREBP1C 
expression can be activated in the presence of LXR agonist (Browning & 
Horton, 2004). ChREBP also has been reported as a direct target of LXR (Cha 
HWDO3*=LQFUHDVHGWKHH[SUHVVLRQRI&K5(%365(%3&DQG/;5Į
in NASH patients, which suggests that de-novo lipogenesis may be increased.  
 
 APOE is lipoprotein responsible for VLDL ±TG secretion out from the 
liver to adipose tissue (Mahley & Huang, 1999). APOE deficient mice exhibit 
higher TG, cholesterol accumulation in the liver (Kuipers et al., 1996). An 
elevation of APOE in mice liver leads to an increased the VLDL-TG export 
and also increased the VLDL-APOB production rate. This finding indicates 
that hepatic APOE influences the number of VLDL particles secreted by the 
liver (Maugeais et al., 2000). In this study, Pioglitazone treatment up regulates 
APOE expression indicates that it increased in VLDL-TG secretion out from 
the liver to the adipose tissue.  
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 Overall, Pioglitazone inhibit both stellate cells activation and cell 
proliferation. This ligand also exerts an anti-inflammatory effect leading to an 
improvement liver injury and fibrosis in non-diabetic NASH patients. 
3LRJOLWD]RQHWUHDWPHQWDOVRLQFUHDVHGȕ-oxidation, VLDL-TG export out from 
liver followed by increased lipogenesis, neither of these effects, lead to a 
change in liver fat content, a finding which is supported by clinical data by 
Aithal et al. (2008). 
 
4.5.3. Effects observed in placebo treated non-diabetic NASH patients 
ACC2 and SREBP1C both regulate lipogenesis in the liver (Browning 
& Horton, 2004). Meanwhile, ADIPOR2 is an adiponectin receptor that 
UHJXODWHV 33$5Į DFWLYLW\ :HOHQ HW DO  DQG +0*&6 DFWLYDWHV ȕ-
oxidation and it also a rate limiting enzyme that control ketogenesis (Younossi 
et al., 2005). Placebo treated non-diabetic NASH patients shown to reduce both 
lipogeneVLV DQG ȕ-oxidation activity, in regards to down regulation of these 
genes (ACC2, SREBP1C and HMGCS2). Both conditions also indicate that 
improve steatosis in placebo treated patients compared to pre-trial group. 
 
 Glycerol is produce by lipolysis of adipose tissue; it is also used as 
substrate in the liver for hepatic gluconeogenesis. GPD1 is responsible for 
glycerol metabolism (Patsouris et al., 2004). This indicates that 
gluconeogenesis is decreased in placebo group. 
 
PPAP2C expression was elevated in placebo treated compared to pre-
trial group. PPAP2C converts phosphatidic acid into diacylglycerol (DAG) in 
the liver (Zhang et al., 2000). DAG mediated the activation of protein kinase C 
3.&İLQWKHOLYHUWKDWPD\GHFUHDVHLQVXOLQUHFHSWRUVXEVWUDWH,56) tyrosine 
phosphorylation, PI3K and downstream genes involved in insulin signalling 
which would then lead to insulin resistance (Samuel, 2011; Erion and Shulman, 
2010). Further work is required to elucidate the role of PPAP2C in the 
pathogenesis of NASH. 
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CHAPTER 5 
Primary Human Hepatic stellate cells culture 
5.1. Introduction 
 Hepatic stellate cells (HSCs) are cells that regulate retinoid acid 
metabolism by storing vitamin A and are usually located in the perisinusoidal 
space of disse (Moreira, 2007). Other than that,  HSCs are also involved in the 
regulation hepatic blood flow, portal venous pressure (Friedman et al., 1992) 
and also maintaining the level of basement membrane matrix secretion of type 
IV and VI collagen in hepatic sinusoids (Geerts, 2001; Ikeda et al., 2004). 
Thus, stellate cells play an important role in regulation of hepatic function and 
morphogenesis.  
 
 In quiescent stellate cells, PPAR Ȗ 65(%3& /;5Į &(%3Į DQG ȕ
are adipogenic genes that are highly expressed (She et al, 2005) (Figure 5.1). 
These transcription factors will in turn regulate a large number of metabolic 
and other genes. The expression of these adipogenic genes declines rapidly in 
VWHOODWH FHOOV ZKHQ H[SRVHG WR 71)Į 7*)-Į ȕ DQG 3'*) RU RWKHU SUR-
inflammatory stimuli, leading to transformation into myofibroblasts (MF) 
(Friedman, 2000; She et al., 2005, Figure 5.1). 
 
Figure 5.1: Adipogenic transcriptional factors involved in regulating the quiescent phenotype 
of the hepatic stellate cells. (Adapted from She et al., 2005) 
 
Drug induced liver injury, viral induced hepatitis, metabolic syndrome 
and obesity can all induce NAFLD / NASH (Iredale, 2007). In the case of 
injury induced by one or more of the factors mentioned above, liver cells such 
as hepatocytes and kupffer cells produce reactive oxygen intermediates and 
inflammatory mediators that will activate HSCs to produce type I and IV 
collagen and increase HSC proliferation (Friedman, 2000; Maher, 1999). 
PPAR Ȗ 
SREBP-1C 
CEBPĮ, LXRĮ 
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 Injured sinusoidal endothelial cells then release both fibronectin and 
SODVPLQWKDWDFWLYDWHVWHOODWHFHOOVDQGWUDQVIRUPWKHLQDFWLYHIRUPRI7*)ȕWR
the active, pro-fibrogenic form further promoting fibrogenesis (Friedman, 
2000; 1999). Activated HSCs rapidly lose their adipogenic phenotype, 
followed by an increase in Kruppel-like factor 6 (KLF-6) expressions (Mann & 
Smart, 2002). KLF-6 activates type 1 collagen production which causes 
extracellular matrix accumulation (Mann & Smart, 2002). This phase is known 
as the initiation phase of stellate cell activation (Friedman, 2000).  
 
The next phase of stellate cell activation is perpetuation, where there is 
an increase in cytokine secretion and activation of the cognate receptor tyrosine 
kinases (RTKs) as shown as in Figure 5.2. This in turn leads to accelerated 
extracellular matrix (ECM) remodelling that will worsen liver injury. This 
process is known as fibrosis. As the degree of liver injury worsens, it will 
eventually lead to cirrhosis. Fibrosis is thought to be reversible if injurious 
stimuli are removed or treated (Iimuro & Brenner, 2007) whereas cirrhosis is 
described as an irreversible process (Friedman, 2000). However a recent study 
has reporteG WKDWFLUUKRVLV LQ+&9SDWLHQWV WUHDWHGZLWKDFRPELQDWLRQRI Į-
interferon and Ribavirin may now be reversible (Poynard et al., 2002). 
 
 
Figure 5.2: Initiation and perpetuation phases of stellate cell activation. (Adapted from 
Friedman, 2000) 
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.
 
Figure 5.3: Sinusoidal events in the development of liver fibrosis. Injury to hepatocytes results 
in the recruitment and stimulation of inflammatory cells, as well as the stimulation of resident 
inflammatory cells (including Kupffer cells). Factors released by these inflammatory cells lead 
to transformation of HSCs into a myofibroblast-like phenotype. HSC activation leads to 
accumulation of scar (fibrillar) ECM. The presence of a fibrillar ECM in the Disse space has 
consequences for hepatocyte function, leading to the loss of microvilli and endothelial 
fenestrae. Therefore, the loss of normal tissue architecture contributes to impairment of organ 
function. (Adapted from Iredale, 2007) 
 
Sinusoidal events in liver injury during fibrogenesis are as shown in 
Figure 5.3. In NAFLD and NASH, stellate cells become activated and 
proliferate as described in Chapter 3. Activation of these HSCs occurs 
primarily via increased levels of TNFĮ 3'*)-%% 7*)ȕ 7*)Į DV ZHOO DV
other proinflammatory cytokines (She et al., 2005). PDGF-BB is thought to be 
the most potent cytokine that causes activated HSCs to proliferate (Paik et al., 
2009). Inhibition / reversal of activation of stellate cells and decreased 
proliferation should reduce fibrosis, associated liver injury, and is therefore an 
attractive target for therapeutic intervention in NAFLD and NASH.  
 
In vitro cell culture of primary rat (Da Sliva Morais et al., 2007) and 
human HSCs (Galli et al., 2000) indicate that activation of the adipogenic 
repertoire of genes by PPAR ȖOLJDQGVPD\GHFUHDVHVWHOODWHFHOODFWLYDWLRQ'D
Silva Morais et al., 2007) and reduce cell proliferation (Galli et al., 2000). 
Furthermore, in carbon tetrachloride (CCl4) induced liver injury in rats, 
WUHDWPHQW ZLWK 3LRJOLWD]RQH 3*= UHGXFHG Į60$ DQG type 1 collagen 
production, suggesting that activation of stellate cells and subsequent fibrosis 
PD\EHUHGXFHGE\33$5ȖDJRQLVWV.RQHWDO 
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,QWHUHVWLQJO\ DQRWKHU 33$5 LVRW\SH 33$5 ȕ KDV EHHQ LPSOLFDWHG LQ
stellate cell activation and proliferation (Hellemans et al., 2003) despite 
evidence of an anti-inflammatory role for this nuclear receptor being described 
LQERWK&URKQ¶V'LVHDVHDQGXOFHUDWLYHFROLWLV3HWHUVHWDO5LYDOHWDO
7KHUROHRI33$5ȕLQ+6&VLVVWLOOXQFOHDUDQd requires further study. 
 
$YDULHW\RIRWKHUQXFOHDUUHFHSWRUVLQFOXGLQJ/;5Į6KHHWDO
and PXR (Wright, 2006) are known to be expressed in quiescent HSCs. These 
are also potential targets for treatment of NAFLD and NASH as their activation 
has been shown to decrease inflammation and immune cell activation (Wallace 
et al., 2010; Scholz et al., 2009). Data from existing HSC culture experiments 
are complicated by the range of culture conditions and number of passages of 
HSC after initial isolation. This can make inter-experimental comparisons 
difficult and extrapolation to the phenotype of HSCs in vivo highly speculative. 
 
In this chapter, the aims were to examine the effects of culture 
conditions and length of time in culture upon HSC activation and proliferation 
rates. Once this was achieved, the effects of nuclear receptor ligands upon 
stellate cell gene expression and proliferation at various stages at cell culture 
and activation were studied. 
 
Results: 
5.2. Human Hepatic stellate cells cultured on different surfaces 
Freshly isolated human hepatic stellate cells (HSCs) were plated either on 
plastic, collagen type 1 or matrigel coated plates for 1 week. The depth of 
matrigel cast in the well is about 0.4mm thick. Images were taken and both 
gene and protein expression were studied as shown overleaf.  
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Human HSC on plastic surface (Day 1) freshly isolated 
   
 
Human HSC on Collagen type 1 surface (Day 1) freshly isolated 
 
   
 
   Human HSC on Matrigel surface (Day 1) freshly isolated 
   
            (10X magnification)      (20X magnification) 
Figure 5.4: Day 1 of human hepatic stellate cells plated on different surfaces. The 
stellate cells remained round and contain retinol droplets on plastic and matrigel 
surfaces. HSCs grown on type 1 collagen show some star shaped cell morphology (as 
shown by pink arrows) indicating the initiation of activation. 
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Human HSC on plastic surface (Day 4) 
 
  
 
Human HSC on Collagen type 1 surface (Day 4)  
 
  
 
Human HSC on Matrigel surface (Day 4)  
 
  
             (10X magnification)      (20X magnification) 
Figure 5.5: Day 4 of human hepatic stellate cells plated on different surfaces. The 
stellate cells remain round and contain retinol droplets on matrigel. HSCs plated on 
plastic and collagen now show star shaped cell morphology and are increased in size 
(as shown by pink arrows).  
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Human HSC on plastic surface (Day 7)  
 
  
 
Human HSC on Collagen type 1 surface (Day 7)  
 
  
 
Human HSC on Matrigel surface (Day 7)  
 
  
            (10X magnification)                   (20X magnification) 
Figure 5.6: Day 7 of human hepatic stellate cells plated on different surfaces. The 
stellate cells plated on matrigel remain round and contain retinol (as shown by yellow 
arrows), but some HSCs were activated, possibly due to thinning of the matrigel layer 
over time (as shown by pink arrows). Cells plated on collagen and plastic have now 
taken on the classic activated stellate cell star shape (as shown by pink arrows).  
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5.3. Human Hepatic stellate cells (HSCs) (Day 14) before sub-culturing  
 HSCs become activated when plated on plastic surfaces as previously 
reported by Bachem et al. (1992). In a subsequent experiment, freshly isolated 
human hepatic stellate cells were plated on plastic and cultured for 14 days. 
The cells were then sub-cultured and plated them on different surfaces (plastic, 
collagen type 1 and matrigel) for a further 7 days. The aim of this experiment 
was to observe potential changes in cell morphology; in particular would 
plating on matrigel reverse cell activation. 
  
  
  (10X magnification)                (20X magnification) 
Figure 5.7: Human Hepatic stellate cells (HSCs) (Day 14) before sub-culturing. 
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Human HSC sub-culture plated on plastic surface (Day 1)  
 
  
 
Human HSC sub-culture plated on collagen type 1 surface (Day 1)  
 
  
 
Human HSC sub-culture plated on matrigel surface (Day 1)  
 
  
 
 (10X magnification)    (20X magnification) 
Figure 5.8: Human hepatic stellate plated on different surfaces following     
sub-culture and day 1 of the culture on new surfaces. 
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Human HSC sub-culture plated on plastic surface (Day 4)  
 
  
Human HSC sub-culture plated on collagen type 1 surface (Day 4)  
 
  
Human HSC sub-culture plated on matrigel surface (Day 4)  
 
  
  (10X magnification)                            (20X magnification) 
Figure 5.9: Human hepatic stellate plated on different surfaces following     
sub-culture and day 4 of the culture on new surfaces. 
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Human HSC sub-culture plated on plastic surface (Day 7)  
 
  
Human HSC sub-culture plated on collagen type 1 surface (Day 7) 
  
Human HSC sub-culture plated on matrigel surface (Day 7) 
  
          (10X magnification)   (20X magnification)Figure 4.10:  
Figure 5.10: Human hepatic stellate cells plated on different surfaces following 
sub-culture and day 7 of the culture on new surfaces. No change in morphology 
was observed. Therefore, HSC activation is irreversible and does not appear to 
alter when they are plated on surfaces such as matrigel, which can maintain 
quiescence in freshly isolated cells. 
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 Subsequent studies focussed on the changes in gene expression 
associated with changes in HSC phenotype as shown in Table 5.1. 
Table 5.1: List of genes included for mRNA expression analysis in this study. 
Gene Abbreviation 
Adipogenic Genes 
33$5Ȗ 3HUR[LVRPHSUROLIHUDWRUDFWLYDWHGUHFHSWRUȖ 
SREBP1C Sterol regulatory element binding protein -1C 
&(%3Į &&$7HQKDQFHUELQGLQJSURWHLQĮ 
&(%3ȕ &&$7HQKDQFHUELQGLQJSURWHLQȕ 
/;5Į Liver-X-receptor 
Fatty Acid Transporters 
CD36 Fatty acid tranlocase 
FABP4 Fatty acid binding protein 4 
Nuclear Receptors 
33$5ȕ 3HUR[LVRPHSUROLIHUDWRUDFWLYDWHGUHFHSWRUȕ 
/;5ȕ Liver-X-receptor 
PXR Pregnane-X-receptor 
FXR Farnesoid-X-receptor 
HSC Markers 
Į60$ Į-smooth muscle actin 
CRBP1 Cellular retinol binding protein 1 
GFAP Glial fibrillary acidic protein 
CSRP2 Cysteine and glycine-rich protein 2 
7*)ȕ 7UDQVIRUPLQJJURZWKIDFWRUȕ1 
 
All the human hepatic stellate cell cDNA samples were preamplified before 
Taqman RT-PCR run, as described in Chapter 2 (section 2.5). Both Adipsin 
and Cyclooxygenase 2 (COX-2) were studied but no expression was observed, 
regardless of cellular activation state. 
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5.4. Gene expression in isolated stellate cells cultured on different surfaces 
for 7 days  
 
 
 
Figure 5.11: PPAR Ȗ Į60$ DQG 7*)ȕ JHQH H[SUHVVLRQ LQ KXPDQ VWHOODWH FHOOV
plated on different surfaces on Day 7 of culture. mRNA level measured using Taqman 
Real-WLPH 3&5 YDOXHV  VKRZQ UHODWLYH WR  ȕ-actin, n = 8 for each group. Data is 
presented as mean ± S.E.M. (*: p<0.05; **: p<0.01; ***: p <0.000). 
33$5ȖJHQHH[SUHVVLRQLQKXPDQVWHOODWHFHOOVRQ'D\RQGLIIHUHQWVXUIDFH 
Į60$JHQHH[SUHVVLRQLQKXPDQVWHOODWHFHOOVRQ'D\RQGLIIHUHQWVXUIDFH 
7*)ȕ gene expression in human stellate cells on Day 7 on different surface 
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Table 5.2: Gene expression levels in human hepatic stellate cells cultured on 3 
different surfaces for 7 days 
Adipogenic 
Genes 
DAY 7  
PLASTIC 
DAY 7  
COLLAGEN 
DAY 7 
MATRIGEL P VALUE 
SREBP-1C 
0.038 
± 0.010 
0.022  
± 0.004 
0.046  
± 0.016 NS 
&(%3Į 
0.544 
± 0.138 
0.523 
± 0.078 
0.505 
± 0.153 NS 
&(%3ȕ 
0.747 
± 0.270a 
0.184 
± 0.047a 
0.217 
± 0.071 
0.030a 
 
/;5Į 
1.769 
± 0.524a,b 
0.520 
± 0.112a 
0.500 
± 0.177b 
0.014a; 
0.016b 
Fatty acid  
Transporter 
DAY 7  
PLASTIC 
DAY 7  
COLLAGEN 
DAY 7 
MATRIGEL P VALUE 
CD36 
0.650 
± 0.101a,b 
0.197 
± 0.033a 
0.041 
± 0.017b 
0.000a,b 
 
FABP4 
3.637 
± 1.159b 
3.625 
± 0.817 
0.801 
± 0.458b 
0.049b 
 
Nuclear 
receptor 
DAY 7  
PLASTIC 
DAY 7  
COLLAGEN 
DAY 7 
MATRIGEL P VALUE 
33$5ȕ 
0.455 
± 0.057 
0.301 
± 0.066 
0.340  
± 0.068 NS 
LXR ȕ 
0.527 
± 0.135 
0.226 
± 0.043 
0.403 
± 0.137 NS 
PXR 
0.372 
± 0.102 
0.176 
± 0.040c 
0.519 
± 0.133c 0.021c 
FXR 
0.060 
± 0.021b 
0.051 
± 0.011c 
0.334 
± 0.143b,c 
0.018b; 
0.012c 
HSC 
Marker 
DAY 7  
PLASTIC 
DAY 7  
COLLAGEN 
DAY 7 
MATRIGEL P VALUE 
CRBP1 
1.141 
± 0.415a 
0.070 
± 0.010a 
1.115 
± 0.513 
0.048a 
 
GFAP 
1.289 
± 0.372b 
3.952 
± 1.302 
5.936 
± 2.145b 0.026b 
CSRP2 
0.018 
± 0.001 
0.051 
± 0.016c 
0.005  
± 0.004c 
 
0.019c 
mRNA level measured using Taqman Real-time PCR, values  shown relative to         
ȕ-actin, n = 8 for each group. Data is presented as mean ± S.E.M. 
(a: Day 7 plastic vs Day 7 collagen; b: Day 7 plastic vs Day 7 matrigel;  c: Day 7 
collagen vs Day7 matrigel; NS- Not significant) 
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'D\  SODVWLF SODWHG +6&V VKRZHG DQ LQFUHDVH LQ &(%3ȕ /;5Į
CD36, FA%3 DQG 7*)ȕ H[SUHVVLRQ DQG D UHGXFWLRQ LQ *)$3 H[SUHVVLRQ
significantly compared to other groups. This indicated that HSCs on plastic 
surface were activated and in the early initiation phase, however some of the 
adipogenic genes thought to be associated with quiescence were still expressed 
DW VLPLODU OHYHOV WR WKRVH FHOOV SODWHG RQ PDWULJHO ,QWHUVWLQJO\ Į-SMA 
expression was similar on plastic and matrigel surfaces after 7 days in culture 
suggesting that clear differences in terms of activation state of the HSCs was 
not apparent. 
 
'D\FROODJHQSODWHGFHOOVH[SUHVVHGORZHUOHYHOVRI&5%37*)ȕ
DQG Į60$ DFFRPSDQLHG E\ DQ HOHYDWLRQ LQ &653 7KH FHOO PRUSKRORJ\
indicated that stellate cells plated on collagen were transdifferentiated.  
 
Day 7 matrigel SODWHG+6&VKDGKLJKHUOHYHOVRI33$5Ȗ3;5);5
and GFAP expression and surprisingly, reduced FABP4 expression.  
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5.5. Gene expression in activated HSCs culture on different surfaces 
 
 
 
FLJXUH  &653 DQG 7*)ȕ JHQH H[SUHVVLRQ LQ KXPDQ DFWLYDWHG VWHOODWH FHOOV
plated on different surfaces for 7 days. mRNA level measured using Taqman Real-
WLPH3&5YDOXHVVKRZQUHODWLYHWRȕ-actin, n = 8 for each group. Data is presented as 
mean ± S.E.M. (*: p<0.05; **: p<0.01; ***: p <0.000). 
Activated stellate cells plated on collagen surfaces increased in CSRP2 
H[SUHVVLRQDQGGHFUHDVHGLQ7*)ȕH[SUHVVLRQFRPSDUHGWRRWKHUJURXSV 
 
 
 
CSRP2 gene expression in human activated stellate cells on Day 7 on different 
surface 
7*)ȕ gene expression in human activated stellate cells on Day 7 on different 
surface 
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5.5. Gene expression in activated HSCs culture on different surfaces 
 
 
Figure 5.13: CD36 and FABP4 gene expression in human activated stellate cells 
plated on different surfaces for 7 days. mRNA level measured using Taqman Real-
WLPH3&5YDOXHVVKRZQUHODWLYHWRȕ-actin, n = 8 for each group. Data is presented as 
mean ± S.E.M. (*: p<0.05; **: p<0.01; ***: p <0.000). 
Both CD36 and FABP4 expression increased significantly in collagen plated 
activated stellate cells in culture compared to other group. 
 
 
 CD36 gene expression in human activated stellate cells on Day 7 on different surface 
 
FABP4 gene expression in human activated stellate cells on Day 7 on different 
surface 
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Table 5.3: Gene expression levels of HSCs grown for 14 days on plastic 
followed by 7 days culture on new tissue culture surfaces. 
Adipogenic  
genes 
DAY 7 on 
PLASTIC 
DAY 7 on 
COLLAGEN  
DAY 7 on 
MATRIGEL 
 
 P VALUE 
33$5Ȗ 
0.111  
± 0.044 
0.004  
± 0.001 
0.071  
± 0.035 NS 
SREBP-1C 
0.053  
± 0.017 
0.062  
± 0.014 
0.070  
± 0.016 NS 
&(%3Į 
0.010  
± 0.003 
0.022 
 ± 0.004 
0.021 
 ± 0.006 NS 
&(%3ȕ 
0.150 
 ± 0.054 
0.101  
± 0.017 
0.174  
± 0.044 NS 
/;5Į 
0.033  
± 0.011 
0.022  
± 0.004 
0.035  
± 0.009 NS 
Nuclear  
receptor 
DAY 7 on 
PLASTIC 
DAY 7 on 
COLLAGEN  
DAY 7 on 
MATRIGEL 
 
 P VALUE 
33$5ȕ 
0.588  
± 0.139 
1.029  
± 0.315 
0.784 
± 0.061 NS 
/;5ȕ 
0.173  
± 0.054 
0.276  
± 0.059 
0.271  
± 0.034 NS 
PXR 
0.023  
± 0.011 
0.005  
± 0.001 
0.024  
± 0.005 NS 
FXR 
0.268  
± 0.117 
0.197  
± 0.032 
0.206  
± 0.062 NS 
HSC  
marker 
DAY 7 on 
PLASTIC 
DAY 7 on 
COLLAGEN  
DAY 7 on 
MATRIGEL 
 
 P VALUE 
Į60$ 
0.688  
± 0.279 
0.296  
± 0.039 
0.927  
± 0.274 NS 
CRBP1 
0.160  
± 0.062 
0.050 
 ± 0.004 
0.260  
± 0.111 NS 
GFAP 
0.014  
± 0.005 
0.091  
± 0.058 
0.052  
± 0.040 NS 
mRNA level measured using Taqman Real-time PCR, values  shown relative to         
ȕ-actin, n = 8 for each group. Data is presented as mean ± S.E.M. (a: Day 7 on plastic vs 
Day 7 on collagen; b: Day 7 on plastic vs Day 7 on matrigel; c: Day 7 on collagen vs Day 7 on 
matrigel; NS: Not significant).  
 No clear pattern of changes in gene expression on different surfaces or 
at different time points was observed in terms of cells either maintaining their 
adipogenic phenotype or becoming activated. Overall, levels of expression of 
many of the gens studied, particularly after 21 days in culture were low. It was 
possible that the HSCs had effectively become de-differentiated to a certain 
degree. 
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5.6. Investigation of changes in human HSCs phenotype over time in 
culture 
 Human HSCs phenotypic changes and changes in underlying gene 
expression levels are not described clearly in the literature. Thus, the aim of 
this section of the study was to describe the changes in stellate cells activation 
over time.  
 
 
Figure 5.14: PPAR ȖDQG65(%3&JHQHH[SUHVVLRQ LQKXPDQKHSDWLFVWHOODWHFHOOV
plated on plastic over time in culture. mRNA level measured using Taqman Real-time 
3&5 YDOXHV  VKRZQ UHODWLYH WR ȕ-actin, n = 8 for each group. Data is presented as 
mean ± S.E.M. (*: p<0.05; **: p<0.01; ***: p <0.000). 
PPAR Ȗ H[SUHVVLRQ GHFUHDVHG VLJQLILFDQWO\ RQ GD\  FRPSDUHG WR GD\ 
SREBP1C expression was at the highest in fresh stellate cells group compared 
to other group. 
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 5.6. Investigation of changes in Human HSCs phenotype over time in 
culture 
 
 
)LJXUH&(%3ĮDQG/;5ĮJHQHH[SUHVVLRQLQKXPDQKHSDWLFVWHOODWHFHOOVSODWHG
on plastic over time in culture. mRNA level measured using Taqman Real-time PCR, 
values  shown relative tRȕ-actin, n = 8 for each group. Data is presented as mean ± 
S.E.M. (*: p<0.05; **: p<0.01; ***: p <0.000). 
%RWK &(%3Į DQG /;5Į ZHUH KLJKO\ H[SUHVVHG LQ IUHVK VWHOODWH FHOOV JURXS
compared to other group. 
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5.6. Investigation of changes in Human HSCs phenotype over time in 
culture 
 
 
)LJXUHĮ60$DQG7*)ȕJHQHH[SUHVVLRQLQKXPDQKHSDWLFVWHOODWHFHOOVSODWHG
on plastic over time in culture. mRNA level measured using Taqman Real-time PCR, 
values  VKRZQUHODWLYHWRȕ-actin, n = 8 for each group. Data is presented as mean ± 
S.E.M. (*: p<0.05; **: p<0.01; ***: p <0.000). 
Į60$ H[SUHVVLRQ ZDV LQFUHDVHG VLJQLILFDQWO\ RQ GD\  FRPSDUHG WR RWKHU
JURXS7*)ȕZDVDWWKHKLJKHVWLQIUHVKVWHOODWHFHOOVJURXp compared to day 7 
and day 21. 
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5.6. Investigation of changes in Human HSCs phenotype over time in 
culture 
Table 5.4: Gene expression in human hepatic stellate cells plated on plastic 
over time in culture. 
Adipogenic 
genes Fresh HSCs DAY 7   DAY 14  DAY 21  P VALUE 
&(%3ȕ 
7.469 
± 2.417a,b,c 
0.747 
± 0.270a 
0.945 
± 0.079b 
0.150 
± 0.054c 
0.005a,; 0.032b;  
0.003c 
Fatty acid 
transporter Fresh HSCs DAY 7   DAY 14  DAY 21  P VALUE 
CD36 
3.715 
± 0.913a,b,c 
0.650 
± 0.101a 
0.551 
± 0.060b 
0.038 
± 0.017c 0.000a,b,c 
FABP4 
0.747 
± 0.413 
3.637 
± 1.159d,e 
0.195 
± 0.048d  
0.089 
± 0.005e 
0.037d; 
 0.030e 
Nuclear 
receptor Fresh HSCs DAY 7   DAY 14  DAY 21  P VALUE 
33$5ȕ 
1.389 
± 0.571 
0.455 
± 0.057 
0.830 
± 0.682 
0.588 
± 0.139 
 
NS 
/;5ȕ 
2.151 
± 0.576a,c 
0.527 
± 0.135a 
0.843 
± 0.108 
0.173 
± 0.054c 
0.006a;  
 0.001c 
PXR 
3.687 
± 0.867a,b,c 
0.372 
± 0.102a 
0.150 
± 0.002b 
0.023 
± 0.011c 
0.000a,c; 
0.001b 
FXR 
24.691 
± 4.903a,b,c 
0.060 
± 0.021a 
2.292 
± 0.392b 
0.268 
± 0.117c 0.000a,b,c 
HSC 
Marker Fresh HSCs DAY 7   DAY 14  DAY 21  P VALUE 
CRBP1 
1.206 
± 0.271 
1.141 
± 0.415 
1.390 
± 0.435 
0.160 
± 0.062 NS 
GFAP 
0.965 
± 0.468 
1.289 
± 0.372 
2.436 
± 0.107f 
0.014 
± 0.005f  0.003f  
CSRP2 
1.734 
± 0.313a,c 
0.018 
± 0.001a,d 
1.118 
± 0.235d,f 
0.016 
± 0.001c,f 
0.000a,c;0.004d; 
0.007f 
mRNA levels were measured using Taqman Real-time PCR, values are shown relative 
WRȕ-actin, n = 8 for each group. (a: Fresh HSC vs. Day 7 HSC; b: Fresh HSC vs. Day 14; c: 
Fresh HSC vs. Day 21; d: Day 7 vs. Day 14; e: Day 7 vs. Day 21;  f: Day 14 vs. Day 21) 
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Stellate cell gene expression was studied from Day 0 to Day 21 in cells 
SODWHG RQ SODVWLF 65(%3& &(%3Į &(%3ȕ /;5Į /;5ȕ &' 3;5
);5DQG7*)ȕH[SUHVVLRQZHUHDOOKLJKHVWLQIUHVKO\LVRODWHG+6&VDQGWKH
mRNA levels of these genes decreased significantly by day 7 and continued to 
fall at day 21. Surprisingly, given their role in the adipogenic phenotype of 
+6&V 33$5 Ȗ DQG )$%3 H[SUHVVLRQ LQFUHDVHG DW GD\  UHODWLYH WR IUHVKO\
isolated cells and then gradually decreased. 
 
Į60$H[SUHVVLRQZDVRQO\VLJQLILFDQWOy elevated at day 14 and CSRP2 
levels were also highest at this time point. This suggests that HSCs may only 
become fully activated after 14 days in culture. GFAP expression were 
increased gradually day 0 to day 14, but decreased significantly at the end of 
the culture. On day 21, gene expression in general was at the lowest levels. 
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5.7. Human HSC proliferation rate assessment using PCNA expression 
levels 
Human HSC proliferation rates were assessed initially by determining the level 
of proliferating cell nuclear antigen using western blotting. 
5.7.1. Day 7 HSCs on Matrigel coated surface 
               ȕ-actin (42KDa) 
              PCNA (36KDa) 
 
5.7.2. Day 7 HSCs on collagen coated surface 
 
             ȕ-actin (42KDa) 
              PCNA (36KDa) 
 
5.7.3. Day 7 on Matrigel coated surface after subculturing 
 
              ȕ-actin (42KDa) 
              PCNA (36KDa) 
 
5.7.4. Day 7 on collagen coated surface after subculturing 
 
              ȕ-actin (42KDa) 
              PCNA (36KDa) 
 
5.7.5.PCNA protien levels in Human HSCs over time when plated     
         on plastic  
       ȕ-actin (42KDa) 
       PCNA (36KDa) 
  Fresh HSC       Day 7                 Day 14             Day 21  
HSCs plated on matrigel did not show any PCNA expression whereas collagen 
plated HSCs show clear PCNA expression, suggesting higher level of mitosis. 
Day 14 HSCs show higher PCNA expression compared to freshly isolated 
HSCs. Both day 7 and 21 HSCs in culture did not show PCNA expression.  
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5.8. Effects of PDGF-BB on HSCs proliferation and gene expression 
PDGF-BB is a potent mitogenic factor that activates and causes the 
proliferation of stellate cells (Paik et al., 2009). PDGF is released during liver 
injury by kupffer cells. This section of the study aimed to determine the effects 
of PDGF-BB (Sigma, UK) upon stellate cell proliferation and activation to 
determine whether treatment with potentially anti-inflammatory and anti-
proliferative nuclear receptor ligands [(Pioglitazone: Molekula, Dorset); 
(GW0742 & GSK0660: Tocrisolve, UK); (GW3965: Sigma, UK)] could 
inhibit the effects of PDGF-BB. (As shown over leaf) 
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5.8.1. Effects of Pioglitazone (PGZ) in PDGF-BB treated freshly isolated HSCs 
Freshly isolated HSCs were incuEDWHGZLWKYHKLFOH'0623*=ȝ0IRUKRXUVFRQVHFXWLYHO\$IWHUKRXUVRIGUXJ WUHDWPHQW3'*)-BB 
(15ng/ml) was added for 48hours consecutively, followed by RNA extraction for gene expression analysis. 
  
  
 
Figure 5.17: Effect of PDGF-BB incubation on freshly isolated HSCs for 48hours followed by treatment with Pioglitazone (PGZ). mRNA level measured 
using Taqman Real-time PCR, valuHVVKRZQUHODWLYHWRȕ-actin, n = 8 for each group. Data is presented as mean ± S.E.M. (*: p<0.05; **: p<0.01; ***: p <0.000). 
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Table 5.5: Effects of PDGF-BB incubation on freshly isolated HSCs for 48 hours followed by treatment with Pioglitazone on gene expressions. 
Adipogenic 
genes Vehicle 
PDGF 
(15ng/ml) 
PGZ  
(5µM) 
PGZ (5µM) + 
PDGF(15ng/ml) P VALUE 
SREBP1C 
0.605  
± 0.196a 
0.000  
± 0.000a,c 
2.529  
± 0.952  
3.820  
± 1.226c  
0.000a; 
0.005c 
&(%3Į 
1.429 
± 0.227a 
0.553 
± 0.168a 
0.614 
± 0.218 
1.353 
± 0.417 0.043a 
&(%3ȕ 
1.305 
± 0.159 
0.633 
± 0.087 
1.026 
± 0.265 
0.612 
± 0.273 
 
NS 
/;5Į 
1.118 
± 0.059a,b 
0.417 
± 0.169a 
0.505 
± 0.190b 
0.866 
± 0.146 
0.006a;  
0.013b 
Fatty acid 
transporter Vehicle 
PDGF 
(15ng/ml) 
PGZ  
(5µM) 
PGZ (5µM) + 
PDGF(15ng/ml) P VALUE 
CD36 
0.915 
± 0.118 
1.304 
± 0.896 
0.870 
± 0.210 
2.391 
± 0.924 NS 
Nuclear 
receptor Vehicle 
PDGF 
(15ng/ml) 
PGZ  
(5µM) 
PGZ (5µM) + 
PDGF(15ng/ml) P VALUE 
/;5ȕ 
0.886 
± 0.299 
0.410 
± 0.131 
0.803 
± 0.282 
0.844 
± 0.431 NS 
PXR 
0.324 
± 0.114 
0.462 
± 0.277 
1.113 
± 0.276 
3.003 
± 1.451 NS 
FXR 
1.503 
± 0.330a 
0.318 
± 0.269a 
1.353 
± 0.838 
2.680 
± 1.656 0.003a 
HSC marker  Vehicle 
PDGF 
(15ng/ml) 
PGZ  
(5µM) 
PGZ (5µM) + 
PDGF(15ng/ml) P VALUE 
CRBP1 
1.098 
± 0.280a 
0.084 
± 0.051a,c 
0.589 
± 0.223 
1.431 
± 0.367c 
0.016a; 
0.003c 
Į60$ 
0.714 
± 0.151 
1.381 
± 0.888 
0.462 
± 0.127 
0.198 
± 0.192 NS 
GFAP 
0.913 
± 0.276a 
0.096 
± 0.059a 
0.822 
± 0.345 
0.665 
± 0.211 0.037a 
CSRP2 
0.922 
± 0.133a 
5.167 
± 3.656a 
0.703 
± 0.132 
1.295 
± 0.311 0.029a 
 
(a: Vehicle vs. PDGF; b: Vehicle vs. PGZ ; c:PDGF vs. (PGZ + PDGF); NS: not significant). mRNA levels measured using Taqman Real-time PCR, values  shown relative to 
ȕ-actin, n = 8 for each group. Data is presented as mean ± S.E.M.   
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PDGF-%%GHFUHDVHG65(%3&&(%3Į/;5Į);5&5%3DQG*)$3IROORZHGE\DQLQFUHDVHG33$5ȕDQG&653H[SUHVVLRQLQIUHVKOy 
LVRODWHG+6&V0HDQZKLOH3*=LQFUHDVHG65(%3&33$5Ȗ)$%3&5%3DQGGHFUHDVHG7*)ȕH[SUHVVLRQLQ3'*)-BB treated HSCs. 
3*=DOVRLQFUHDVHG33$5ȕH[SUHVVLRQFRPSDUHGWRYHKLFOH 
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5.8.2. Effects of LXR Agonist GW3965 in PDGF-BB treated freshly isolated HSCs 
)UHVKO\LVRODWHG+6&VZHUHLQFXEDWHGZLWKYHKLFOH'062*:ȝ0IRUKRXUVFRQVHFXWLYHO\$IWHUKRXUVRIGUug treatment, PDGF-BB 
(15ng/ml) was added for 48hours consecutively, followed by RNA extraction for gene expression analysis. 
  
  
Figure 5.18: Effect of PDGF-BB incubation on freshly isolated HSCs for 48hours followed by treatment with GW3965. mRNA level measured using Taqman 
Real-WLPH3&5YDOXHVVKRZQUHODWLYHWRȕ-actin, n = 8 for each group. Data is presented as mean ± S.E.M. (*: p<0.05; **: p<0.01; ***: p <0.000). 
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5.8.2. Effects of LXR Agonist GW3965 in PDGF-BB treated freshly isolated HSCs 
  
 
 
 
Figure 5.19: Effect of PDGF-BB incubation on freshly isolated HSCs for 48hours followed by treatment with GW3965. mRNA level measured using Taqman 
Real-time PCR, values  shRZQUHODWLYHWRȕ-actin, n = 8 for each group. Data is presented as mean ± S.E.M. (*: p<0.05; **: p<0.01; ***: p <0.000). 
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Table 5.6: Effects of PDGF-BB incubation on freshly isolated HSCs for 48 hours followed by treatment with GW3965 on gene expressions. 
 
Adipogenic 
genes Vehicle 
PDGF 
(15ng/ml) 
GW3965  
(2µM) 
GW3965 (2µM) + 
PDGF(15ng/ml) P VALUE 
&(%3Į 
1.429 
± 0.227a 
0.553 
± 0.168a 
0.841 
± 0.325 
0.343 
± 0.210 
 
0.043a 
&(%3ȕ 
1.305 
± 0.159b 
0.633 
± 0.087 
0.521 
± 0.159b 
0.805 
± 0.378 
 
0.036b 
/;5Į 
1.118 
± 0.059a 
0.417 
± 0.169a 
0.537 
± 0.188 
0.693 
± 0.279 0.006a 
Fatty acid 
transporter Vehicle 
PDGF 
(15ng/ml) 
GW3965  
(2µM) 
GW3965 (2µM) + 
PDGF(15ng/ml) P VALUE 
CD36 
0.915 
± 0.118 
1.304 
± 0.896 
0.969 
± 0.507 
0.563 
± 0.335 NS 
Nuclear 
receptor Vehicle 
PDGF 
(15ng/ml) 
GW3965  
(2µM) 
GW3965 (2µM) + 
PDGF(15ng/ml) P VALUE 
/;5ȕ 
0.886 
± 0.299 
0.410 
± 0.131 
0.867 
± 0.195 
0.788 
± 0.350 NS 
PXR 
0.324 
± 0.114b 
0.462 
± 0.277 
6.105 
± 1.590b 
1.385 
± 0.346 0.001b 
FXR 
1.503 
± 0.330a,b 
0.318 
± 0.269a 
0.004 
± 0.001b 
0.006 
± 0.001 
0.003a 
0.001b 
HSC  
marker  Vehicle 
PDGF 
(15ng/ml) 
GW3965  
(2µM) 
GW3965 (2µM) + 
PDGF(15ng/ml) P VALUE 
CRBP1 
1.098 
± 0.280a 
0.084 
± 0.051a 
0.741 
± 0.489 
0.548 
± 0.286 0.016a 
GFAP 
0.913 
± 0.276a 
0.096 
± 0.059a 
0.709 
± 0.225 
0.550 
± 0.258 0.037a 
 
(a: Vehicle vs. PDGF; b:Vehicle vs. GW3965; c: PDGF vs. (GW3965 + PDGF); NS: Not significant). mRNA levels measured using Taqman Real-time PCR, values  shown 
UHODWLYHWRȕ-actin, n = 8 for each group. Data is presented as mean ± S.E.M.   
 
*:LQFUHDVHG65(%3&DQG33$5ȖDQGUHGXFHG)$%3Į60$&653DQG7*)ȕLQ3'*)-BB treated cells. GW3965 alone increased 
65(%3&33$5Ȗ33$5ȕ3;5DQGUHGXFHG&(%3ȕDQG);5H[SUHVVLRQFRPSDUHGWRYHKLFOH 
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5.8.3. Effects of PPAR ȕ Agonist (GW0742) in PDGF-BB treated freshly isolated HSCs 
Freshly isolated HSCs were incubated with vehicle (0.004% DMSO), GW0742 (100nM) for 72hours consecutively. After 24 hours of drug 
treatment, PDGF-BB (15ng/ml) was added for 48hours consecutively, followed by RNA extraction for gene expression analysis. 
  
 
  
 
Figure 5.20: Effect of PDGF-BB incubation on freshly isolated HSCs for 48hours followed by treatment with GW0742. mRNA level measured using Taqman 
Real-time PCR, vDOXHVVKRZQUHODWLYHWRȕ-actin, n = 8 for each group. Data is presented as mean ± S.E.M. (*: p<0.05; **: p<0.01; ***: p <0.000). 
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5.8.3. Effects of PPAR ȕ Agonist (GW0742) in PDGF-BB treated freshly isolated HSCs 
 
  
 
  
 
Figure 5.21: Effect of PDGF-BB incubation on freshly isolated HSCs for 48hours followed by treatment with GW0742. mRNA level measured using Taqman 
Real-time PCR, values  shown relaWLYHWRȕ-actin, n = 8 for each group. Data is presented as mean ± S.E.M. (*: p<0.05; **: p<0.01; ***: p <0.000). 
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Table 5.7: Effects of PDGF-BB incubation on freshly isolated HSCs for 48 hours followed by treatment with GW0742 on gene expressions. 
 
Adipogenic 
genes Vehicle 
PDGF 
(15ng/ml) 
GW0742 
(100nM) 
GW0742(100nM) + 
PDGF(15ng/ml) P VALUE 
&(%3Į 
1.429 
± 0.227a 
0.553 
± 0.168a 
1.792 
± 0.332 
1.480 
± 0.636 0.043a 
&(%3ȕ 
1.305 
± 0.159 
0.633  
± 0.087 
2.930  
± 0.899 
3.130 
± 0.888 NS 
/;5Į 
1.118  
± 0.059a 
0.417  
± 0.169a 1.371 ± 0.618 
1.771 
± 0.506 0.006a 
Fatty acid 
transporter Vehicle 
PDGF 
(15ng/ml) 
GW0742 
(100nM) 
GW0742(100nM) + 
PDGF(15ng/ml) P VALUE 
FABP4 
0.698 
± 0.140 
0.659  
± 0.025 
0.147  
± 0.100 
0.137 
± 0.085 NS 
Nuclear 
receptor Vehicle 
PDGF 
(15ng/ml) 
GW0742 
(100nM) 
GW0742(100nM) + 
PDGF(15ng/ml) P VALUE 
/;5ȕ 
0.886 
± 0.299 
0.410 
± 0.131 
2.561 
± 1.452 
1.182 
± 0.351 NS 
HSC  
marker  Vehicle 
PDGF 
(15ng/ml) 
GW0742 
(100nM) 
GW0742(100nM) + 
PDGF(15ng/ml) P VALUE 
Į60$ 
0.714  
± 0.151 
1.381  
± 0.888 
0.338  
± 0.129 
0.188  
± 0.073 
 
NS 
GFAP 
0.913 
 ± 0.276a 
0.096  
± 0.059a 
11.055  
± 8.072 
5.664  
± 2.704 
0.037a 
 
7*)ȕ 
0.726  
± 0.095 
2.616  
± 1.506 
2.929  
± 0.164 
3.001  
± 0.621 
 
NS 
(a: Vehicle vs. PDGF; b: Vehicle vs. GW0742; c: PDGF vs. (GW0742 + PDGF); NS: Not significant). mRNA levels measured using Taqman Real-time PCR, values  shown 
UHODWLYHWRȕ-actin, n = 8 for each group. Data is presented as mean ± S.E.M.   
   
GW0742 increased PPAR Ȗ&');5&5%3DQGUHGXFHG&653H[SUHVVLRQLQ3'*)-BB treated freshly isolated HSCs.GW0742 increased 
PPAR ȕ3;5DQG&5%3EXt reduced SREBP1C expression compared to vehicle. 
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(IIHFWVRI33$5ȕ$QWDJRQLVW*6.LQ3'*)-BB treated freshly isolated HSCs 
)UHVKO\ LVRODWHG +6&V ZHUH LQFXEDWHG ZLWK YHKLFOH  '062 *6. ȝ0 IRU KRXUV FRQVHFXWLYHO\ $IWHU  KRurs of drug 
treatment, PDGF-BB (15ng/ml) was added for 48hours consecutively, followed by RNA extraction for gene expression analysis. 
  
 
Figure 5.22: Effect of PDGF-BB incubation on freshly isolated HSCs for 48hours followed by treatment with GSK0660. mRNA level measured using 
Taqman Real-WLPH3&5YDOXHVVKRZQUHODWLYHWRȕ-actin, n = 8 for each group. Data is presented as mean ± S.E.M. (*: p<0.05; **: p<0.01; ***: p <0.000).  
GSK0660 increased FABP4 and PXR expression in PDGF-BB treated freshly isolated HSCs. GSK0660 increased SREBP1C and FABP4 expression 
compared to vehicle group. 
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Table 5.8: Effects of PDGF-BB incubation on freshly isolated HSCs for 48 hours followed by treatment with GSK0660 on gene expressions. 
Adipogenic 
genes Vehicle 
PDGF 
(15ng/ml) 
GSK0660 
(1µM) 
GSK0660 (1µM) + 
PDGF(15ng/ml) P VALUE 
PPAR Ȗ 
0.479 
± 0.097 
0.021 
± 0.016 
0.688 
± 0.387 
1.174 
± 0.499 
 
NS 
&(%3Į 
1.429 
± 0.227a 
0.553 
± 0.168a 
1.221 
± 0.516 
0.831 
± 0.469 0.043a 
&(%3ȕ 
1.305 
± 0.159 
0.633  
± 0.087 
4.437 
± 2.166 
3.842 
± 1.493 
 
NS 
/;5Į 
1.118  
± 0.059a 
0.417  
± 0.169a 
1.296 
± 0.354 
1.529 
± 0.769 
 
0.006a 
Fatty acid 
transporter Vehicle 
PDGF 
(15ng/ml) 
GSK0660 
(1µM) 
GSK0660 (1µM) + 
PDGF(15ng/ml) P VALUE 
CD36 
0.915 
± 0.118 
1.304 
± 0.896 
1.867 
± 0.249 
2.074 
± 0.517 
 
NS 
Nuclear 
receptor Vehicle 
PDGF 
(15ng/ml) 
GSK0660 
(1µM) 
GSK0660 (1µM) + 
PDGF(15ng/ml) P VALUE 
PPAR ȕ 
0.272  
± 0.054a 
1.382 
± 0.341a 
1.094 
± 0.335 
1.595 
± 0.562 
 
0.044a 
/;5ȕ 
0.886 
± 0.299 
0.410 
± 0.131 
1.000 
± 0.128 
0.962 
± 0.376 
 
NS 
FXR 
1.503 
± 0.330a 
0.318 
± 0.269a 
1.031 
± 0.427 
0.405 
± 0.307 
 
0.003a 
HSC  
marker  Vehicle 
PDGF 
(15ng/ml) 
GSK0660 
(1µM) 
GSK0660 (1µM) + 
PDGF(15ng/ml) P VALUE 
CRBP1 
1.098  
± 0.280a 
0.084  
± 0.051a 
1.044 
± 0.160 
1.208 
± 0.163 
 
0.016a 
Į60$ 
0.714  
± 0.151 
1.381  
± 0.888 
0.602 
± 0.399 
0.233 
± 0.156 
 
NS 
GFAP 
0.913 
 ± 0.276a 
0.096  
± 0.059a 
2.886 
± 1.366 
3.946 
± 1.551 
 
0.037a 
CSRP2 
0.922  
± 0.133a 
5.167 
± 3.656a 
1.089 
± 0.242 
1.752 
± 0.549 
  
0.029a 
7*)ȕ 
0.726  
± 0.095 
2.616  
± 1.506 
2.794 
± 0.325 
1.808 
± 0.659 
 
NS 
(a: Vehicle vs. PDGF; b: Vehicle vs. GSK0660; c: PDGF vs. (GSK0660 + PDGF); NS: not significant). mRNA levels measured using Taqman Real-time PCR, values  shown 
UHODWLYHWRȕ-actin, n = 8 for each group. Data is presented as mean ± S.E.M.   
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5.8.5. Effects of PDGF-BB incubation on freshly isolated HSCs for 48hours followed by treatment with Pioglitazone (PGZ) & LXR 
Agonist (GW3965), 33$5ȕ Agonist and 33$5ȕ Antagonist (GSK0660) on cell proliferation assay 
)UHVKO\ LVRODWHG+6&VZHUH LQFXEDWHGRQYHKLFOH '0623*=ȝ0*:ȝ0*:Q0	*6.ȝ0IRU
72hours consecutively. After 24hours of drug treatment, PDGF-BB (15ng/ml) was added for 48hours consecutively, followed by MTT assay for 
cell proliferation analysis 
  
  
Figure 5.23: Effect of PDGF-BB incubation on freshly isolated HSCs for 48hours followed by treatment with Pioglitazone (PGZ) & LXR Agonist (GW3965), 
PPARȕ$JRQLVWDQG33$5ȕ Antagonist (GSK0660) on cell proliferation assay (**: p<0.05; ***: p<0.005).  
PGZ, GW3965, GW0742 and GSK0660 reduced PDGF-BB induced cell proliferation in freshly isolated HSCs. 
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5.8.6. Effects of Pioglitazone (PGZ) in PDGF-BB treated Day 7 HSCs 
'D\+6&VZHUHLQFXEDWHGRQYHKLFOH'062DQG3*=ȝ0IRUKRXUVFRQVHFXWLYHO\2QGD\3'*)-BB (15ng/ml) was added 
for 48hours consecutively, followed by RNA extraction for gene expression analysis. 
  
 
Figure 5.24: Effect of PDGF-BB incubation on day 7 HSCs for 48hours followed by treatment with PGZ. mRNA level measured using Taqman Real-time 
3&5YDOXHVVKRZQUHODWLYHWRȕ-actin, n = 8 for each group. Data is presented as mean ± S.E.M. (*: p<0.05; **: p<0.01; ***: p <0.000).  
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Table 5.9: Effects of PDGF-BB incubation on Day 7 HSCs for 48 hours followed by Pioglitazone treatment on gene expressions. 
Adipogenic 
genes Vehicle 
PDGF 
(15ng/ml) 
PGZ  
(5µM) 
PGZ (5µM) + 
PDGF(15ng/ml) P VALUE 
PPAR Ȗ 
1.412  
± 0.451 
0.842  
± 0.250 
0.606  
± 0.031 
0.591  
± 0.357 NS 
SREBP1C 
0.002  
± 0.000 
0.001  
± 0.000 
0.003  
± 0.001 
0.003  
± 0.001 NS 
&(%3Į 
0.251  
± 0.112 
0.106  
± 0.006 
0.314  
± 0.097 
0.363  
± 0.225 NS 
&(%3ȕ 
0.594  
± 0.209 
1.399  
± 0.936 
0.525  
± 0.285 
0.647  
± 0.374 NS 
/;5Į 
0.395  
± 0.145 
0.370  
± 0.092 
0.256  
± 0.069 
0.267  
± 0.088 NS 
Fatty acid 
transporter Vehicle 
PDGF 
(15ng/ml) 
PGZ  
(5µM) 
PGZ (5µM) + 
PDGF(15ng/ml) P VALUE 
CD36 
0.409  
± 0.179 
0.293  
± 0.100 
0.068  
± 0.057 
0.466  
± 0.406 NS 
Nuclear 
receptor Vehicle 
PDGF 
(15ng/ml) 
PGZ  
(5µM) 
PGZ (5µM) + 
PDGF(15ng/ml) P VALUE 
/;5ȕ 
0.636  
± 0.257 
0.610  
± 0.139 
0.570  
± 0.069 
0.629  
± 0.357 NS 
PXR 
1.080  
± 0.197 
0.639  
± 0.024 
2.647  
± 0.651 
2.500  
± 0.931 
 
NS 
FXR 
0.001  
± 0.000 
0.001 ± 
0.000 
0.002  
± 0.000 
0.002  
± 0.001 NS 
HSC 
marker  Vehicle 
PDGF 
(15ng/ml) 
PGZ  
(5µM) 
PGZ (5µM) + 
PDGF(15ng/ml) P VALUE 
CRBP1 
0.330  
± 0.125 
0.432  
± 0.112 
0.572  
± 0.042 
0.391  
± 0.092 NS 
GFAP 
0.674  
± 0.253 
0.852  
± 0.360 
1.463  
± 0.495 
1.663  
± 0.883 NS 
CSRP2 
0.503  
± 0.068 
0.627  
± 0.160 
0.381  
± 0.044 
0.282  
± 0.095 NS 
7*)ȕ 
0.859  
± 0.178 
0.983  
± 0.348 
0.848  
± 0.013 
0.650  
± 0.262 NS 
[NS: not significant]. mRNA levels measured using Taqman Real-WLPH3&5YDOXHVVKRZQUHODWLYHWRȕ-actin, n = 8 for each group. Data is presented as mean ± S.E.M.   
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PDGF-BB has much less effect upon gene expression in cells cultured for 7 days as compared to freshly isolated cells. No significant different 
between vehicle and PDGF-BB treated HSCs on day 7. PGZ increased FABP4 expression and GHFUHDVHGĮ60$OHYHOVLQ3'*)-BB treated Day 
7 HSCs. PGZ increased both 33$5ȕ and FABP4 expression compared to vehicle. 
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5.8.7. Effects of LXR Agonist (GW3965) in PDGF-BB treated Day 7 HSCs 
'D\+6&VZHUHLQFXEDWHGRQYHKLFOH'062DQG*:ȝ0IRUKRXUVFRQVHFXWLYHO\. On day 8, PDGF-BB (15ng/ml) was 
added for 48hours consecutively, followed by RNA extraction for gene expression analysis. 
  
Figure 5.25: Effect of PDGF-BB incubation on day 7 HSCs for 48hours followed by treatment with GW3965. mRNA level measured using Taqman Real-time 
3&5YDOXHVVKRZQUHODWLYHWRȕ-actin, n = 8 for each group. Data is presented as mean ± S.E.M. (*: p<0.05; **: p<0.01; ***: p <0.000).  
GW3965 reduced FABP4 expression in PDGF treated Day 7 HSCs. MeanwhiOH *: DORQH LQFUHDVHG 33$5 ȕ expression but reduced 
FABP4 expression. All the other genes show no significant difference as shown in Table 5.7.1. over leaf. 
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Table 5.10: Effects of PDGF-BB incubation on Day 7 HSCs for 48 hours followed by GW3965 treatment on gene expressions. 
Adipogenic 
genes Vehicle 
PDGF 
(15ng/ml) 
GW3965  
(2µM) 
GW3965 (2µM) + 
PDGF(15ng/ml) P VALUE 
33$5Ȗ 
1.412  
± 0.451 
0.842  
± 0.250 
0.972  
± 0.427 
1.390  
± 0.665 NS 
SREBP1C 
0.002  
± 0.000 
0.001  
± 0.000 
1.465  
± 1.140 
0.971  
± 0.691 NS 
&(%3Į 
0.251  
± 0.112 
0.106  
± 0.006 
0.394  
± 0.209 
0.571  
± 0.182 NS 
&(%3ȕ 
0.594  
± 0.209 
1.399  
± 0.936 
2.617  
± 1.282 
0.667  
± 0.273 NS 
/;5Į 
0.395  
± 0.145 
0.370  
± 0.092 
1.289  
± 0.255 
1.466  
± 0.570 NS 
Fatty acid 
transporter Vehicle 
PDGF 
(15ng/ml) 
GW3965  
(2µM) 
GW3965 (2µM) + 
PDGF(15ng/ml) P VALUE 
CD36 
0.409  
± 0.179 
0.293  
± 0.100 
0.665  
± 0.427 
1.599  
± 1.061 NS 
Nuclear 
receptor Vehicle 
PDGF 
(15ng/ml) 
GW3965  
(2µM) 
GW3965 (2µM) + 
PDGF(15ng/ml) P VALUE 
/;5ȕ 
0.636  
± 0.257 
0.610  
± 0.139 
1.263  
± 0.557 
0.428  
± 0.147 NS 
PXR 
1.080  
± 0.197 
0.639  
± 0.024 
4.943  
± 1.795 
4.835  
± 2.053 NS 
FXR 
0.001  
± 0.000 
0.001  
± 0.000 
0.006  
± 0.001 
0.005  
± 0.002 NS 
HSC  
marker  Vehicle 
PDGF 
(15ng/ml) 
GW3965  
(2µM) 
GW3965 (2µM) + 
PDGF(15ng/ml) P VALUE 
CRBP1 
0.330  
± 0.125 
0.432  
± 0.112 
0.768  
± 0.111 
1.406  
± 1.133 NS 
Į60$ 
2.429  
± 1.006 
1.764  
± 0.656 
1.413  
± 0.861 
0.556  
± 0.277 NS 
GFAP 
0.674  
± 0.253 
0.852  
± 0.360 
1.247  
± 0.259 
0.416  
± 0.182 NS 
CSRP2 
0.503  
± 0.068 
0.627  
± 0.160 
0.558  
± 0.166 
0.425  
± 0.184 NS 
7*)ȕ 
0.859  
± 0.178 
0.983  
± 0.348 
1.436  
± 0.302 
0.770  
± 0.383 NS 
[NS: Not significant]. mRNA levels measured using Taqman Real-WLPH3&5YDOXHVVKRZQUHODWLYHWRȕ-actin, n = 8 for each group. Data is presented as mean ± S.E.M.   
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5.8.8. Effect of 33$5ȕ Agonist (GW0742) in PDGF-BB treated on Day 7 HSCs 
Day 7 HSCs were incubated on vehicle (0.004% DMSO), GW0742 (100nM) for 72hours consecutively. On day 8, PDGF-BB (15ng/ml) was 
added for 48hours consecutively, followed by RNA extraction for gene expression analysis. 
  
  
 
Figure 5.26: Effect of PDGF-BB incubation on day 7 HSCs for 48hours followed by treatment with GW0742. mRNA level measured using Taqman Real-time 
PCR, values  shown relative WRȕ-actin, n = 8 for each group. Data is presented as mean ± S.E.M. (*: p<0.05; **: p<0.01; ***: p <0.000).  
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Table 5.11: Effects of PDGF-BB incubation on Day 7 HSCs for 48 hours followed by GW0742 treatment on gene expressions. 
. 
Adipogenic 
genes Vehicle 
PDGF 
(15ng/ml) 
GW0742 
(100nM) 
GW0742(100nM) + 
PDGF(15ng/ml) P VALUE 
33$5Ȗ 
1.412  
± 0.451 
0.842 ± 
0.250 
5.340 ± 
2.307 
3.975  
± 1.425 
  
NS 
SREBP1C 
0.002  
± 0.000 
0.001  
± 0.00 
0.005  
± 0.002 
0.008  
± 0.003 NS 
&(%3Į 
0.251  
± 0.112 
0.106  
± 0.006 
1.194  
± 0.489 
2.327  
± 1.430 NS 
&(%3ȕ 
0.594  
± 0.209 
1.399  
± 0.936 
2.788  
± 1.496 
2.901  
± 1.994 NS 
/;5Į 
0.395  
± 0.145 
0.370  
± 0.092 
1.187  
± 0.497 
0.645  
± 0.374 NS 
Fatty acid 
transporter Vehicle 
PDGF 
(15ng/ml) 
GW0742 
(100nM) 
GW0742(100nM) + 
PDGF(15ng/ml) P VALUE 
CD36 
0.409  
± 0.179 
0.293  
± 0.100 
0.023  
± 0.016 
0.586  
± 0.430 NS 
Nuclear 
receptor Vehicle 
PDGF 
(15ng/ml) 
GW0742 
(100nM) 
GW0742(100nM) + 
PDGF(15ng/ml) P VALUE 
33$5ȕ 
0.375  
± 0.121 
0.229  
± 0.047 
12.638  
± 8.692 
1.952  
± 0.837 NS 
PXR 
1.080  
± 0.197 
0.639  
± 0.024 
15.305 
 ± 11.899 
6.050  
± 1.208 NS 
FXR 
0.001  
± 0.000 
0.001  
± 0.000 
0.013  
± 0.010 
0.009  
± 0.004 NS 
HSC  
marker  Vehicle 
PDGF 
(15ng/ml) 
GW0742 
(100nM) 
GW0742(100nM) + 
PDGF(15ng/ml) P VALUE 
GFAP 
0.674  
± 0.253 
0.852 ± 
0.360 
4.364 ± 
3.159 
2.326  
± 0.954 NS 
CSRP2 
0.503 
 ± 0.068 
0.627 ± 
0.160 
1.067 ± 
0.403 
0.616  
± 0.307 NS 
7*)ȕ 
0.859  
± 0.178 
0.983 ± 
0.348 
0.627 ± 
0.621 
0.710  
± 0.434 NS 
 
(NS: Not significant). mRNA levels measured using Taqman Real-WLPH3&5YDOXHVVKRZQUHODWLYHWRȕ-actin, n = 8 for each group. Data is presented as mean ± S.E.M.   
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PDGF-BB has much less effect upon gene expression in cells cultured for 7 days as compared to freshly isolated cells. No significant different 
between vehicle and PDGF-%% WUHDWHG +6&V RQ GD\ *: UHGXFHG ERWK )$%3 DQG Į60$ OHYHOV DQG LQFUHDVHG &5%3 OHYHOV LQ    
PDGF-BB WUHDWHG'D\+6&V*:LQFUHDVHG/;5ȕDQGUHGXFHG)$%3H[SUHVVLRQFRPSDUHGWRYHKLFOH 
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5.8.9. Effect of 33$5ȕ Antagonist (GSK0660) in PDGF-BB treated on Day 7 HSCs 
Day 7 HSCs were incubated on vehicle (0.004% DMSO) and GSK0ȝ0IRUKRXUVFRQVHFXWLYHO\2QGD\3'*)-BB (15ng/ml) was 
added for 48hours consecutively, followed by RNA extraction for gene expression analysis. 
  
Figure 5.27: Effect of PDGF-BB incubation on day 7 HSCs for 48hours followed by treatment with GSK0660. mRNA level measured using Taqman Real-
WLPH3&5YDOXHVVKRZQUHODWLYHWRȕ-actin, n = 8 for each group. Data is presented as mean ± S.E.M. (*: p<0.05; **: p<0.01; ***: p <0.000).  
GSK0660 increased both SREBP1C and CRBP1 level compared to vehicle. No other gene expressions showed any significant difference (as 
shown in Table 5.8.1. over leaf). 
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Table 5.12: Effects of PDGF-BB incubation on Day 7 HSCs for 48 hours followed by GSK0660 treatment on gene expressions. 
Adipogenic 
genes Vehicle 
PDGF 
(15ng/ml) 
GSK0660 
(1µM) 
GSK0660 (1µM) + 
PDGF(15ng/ml) P VALUE 
PPAR Ȗ 
1.412  
± 0.451 
0.842  
± 0.250 
3.831  
± 1.502 
3.092  
± 1.212 NS 
&(%3Į 
0.251  
± 0.112 
0.106  
± 0.006 
0.491  
±  0.149 
0.435  
± 0.334 NS 
&(%3ȕ 
0.594  
± 0.209 
1.399  
± 0.936 
1.949  
± 0.669 
0.119  
± 0.075 NS 
/;5Į 
0.395  
± 0.145 
0.370  
± 0.092 
0.460  
± 0.270 
0.308  
± 0.179 NS 
Fatty acid 
transporter Vehicle 
PDGF 
(15ng/ml) 
GSK0660 
(1µM) 
GSK0660 (1µM) + 
PDGF(15ng/ml) P VALUE 
CD36 
0.409  
± 0.179 
0.293  
± 0.100 
1.076  
± 1.073 
0.003  
± 0.001 NS 
FABP4 
0.382  
± 0.092 
0.406  
± 0.127 
0.099  
± 0.099 
0.246  
± 0.245 NS 
Nuclear 
receptor Vehicle 
PDGF 
(15ng/ml) 
GSK0660 
(1µM) 
GSK0660 (1µM) + 
PDGF(15ng/ml) P VALUE 
PPAR ȕ 
0.375  
± 0.121 
0.229  
± 0.047 
6.806  
± 5.692 
2.381  
± 1.135 NS 
/;5ȕ 
0.636  
± 0.257 
0.610  
± 0.139 
1.519  
± 0.761 
0.759  
± 0.496 NS 
PXR 
1.080  
± 0.197 
0.639  
± 0.024 
9.645  
± 3.411 
4.140  
± 1.994 NS 
FXR 
0.001  
± 0.000 
0.001  
± 0.000 
0.009  
± 0.003 
0.008  
± 0.003 NS 
HSC  
marker  Vehicle 
PDGF 
(15ng/ml) 
GSK0660 
(1µM) 
GSK0660 (1µM) + 
PDGF(15ng/ml) P VALUE 
Į60$ 
2.429  
± 1.006 
1.764  
± 0.656 
0.202  
± 0.197 
1.804  
± 1.266 NS 
GFAP 
0.674  
± 0.253 
0.852  
± 0.360 
4.231  
± 3.212 
2.010  
± 1.204 NS 
CSRP2 
0.503  
± 0.068 
0.627  
± 0.160 
1.130  
± 0.450 
0.802  
± 0.142 NS 
7*)ȕ 
0.859  
± 0.178 
0.983  
± 0.348 
2.245  
± 1.011 
1.125  
± 0.733 NS 
[NS: Not significant]. mRNA levels measured using Taqman Real-WLPH3&5YDOXHVVKRZQUHODWLYHWRȕ-actin, n = 8 for each group. Data is presented as mean ± S.E.M.   
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5.8.10. Effect of Pioglitazone (PGZ) & /;5$JRQLVW*:DQG33$5ȕ Agonist (GW0742) in PDGF-BB treated Day 7 HSCs on cell 
proliferation assay  
Day 7 HSCs were incubated with vehicle (0.004%), PGZ or GW3965 for 72hours consecutively. On day 8, PDGF-BB was added for 48hours 
consecutively, followed by MTT assay for cell proliferation analysis. 
  
 
Figure 5.28: Effect of Pioglitazone (PGZ) & LXR Agonist (GW3965) and PPAR ȕ Agonist (GW0742)in PDGF-BB treated Day 7 HSCs on cell proliferation assay (**: 
p<0.05; ***: p<0.005).  
PGZ reduced cell proliferation compared to vehicle group, whereas GW3965 reduced PDGF-BB induced cell proliferation in day 7 HSCs. There 
are no significant effects of GW0742 treatment. 
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5.9. Discussion 
 In this chapter, the primary objective was to produce an in vitro cell 
culture model that is representative of human HSC   in vivo  and to model both 
quiescent and activated myofibroblastic phenotypes. The second objective was 
to determine the effect of potentially therapeutic nuclear receptor agonists and 
antagonists upon quiescent and activated stellate cell proliferation and gene 
expression. 
 
 Culturing the human stellate cells for different lengths of time and on 
different culture surfaces was assessed for the ability to generate quiescent and 
myofibroblastic HSCs. Day 7 HSC plated on plastic expressed a number of 
adipogenic genes at comparable levels to cells plated on matrigel suggesting 
that they had not become fully transdifferentiated into myofibroblast. &(%3ȕ
expression was highest in HSC grown on plastic as compared to other surfaces. 
Ribosomal S-6 kinase (RSK) activation and phosphorylation of Thr217 of 
&(%3ȕKDVEHHQVKRZQWRSURPRWHOLYHUILEURVLVERWKLQKXPDQVDQGLQDQLPDO
models (Buck & Chojkier, 7KHUHIRUHWKHHOHYDWLRQRI&(%3ȕLQ+6&V
plated on plastic may be indicative of an activated phenotype. The lower levels 
of GFAP expression observed in the HSCs plated on plastic could occur as a 
UHVXOW RI WKH LQFUHDVHG 7*)ȕ H[SUHVVLRQ &DUURWWL Ht al., 2008; Gressner & 
Weiskirchen, 2006). Interestingly, the results of PCNA expression protein 
analysis indicated that HSCs plated on plastic were not proliferating at a rapid 
UDWH7*)ȕKDVEHHQUHSRUWHGWRUHJXODWHSUROLIHUDWLRQDQGDFWLYDWLRQRIVWHOlate 
cells (Gressner & Weiskirchen, 2006; Robert & Sporn, 1993; Robert, 1998). It 
LV SRVVLEOH WKDW HOHYDWHG 7*)ȕ H[SUHVVLRQ PD\ LQKLELW PLWRVLV 5REHUW 	
Sporn, 1993; Robert, 1998). 
 
 CSRP2 is involved in stellate cell transdifferentiation, is a marker of 
myofibroblastic activation and is not expressed in hepatocytes, kupffer cells or 
sinusoidal endothelial cells (Weiskirchen et al., 2001). HSCs plated on 
collagen had the highest levels of CSRP2 and showed the clearest 
morphological signs of transdifferentiation. 
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Matrigel plated cells had the highest levels of PPAR Ȗ DQG 3;5
expression both of which are reported to inhibit stellate cell transdifferentiation 
(Haughton et al., 2006; She et al., 2005; Miyahara et al., 2000). FXR 
expression was also high in matrigel plated HSCs, and may be responsible for 
LQKLELWLRQRIĮ(1) collagen production (Fiorucci et al., 2004b). Also, the HSCs 
plated on matrigel had low levels of proliferation in agreement with Gaca et al. 
(2003). 
 
Overall, cells plated on plastic, collagen and matrigel behaved in a 
similar way to that previously described in the literature. HSCs grown on 
matrigel showed the lowest level of expression of activated HSC marker genes 
and had the lowest proliferation rates as assessed by PCNA protein content.  
 
 HSCs become activated when plated on plastic surfaces as previously 
reported by Bachem et al. (1992). Therefore in this study, stellate cells were 
activated and then plated on different surfaces to determine whether activation 
can be reversed by plating them on matrigel surface. No change in HSCs 
morphology was observed nor was adipogenic and nuclear receptor gene 
expression altered when HSCs were sub-cultured on matrigel after previously 
being cultured on plastic.  
 
Previous studies have reported that, PPAR Ȗ 65(%3-1C liver-X-
receptor (LXR)-Į&&$$7HQKDQFHGELQGLQJSURWHLQIDPLO\&(%3-ĮDQGȕ 
which are adipogenic transcriptional factors, are highly expressed in HSCs 
which help to maintain quiescent phenotype (Hazra et al., 2004; She et al., 
2005). In liver injury, HSC are activated and expression of the adipogenic 
transcriptional factors are reduced resulting in HSC transdifferentiation into 
activated myofibroblasts (Miyahara et al., 2000; Hazra et al., 2004; She et al., 
2005). Figure 5.29 shows the genes that are expressed in quiescent and 
activated stellate cells, and it indicates the roles of various growth factors and 
transcription factors in the two phases of stellate cell activation. 
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Figure 5.29: Quiescent and activated stellate cells gene expression. Quiescent 
stellate cells express a number of transcription factors which regulate the 
quiescent phenotype (names in blue). Once appropriate stimuli are received by 
the HSC, they undergo an initiation phase of activation, followed by 
perpetuation. Activated HSCs acquire expression of a number of transcription 
factors that quiescent cells did not have (names in red). Transcription factors 
shown in green are either equivalently expressed in both quiescent and 
activated HSCs (Ets) or their function remains poorly defined (Id1/2). 
(Adapted from Mann & Mann, 2009). 
(RAR: retinoid acid receptor; RXR: retinoid X-receptor; Lhx2: LIM 
Homoebox 2; MeCP2: methyl CpG binding protein 2; CREB: cyclic AMP 
response element binding protein; AP: activator protein; NF1: Nuclear factor 1; 
PRX: paired type Homoebox; KLF6: Kruppel like factor 6; MyoD: Myogenic 
D; c-Myb: Myb family protein; Id: Inhibitor of DNA binding; Ets1:E26 
transformation-specific 1; Sp1:specificity protein 1; SMAD: SMAD, mothers 
against decapentaplegic ; Mef2: Monocyte enhancer factor 2; Runx1a: runt-
related transcription factor ; RSK: ribosomal S-6 kinase; TIMP1: Tissue 
inhibitor metaloporteinase 1; C/EBP: CCAT enhancer binding protein; PXR: 
Preganane X-receptor; FXR: Farnesoid X-receptor; PPAR: peroxisome 
proliferator activator receptor; NFkB: nuclear factor kappa beta). 
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 PPAR Ȗ3;5);5&(%3Įhave all been reported as being expressed 
at high levels in quiescent stellate cells ZKHUHDV &(%3ȕ LV H[SUHVVHG LQ
activated stellate cells as shown in Figure 5.29 above (Mann & Mann, 2009). 
The data in this study indicates that in freshly isolated HSCs SREBP1C, 
&(%3Į /;5Į /;5ȕ 3;5 );5 DQG &' are all expressed at relatively 
high levels and expression declines over time in culture. &RQYHUVHO\&(%3ȕ 
&653DQG7*)ȕZHUHKLJKHst in freshly isolated HSC as compared to cells 
grown for 7, 14 or 21 days. This may indicate an overall de-differentiation of 
HSCs over time rather than transdifferentiation into myofibroblasts. However it 
is noteworthy that DVȕ-actin expression increased 6 times during stellate cells 
activation in a rat model (Derek Mann, personal communication university of 
1RWWLQJKDP  DQG WKDW LQ WKHVH VWXGLHV ȕ-actin was used as a reference 
gene, this may have potential confound effect, if the same is true in the current 
model.  Indeed many previous studies have used HSC that are passaged up to 5 
times in their experiments (Handy et al., 2010; Jameel et al., 2009). It may well 
be that when left in culture HSC in fact become partially dormant and have an 
intermediate phenotype that is neither activated nor quiescent; however, a 
comparison of gene expression profiles with HSC passaged several times and 
the normalisation using other reference gene [Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH)] will be required to substantiate this. 
 
 If the observed reduction in nuclear receptor and adipogenic gene 
expression over time is indicative of an activated phenotype, as indicated in 
part by the data from this study and from previous work, they may not be 
expressed at sufficient level in activated stellate cells to be a functional 
therapeutic target. This may indicate that .the therapeutic effects of nuclear 
receptor ligands. 
 
 PDGF-BB released by kupffer cells in vivo will bind to the PDGFB 
receptor (PDGFBR) on HSCs. This will in turn, lead to stellate cell activation 
and proliferation (Bonner, 2004; Pinzani et al., 1996). The next phase of this 
study was to determine the effects of nuclear receptor ligands upon blocking 
PDGF-BB mediated activation and proliferation of freshly isolated HSCs and 
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HSCs cultured for 7 days in an attempt to model the effects of nuclear receptor 
ligands upon quiescent and activated stellate cells respectively. 
 
PDGF-BB treatment of freshly isolated HSCs reduced both adipogenic 
gene and CRBP1 expression, but increased PPAR ȕDQG&653H[SUHVVLRQDQG
FHOO SUROLIHUDWLRQ 33$5ȕ KDV EHHQ GHVFULEHG DV EHLQJ D SURPRWHU RI VWHOODWH
cell activation and proliferation (Hellemans et al., 2003). CSRP2 is a marker 
for stellate cell transdifferentiation as reported in a previous study 
(Weiskirchen et al., 2001). Current findings suggest that, PDGF-BB induced 
stellate cells transdifferentiation into activated phenotype.  
 
Davis et al. (1990) has reported that, retinoic acid incubation in rat 
stellate cells, inhibit cell proliferation, interstitial collagen production as well as 
7*)ȕH[SUHVVLRQ7KXVUHGXFWLRQLQ&5%3E\3'*)-BB, leads to increased 
cell proliferation in this study. 
  
3LRJOLWD]RQH 3*= LV D 33$5 Ȗ OLJDQG UHSRUWHG WR H[HUW DQWL-
inflammatory and anti-fibrotic effects as described in Chapter 3 & 4. 
Pioglitazone treatment of PDGF-BB activated stellate cells restored both the 
adipogenic gene expression and nuclear receptor expression. PGZ also 
abolished PDGF-BB induced stellate cell proliferation and induction of 
DFWLYDWLRQPDUNHUV VXFK DVĮ-SMA. PGZ also iQFUHDVHG)$%3DQG33$5ȕ
expression in stellate cells. FABP4 is a fatty acid transporter which has been 
shown to play a role in maintaining the adipogenic phenotype of the stellate 
cells (Larter et al., 2008). 
 
GW3965 is an LXR agonist that can exert anti-inflammatory effects 
3DUN HW DO  *: VLJQLILFDQWO\ LQFUHDVHG 65(%3& DQG 33$5 Ȗ
expression in PDGF treated HSCs, whereas FABP4 expression was reduced as 
were activational markers. These data suggest that LXR activation can block 
stellate cell activation and proliferation induced by PDGF-BB, but the 
PHFKDQLVPRIDFWLRQLQWHUPVRIVLJQDOWUDQVGXFWLRQ*:UHGXFHG&(%3ȕ
H[SUHVVLRQDQGWKDWRI33$5ȕDVFRPSDUHGWRYHKLFOHWUHDWHGFHOOV 
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PDGF-%% 3LRJOLWD]RQH DQG *: DOO LQFUHDVHG 33$5 ȕ 
expression, which indicates that signals that both promote and repress stellate 
FHOODFWLYDWLRQFDQ LQFUHDVH33$5ȕH[SUHVVLRQ33$5ȕ LV WKRXJKW WRSOD\D
role in regulating retinol ester (RE) levels in rat stellate cells (Hellemans et al., 
2003) and has also been implicated in stellate cell activation and proliferation 
+HOOHPDQV HW DO  6KDQ HW DO  GHPRQVWUDWHG WKDW 33$5 ȕ QXOO
mice treated with CCl4 KDG LQFUHDVHG KHSDWLF $/7 71)Į DQG Į60$
expression levels, which they attributed to increased NFKß activation as 
FRPSDUHGWRZLOGW\SHPLFH7KXVLQWKHDEVHQFHRI33$5ȕKHSDWR[LFLW\DQG
liver fibrosis are exacerbated in response to chemically induced liver injury 
6KDQ HW DO  3;5 DQG 33$5 ȕ DFWLYDWLRQ KDYH EHHQ GHPRQVWUDWHG WR
block NFkB-mediated transcriptional activation of inflammatory genes in the 
OLYHU:DKOL,QFRQWUDVW33$5ȕKDVDOVREHHQVKRZQWRLQFUHDVHFHOO
proliferation in skin during wound healing (Michalik & Wahli, 2006) and 
potentiate colon poly formation in colon carcinogenesis animal model (Harman 
HWDO7KXVWKHUROHRI33$5ȕLQVWHOODWHFHOOVDQGLQGHHGLQDOOFHOOXODU
systems is undetermined in terms of whether activation is pro-proliferative and 
pro-inflammatory or the reverse.  
 
 This study sKRZHG WKDW WUHDWPHQW ZLWK WKH 33$5 ȕ DJRQLVW *:
LQFUHDVHG33$5Ȗ&'3;5DQG&5%3H[SUHVVLRQDQGGHFUHDVHG&653
expression and cell proliferation induced by PDGF-BB in freshly isolated 
+6&V 7KHVH HIIHFWV LQGLFDWH WKDW DFWLYDWLRQ RI 33$5 ȕ LQ Ireshly isolated 
HSCs does not promote stellate cell activation and proliferation as has been 
previously described (Hellemans et al., 2003). GW0742 also increased      
33$5 ȕ 3;5 DQG &5%3 DQG UHGXFHG 65(%3& H[SUHVVLRQ FRPSDUHG WR
vehicle, indicating that LQTXLHVFHQW+6&VDFWLYDWLRQRI33$5ȕPD\SURPRWH
expression of genes primarily involved in maintenance of stellate cell 
TXLHVFHQFH*6.LVD33$5ȕDQWDJRQLVWWKDWLQWKLVVWXG\ZDVVKRZQWR
increase FABP4 and PXR expression and reduce cell proliferation induced by 
PDGF-BB in freshly isolated HSCs. GSK0660 also elevated FABP4 
H[SUHVVLRQZKHQFRPSDUHGWRYHKLFOHLQFRQWUDVWWR33$5ȕDJRQLVWWUHDWPHQW
*:7KXVWKHHIIHFWVRIERWK33$5ȕDJRQLVWVDQGDQWDJRQLVWVSURPRWH
changes in gene expression that are hard to reconcile with both the received 
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wisdom in terms of the changes in gene expression observed when stellate cells 
become activated and also previous studies by Hellemans et al. (2003) 
H[DPLQLQJWKHUROHRI33$5ȕLQ+6& 
 
The effects of PDGF-BB were also studied in stellate cells cultured for 
7 days .The response of these cells to PDGF was minimal when compared to 
freshly isolated HSCs. This perhaps could be viewed as further evidence to 
suggest that when HSCs are cultured for any given length of time without sub-
culturing, they de-differentiate rather than trans-differentiate.  
 
In summary, the nuclear receptor ligands used in this study can clearly 
inhibit both proliferation and activation of quiescent stellate cells when 
challenged with PDGF-%% 7KH UROH RI 33$5 ȕ KRZHYHU LV XQFOHDU DV ERWK
agonist and antagonist seemed to promote the expression of genes associated 
ZLWK D TXLHVFHQW +6& SKHQRW\SH DQG WKH 33$5 ȕ DQWDJRQLVW *6.
decreased PDGF-BB induced HSC proliferation. 
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CHAPTER 6 
General Discussion 
 
 Pioglitazone is a Thiazolidinediones (TZD) peroxisome proliferator 
DFWLYDWHG UHFHSWRU 33$5 Ȗ DJRQLVW ,W H[HUWV LWV HIIHFW E\ DFWLYDWLQJ ERWK
33$5 Ȗ DQG 33$5 Ȗ LVRIRUPV DV UHSRUWHG LQ &9-1 cells (Lehmann et al., 
1995) and also promotes cell differentiation in adipose tissue (Spiegelman & 
Flier, 1996)+RZHYHU WKH HIIHFWV RI33$5ȖDFWLYDWLRQDIWHU7=' WUHDWPHQW
have not been reported in detail in human liver. PGZ treatment in non-diabetic 
NASH patients did not apSHDUWRLQGXFH33$5ȖH[SUHVVLRQDWWKHP51$OHYHO
in whole liver, but an increase in expression was seen in human hepatic stellate 
cells in culture as seen in Chapter 5. This finding indicates that PGZ mediates 
at least some of its effects by acting direcWO\XSRQ33$5Ȗ LQKXPDQKHSDWLF
stellate cells rather than acting upon whole body lipid metabolism. However 
WKHHIIHFWVRI3*=XSRQ33$5ȖH[SUHVVLRQLQNXSIIHUFHOOVZDVQRWREVHUYHG
in this study, but it has been reported that kupffer cell expressed botK33$5Į
DQG 33$5 Ȗ (YHUHWW HW DO  *LYHQ WKH LPSRUWDQFH RI .XSIIHU FHOOV LQ
hepatic inflammation, it is likely that PGZ may also exert some of its effects 
upon tissue resident immune cells in the liver. 
 
33$5ȕH[SUHVVLRQZDVLQGXFHGDIWHU3*=WUHatment both in vivo and 
LQVWHOODWHFHOOV LQFXOWXUHDQG WKHVHILQGLQJVDSSHDU WREHQRYHO33$5ȕKDV
been reported to promote cell proliferation in stellate cells (Hellemans et al., 
2003) and also implicated in regulating proinflammatory genes in mice treated 
with CCl4 (Shan et al., 2008). Based on current findings, the increase in PPAR 
ȕ H[SUHVVLRQ REVHUYHG LQ 1$6+ SDWLHQWV PD\ EH SULPDULO\ LQ KHSDWRF\WHV
UDWKHU WKDQ VWHOODWH FHOOV DV 33$5 ȕ-positive stellate cells as observed by 
immunohistochemistry were reduced in PGZ-treated individuals. This increase 
in hepatocytes PPARȕFRXOGSRWHQWLDOO\HOHYDWHPLWRFKRQGULDOȕ-oxidation in 
non-diabetic NASH patients treated with PGZ.  
 
,Q IUHVKO\ LVRODWHG VWHOODWH FHOOV LQ FXOWXUH 33$5 ȕ H[SUHVVLRQ ZDV
increased after incubation with PDGF, PGZ, LXR agonist (GW3965) and 
33$5ȕDJRQLVW*:%RWK3'*)DQG*:WUHDWPHQWLQFUHDVHGFHOO
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proliferation. But in PGZ, GW3965 and (GW0742 + PDGF) treated inhibit 
both cell proliferation and the expression of stellate cell activation markers 
such as D-60$7KHIDFWWKDW*:DORQHFDXVHGXSUHJXODWLRQRI33$5Ȗ
CRBP1 and GFAP expression, all 3 genes associated with the quiescent, 
adipogenic stellate cell phenotype, suggests that the relationship between 
33$5 ȕ LQGXFWLRQ and stellate cell phenotype may not be as simple as 
previously described. Further studies are required understand the role of PPAR 
ȕDFWLYDWLRQLQDFWLYDWHGVWHOODWHFHOOVDVFRPSDUHGWRIUHVKO\LVRODWHGFHOOV ,Q
much of the current literature, stellate cells passaged 4 or 5 times are used as a 
model of myofibroblastic cells and it will be interesting to see how these cells 
respond to PPARȕOLJDQGV 
 
FABP4 is a fatty acid binding protein that is highly expressed in 
adipocytes and macrophages and the expression and activation of FABP4 has 
been reported to contribute to the pathogenesis of obesity, metabolic syndrome 
and associated inflammation (Makowski & Hotamisligil, 2004). FABP4 
expression was elevated in NAFLD liver compared to normal liver and NASH 
in this study. PGZ treatment did not increase FABP4 expression in human non-
diabetic NASH liver but increases were observed in human hepatic stellate 
cells in culture. This suggests that in stellate cells, FABP4 may play a different 
role to that observed in adipocytes and immune cells. It may also be true that 
FABP4 expression is associated with the quiescent state, FABP4 ligands may 
induce inflammatory signalling as has been observed in immune cells. Future 
studies should examine the role of FABP4 in both stellate cells and in kupffer 
cells to observe the effects of FABP4 ligands and PGZ, upon cellular activation 
and inflammation in the liver.  
 
Farnesoid X receptor (FXR) expression was studied both in human liver 
and stellate cells. In human liver biopsies, there was no observed difference in 
FXR expression between any of the groups studied. But in human hepatic 
stellate cells FXR expression was shown to be higher in freshly isolated stellate 
cells, as compared to cells cultured for longer periods of time. Furthermore, 
FXR expression was reduced by PDGF treatment and this reduction could be 
reversed by PGZ. The FXR ligand (GW4064) has been reported to induce 
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33$5ȖDQGGHFUHDVHĮFROODJHQĮ60$DQG7,03H[SUHVVLRQLQUDWVWHOODWH
cells in culture (Fiorucci et al., 2005). Thus, PGZ may exert anti-fibrotic effects 
at least in part by increasing stellate cell FXR expression in vivo. A future 
study should examine the effects of the specific FXR ligand (GW4064) and the 
FXR antagonist Guggulsterone upon PDGF-BB incubated HSCs. 
 
PGZ treatment increased PXR expression both in human liver and 
stellate cells. PXR is thought to exert anti-inflammatory effects by inhibiting 
1)N% WUDQVFULSWLRQDO DFWLYLW\ %RWK3*=DQG WKH33$5ȕDJRQLVW *:
increased PXR expression in stellate cells. The PXR agonist Rifampicin has 
been reported to play a role in inhibiting stellate cell proliferation, and 
UHSUHVVHV 7*)ȕ DQG Į60$ H[SUHVVLRQ 7KH HIIHFWV RI 3;5 DJRQLVW ȝ0
65 DQG 3;5 DQWDJRQLVW ȝ0 RI .HWRFRQD]ROH LQKLELW VWHOODWH FHOO
proliferation (was observed but not reported in this study). However, due to 
time constraints the effects of these ligands was not examined in PDGF-BB 
treated HSC.  
 
Cell proliferation was an important measurement in this study. Both 
PCNA and Ki67 expression were used as surrogate markers of cell 
proliferation. PCNA has been reported to be expressed in G1 and S phase 
followed by a decline in expression during G2 and M phase of the cell cycle 
(Foley et al. 1993). Ki67 is a more specific marker to of cell proliferation rate, 
and is used in cancer diagnosis and prognosis e (Scholzen & Gerdes, 2000). 
Ki67 is not expressed during G0 phase of the cell cycle and thus it only is 
detected in the nucleus of dividing cells.  
 
There are several limitations in this study, where in human hepatic 
VWHOODWHFHOOVFXOWXUHȕ-actin was used as the reference gene for Taqman RT-
PCR. During the viva voce examination, Prof Derek Mann advised that 
GAPDH should be used as the reference gene in the future for stellate cells 
JHQH H[SUHVVLRQ ȕ-actin expression increased 6 times during stellate cells 
activation (Derek Mann personal communication, University of Nottingham 
7KHXVDJHRIȕ-actin as the reference gene for stellate cells culture over 
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time period may explain the lower expression RIĮ60$DQG7*)ȕH[SUHVVLRQ
on day 7 and day 21.  
 
)XUWKHUPRUHYHULILFDWLRQRIĮ60$H[SUHVVLRQLQKXPDQKHSDWLFVWHOODWH
cells culture was not performed (immunocytochemistry staining), but the 
PDUNHUV IRU VWHOODWH FHOO DFWLYDWLRQ Į60$ 	 7*)ȕ ZHUH PHDVured using 
Taqman RT-3&5 )RU OLYHU LPPXQRKLVWRFKHPLVWU\ WKH Į60$ DQWLERG\
dilution should be increased either 1:100 or 1:200 due to slightly weak 
immunohistochemistry staining was observed in some samples.  
 
This thesis only examined liver biopsy and human hepatic stellate cell 
samples. There are other cell types that require individual study in order to 
understand the pathogenesis of NAFLD and NASH (see Figure 6.1). Kupffer 
cells, sinusoidal endothelial cells, billiary epithelial cells, platelets and T cells 
are all sources of proinflammatory signals that would activate stellate cells (see 
Figure 6.1). The data in this thesis indicate that PGZ treatment and PPAR J 
activation in general prevents stellate cell activation and proliferation. Future 
studies could examine the role of PPAR J and other nuclear receptors in other 
non-parenchymal cells types such as kupffer cells and sinusoidal endothelial 
cells. 
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Table 6.1: Mechanism pathway of hepatic fibrosis and stellate cell activation 
symbol and abbreviation 
Symbol Abbreviation 
CCL21 Chemokine (C-C motif) ligand 21 
CD40 CD40 molecule, TNF receptor superfamily member 5 
COL Collagen 
EGF Epidermal growth factor 
,)1Ȗ Interferon gamma 
IGF Insulin like growth factor 
IL6 Interleukin 6 
KLF6 Kruppel-like factor 6 
LHX2 LIM homeobox protein 2 
MMP Matrix metaloproteinase 
NS3 Nonstructural  viral protein 3 
NS5 Nonstructural viral protein 5 
PDGF Platelet derived growth factor 
SPARC secreted protein, acidic, cysteine-rich (osteonectin) 
7*)ȕ Transforming growth factor 
TIMP Tissue inhibitor metalloproteinase 
71)Į tumor necrosis factor alpha 
VEGF vascular endothelial growth factor 
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Figure 6.1: Mechanism pathway of hepatic fibrosis and stellate cell activation 
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Appendix 1: Human Primers and Probes used in this study 
 
ȕDFWLQ)RUZDUG3ULPHU 
¶- CCTGGCACCCAGCACAAT- ¶ 
ȕactin Reverse Primer 
¶±GCCGATCCACACGGAGTACT- ¶ 
ȕ actin Probe 
¶ATCAAGATCATTGCTCCTCCTGAGCGC-¶ 
 
HMBS Forward Primer 
¶-ACCTGGTTGTTCACTCCTTGAAG-¶ 
HMBS Reverse Primer 
¶-GGTTTTCCCGCTTGCAGAT-¶ 
HMBS Probe 
¶-ACCTGCCCACTGTGCTTCCTCCTG-¶ 
 
SREBP1C Forward Primer 
¶-GGAGGGGTAGGGCCAAC-¶ 
SREBP1C Reverse Primer 
¶-GTCAAATAGGCCAGGGAAGTC-¶ 
SREBP1C Probe 
¶-CGCGGAGCCATGGATTGCAC-¶ 
 
ChREBP Forward Primer 
¶-AGTATCGACCCCACACTCACAC-¶ 
ChREBP Reverse Primer 
¶-TTATTCAGGCGGATCTTGTCT-¶ 
ChREBP Probe 
¶-GCCTGGCCTACAGTGGCAAGCTG-¶ 
 
GCK Forward Primer 
¶-GCTGGAATCAATTTCCCAGA-¶ 
GCK Reverse Primer 
¶-CTCCCCACACAGGATGAGTT-¶ 
GCK Probe 
¶-AGGGAGTTGCTCACTCAGGA-¶ 
 
PK2 Forward Primer 
¶-CACTAAAGGACCTGAGATCCGAACT-¶ 
PK2 Reverse Primer 
¶-TGTTCTCGTCACACTTTTCCATGT-¶ 
PK2 Probe 
¶-TCATCAAGGGCAGCGGCACTGCA-¶ 
 
PDK4 Forward Primer 
¶-CAAGGATGCTCTGTGATCAGTATTATTT-¶ 
PDK4 Reverse Primer 
¶-TGTGAATTGGTTGGTCTGGAAA-¶ 
PDK Probe 
¶-CATCTCCAGAATTAAAGCTTACACAAGTGAATGGA-¶ 
 
PPAR ȕ)RUZDUGSULPHU   
¶-TGCGGCCATCATTCTGTGT-¶ 
PPAR ȕ5HYHUVHSULPHU 
¶-CAGGATGGTGTCCTGGATAGC-¶ 
PPAR ȕ3UREH 
¶-ACC GGC CAG GCC TCA TGA ACG-¶ 
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33$5Ȗ)RUZDUG3ULPHU 
¶-GAT TCT CCT ATT GAC CCA GAA AGC-¶ 
33$5Ȗ5Hverse Primer 
¶-GCA TCT CTG TGT CAA CCA TGG T-¶ 
33$5Ȗ Probe 
¶-ATTCCTTCACTGATACACTGTCTGCAAACATAT-¶ 
 
FABP4 Forward Primer   
¶-CATAAAGAGAAAACGAGAGGATGATAAAC-¶ 
FABP4 Reverse Primer  
¶-CCCTTGGCTTATGCTCTCTCA-¶ 
FABP4 Probe 
¶-TGCGTCATGAAAGGCGTCACTTCC-¶ 
 
CEBPĮ Forward Primer  
¶-CAAATATTTTGCTTTATCAGCCGATA-¶ 
CEBPĮ Reverse Primer   
¶-CGCACATTCACATTGCACAA-¶ 
CEBPĮ Probe 
¶-AACACTTGTATCTGGCCTCTGTGCCCC-¶ 
 
&(%3ȕ Forward Primer 
¶-GAAGAAACGTCTATGTGTACAGATGAATG-¶ 
&(%3ȕ5HYHUVH3ULPHU 
¶-CCGATTGCATCAACTTCGAA-¶ 
&(%3ȕProbe 
¶-TAAACTCTCTGCTTCTCCCTCTGCCCCTC-¶ 
 
/;5Į)RUZDUG3ULPHU 
¶-GAGGAGTGTGTCCTGCTAGAAGAA-¶ 
/;5Į5HYHUVH3ULPHU 
¶-CCTCCTCTTGCCGCTTCA-¶ 
/;5Į3UREH 
TCCGCCTGAAGAAA 
 
/;5ȕ)RUZDUG3ULPHU 
¶-AGCAGTGCGTCCTTTCTGAAG-¶ 
/;5ȕ5HYHUVH3ULPHU 
¶-CCACAGGTGACTGCGACTGT-¶ 
/;5ȕ3UREH 
AAGAAGAAGATTCGGAAA 
 
PXR Forward Primer  
¶-GCCCAGTGTCAACGCAGAT-¶ 
PXR Reverse Primer 
¶-AGTGGCCTTGTCCCCACATA-¶ 
PXR Probe 
¶-TCGGAGGTCCCCAAATCTGCCG-¶ 
 
FXR Forward Primer 
¶-TCCTCCCAGGGCCTTGA-¶ 
FXR Reverse Primer 
¶-CTTTCACTCCTTCTACGATGTCTTCTAC-¶ 
FXR Probe 
¶-AGTCCATCTCTGACCCAAAACAATCCAAGG-¶ 
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Į60$)RUZDUG3ULPHU  
¶-GCAAGTGATCACCATCGGAAA-¶ 
Į60$Reverse Primer  
¶-GACTCCATCCCGATGAAGGA -¶ 
Į60$ Probe  
¶-AACGTTTCCGCTGCCCAGAGACC-¶ 
 
CRBP1 Forward Primer      
¶-GTGGCCTTGCGCAAAATC-¶ 
CRBP1 Reverse Primer    
¶-CCGTCCTGCACGATCTCTTT-¶ 
CRBP1 Probe     
¶-CAACTTGCTGAAGCCAGA-¶ 
 
GFAP Forward Primer   
¶-GAGATCCGCACGCAGTATGA -¶ 
GFAP Reverse Primer 
¶-ACTTGGAGCGGTACCACTCTTC-¶ 
GFAP Probe  
¶-CAATGGCGTCCAGCAACATGCATG-¶ 
 
CSRP2 Forward Primer   
¶-ACCGTGTACCACGCAGAAGAG-¶ 
CSRP2 Reverse Primer 
¶-AAAGCAGCAGCGGTGGAA-¶ 
CSRP2 Probe  
¶-TGCAGTGTGATGGCAG-¶ 
 
7*)ȕ)RUZDUG3ULPHU  
¶-CGCGCATCCTAGACCCTTT-¶ 
7*)ȕ5HYHUVH3ULPHU 
¶-CTGTGGCAGGTCGGAGAGA-¶ 
7*)ȕ1 Probe 
¶-TCCTCCAGGAGACGGA-¶ 
 
Adipisin Forward Primer  
¶-GGTCACCCAAGCAACAAAGTC-¶ 
Adipsin Reverse Primer  
¶-TCAATAAAGACCAACCAGATGCA-¶ 
Adipsin Probe  
¶-AGCAATGAAGTCATCC-¶ 
 
COX2 Forward Primer  
¶-GAATCATTCACCAGGCAAATTG-¶ 
COX2 Reverse Primer 
¶-CTTTCTGTACTGCGGGTGGAA-¶ 
COX2 Probe 
¶-TGCTGGTGGTAGGAAT-¶ 
 
CD36 Forward Primer 
¶-CTGGAGTCTGGAATTCAGAACGT -¶ 
CD36 Reverse Primer 
¶-GAAGTGAGGATGGGAGAGAAACA -¶ 
CD36 Probe 
¶-CCTGCAGGTTCAGTGCCCCC-¶ 
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Appendix 2: Low density Taqman Arrays Pathway 
Pathway Description: 
Decrease activation/ expression  
Increase activation/expression 
Enzyme    
 
Transcription regulator 
 
Ligand dependent nuclear receptor   
 
Transmembrane receptor 
 
Kinase     
 
Transporter 
 
Peptidase 
 
Phosphate 
 
Chemical endogenous  
 
Growth factor 
 
Cytokine 
 
G-protein coupled receptor 
 
microRNA 
 
Unknown (family)                                      or 
 
Protein- protein interaction 
 
 (Dark red box show higher expression and light pink box show lower expression in this study. 
Transparent box show the gene that is not determined in this study.) 
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NAFLD compared to Normal liver pathway analysis 
Pathway 1: Lipid metabolism, molecular transport, small molecular biochemistry 
 
(ME1:malic enzyme; T3-TR-RXR: T3-TR-RXR Interaction network; THRSP: thyroid 
hormone responsive; FASN: fatty acid synthase, FABP: fatty acid binding protein; LRRC8C: 
leucine rich repeat containing 8 family, member C; AQP7: aquaporin 7; CEBP-AP1: CEBP-
API nucleus complex; CEBPA: CCAT-enhancer binding protein alpha; TNF: tumor necrosis 
factor; ACAT1:acetyl-CoA acetyltransferase 1; SCCG: synuclein gamma; MMP21: matrix 
metallopeptidase 21; Hcg: Chorionic gonadotrophin; ERK1/2: p42/44 mapk; Akt: Protein 
kinase B; Jnk: JUN Kinase; BCL2: lymphoma 2; LDL: low density lipoprotein; 
MFHAS1:malignant fibrous histiocytoma amplified sequence 1; NR1I2: preganane X-receptor; 
XBP1: X-box binding protein; APOBEC3B: apolipoprotein B mRNA editing enzyme) 
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NAFLD compared to Normal liver pathway analysis 
Pathway 2: Cancer, cellular movement, Gene expression 
 
 
(UBA5: ubiquitin like modifier activating enzyme 5; HNF4A: HNF4 dimer; IL5: Interleukin 
15; Pgm: phosphoglucomutase; PAK1: p21 activated kinase 1; PAK3: p21-activated kinase 3; 
PTEN: phospahtase and tensin homolog; ERBB2: v-erb-b2 erythroblastic leukaemia viral 
oncogene homolog 2; S100A1: S100 calcium binding protein A1; S100B: S100 calcium 
binding protein) 
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NASH compared to Normal liver pathway analysis 
Pathway 1: Infection Mechanism, Infection Disease, Lipid Metabolism 
 
 
(ME1:malic enzyme; DEFB3:defensin beta 3; ARFGAP3: ADP ribosylation factor GTPase 
activating protein 3; GPR109B: G-protein coupled receptor 109B ; STARD3: StAR-related 
lipid transfer domain containing 3; ENDOG: endonuclease G; LRRC8C: leucine rich repeat 
containing 8 family, member C; PGM1: phosphoglucomutase 1; IL5: Interleukin 15; RBP3: 
retinol biding protein 3; PLIN4: perilipin 4; FADS1: fatty acid desaturase 1; RCN3: 
reticulocalbin 3; XBP1- X-box binding protein 1; MMD: Monocyte to macrophage 
differentiation associated; PCP4: purkinje cell protein 4; THRSP: thyroid hormone responsive; 
TNF: tumor necrosis factor; TPP2: tripeptidyl peptidase 2; SLC5A2: solute carrier family 5; 
MYC: v-myc myelocytomasis viral oncogene homolog; CIDEC: cell death inducing DFFA-
like effector c; SLC27A5: solute carrier 27, family 5; MLXIPL: MLX interacting protein-like; 
FOXE1:Foxhead box E1; AQP9: aquaporin 9; AOC3: amine oxidase 3; LGALS12: lectin, 
galactoside-binding soluble, 12; PRL2C3:prolactin family 2, subfamily C member 3; IL17B: 
Interleukin 17B; LOC729506: high mobility group nucleosomal biding domain 2 pseudogene; 
ACSL4: acyl-CoA synthetase long chain family 4) 
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NAFLD compared to NASH pathway analysis 
Pathway 1: Lipid Metabolism, small molecular biochemistry, carbohydrate 
metabolism 
 
[ME1:malic enzyme; ARFGAP3: ADP ribosylation factor GTPase activating protein 3; 
STARD3: StAR-related lipid transfer domain containing 3; LRRC8C: leucine rich repeat 
containing 8 family, member C; PGM1: phosphoglucomutase 1; FADS1: fatty acid desaturase 
1; RCN3: reticulocalbin 3; XBP1- X-box binding protein 1; TNF: tumor necrosis factor; TPP2: 
tripeptidyl peptidase 2; SLC5A2: solute carrier family 5; MLXIPL: MLX interacting protein-
like; AQP9: aquaporin 9; LGALS12: lectin galactoside-binding soluble, 12; PRL2C3:prolactin 
family 2, subfamily C member 3; ACSL4: acyl-CoA synthetase long chain family 4; 
TMEM49: transmembrane protein 49; ZNF318: zink finger protein 318; TRIM15: tripartite 
motif containing 15; MGST2: microsomal glutathione S-transferase 2; ORM2:orosomucoid 2; 
LAD1:ladinin 1; HNF4A:hepatocyte nuclear factor 4 alpha; WNT10A:wingless type MMTV 
integration site family, member 10A; PAFAH2:platelet activating factor acetylhyrodrolase 2; 
LGALS42:lectin galactoside-binding soluble 42; G6PC:glucose 6 phosphatase; RTP3:receptor 
transporter protein 3; ZBTB1:zink finger BTB domain containing 11; C21ORF33:chromosome 
21 open reading frame 33; C22ORF28: chromosome 22 open reading frame 28; 
CLTCL1:clathrin, heavy chain like 1; PMPCA: peptidase (mitochondrial processing) alpha; 
SREBF1: sterol regulatory element binding protein factor 1] 
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Pioglitazone compared to Pre-trial pathway analysis 
Pathway 1: Lipid Metabolism, Molecular transport, Small molecule biochemistry 
 
 
(ME1:malic enzyme 1; ACADVL:acyl-CoA dehydrogenase very long chain; ACACB:acetyl 
CoA carboxylase beta; NCOA: interaction network; GPD1: glycerol-3-phosphate 
dehydrogenase 1; UCP2: uncoupling protein 2; PPARGC1A: peroxisome proliferator receptor 
gamma, coactivator alpha; RXRA: retinoid-X-receptor alpha; NR1I2: Pregnane-X-receptor; 
TNFRSF1B: tumor necrosis factor receptor superfamily 1B; IKBKB: inhibitor kappa light 
polypeptide gene enhancer in beta cells; Jnk: JUN KINASE; Pka: protein kinase A; APOE: 
Apolipoprotein E; Rxr: retinoid receptor; IL1: Interleukin 1; P38MAPK:P38 MITOGEN 
ACTIVATED PROTEIN KINASE ; Akt: Protein kinase B; Mapk: MAP Kinase; TCR: T-cell 
receptor; NR1H3: liver-X-receptor alpha; NR1h: LXR; ANGPTL3: angiopoietin-like 3; PPAR 
D: peroxisome proliferator activated receptor delta/beta; NMRAL1:NmrA-like family domain 
containing 1; ABCB10: ATP-binding cassette super family B member 10; NFkB: nuclear 
factor kappa beta)  
        Please note that it is actually ,N%Į (nuclear factor of kappa light polypeptide gene 
enhancer in B-cells inhibitor, alpha) and not IKBKB (inhibitor kappa light polypeptide gene 
enhancer in beta cells). 
* 
* 
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Pioglitazone compared to Pretrial pathway analysis 
Pathway 2: Cancer, cellular movement, Gene expression 
 
(UBA5: ubiquitin like modifier activating enzyme 5; HNF4A: HNF4 dimer; IL5: Interleukin 
15; Pgm: phosphoglucomutase; PAK1: p21 activated kinase 1; PAK3: p21 activated kinase 3; 
PTEN: phospahtase and tensin homolog; ERBB2: v-erb-b2 erythroblastic leukaemia viral 
oncogene homolog 2; S100A1: S100 calcium binding protein A1; S100B: S100 calcium 
binding protein) 
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Placebo compared to Pretrial pathway analysis 
Pathway 1: Cellular assembly & organization, development disorder, 
neurological disease 
 
(PRUNE2: PRUNE HOMOLOG 2; PPAP2A: PHOSPHATIDIC ACID PHOSPAHTASE 
TYPE 2A; UNC119: unc-119 homolog; VGF: VFG nerve growth factor inducible; RASAL1: 
RAS protein activator like 1; PPAP2C: phosphatidic acid phosphatase type 2C; BAT3: HLA-B 
associated transcript 3; APLP1: ameloid beta (A4) precursor like protein 1; APP: ameloid beta 
(A4) precursor; GLI1: GLI family zinc finger 1) 
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